



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :  C07H 21/00, C07K 14/755, C12N 15/11, 15/12	A1	(11) International Publication Number: WO 99/46274  (43) International Publication Date: 16 September 1999 (16.09.99)
(21) International Application Number: PCT/US99/05193  (22) International Filing Date: 10 March 1999 (10.03.99)		(81) Designated States: AU, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RU, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(30) Priority Data: 09/037,601 10 March 1998 (10.03.98) US		Published <i>With international search report.</i>
(71) Applicant: EMORY UNIVERSITY [US/US]; 2009 Ridgewood Drive, Atlanta, GA 30322 (US).		
(72) Inventor: LOLLAR, John, S.; 2568 Oak Crossing Drive, Decatur, GA 30033 (US).		
(74) Agents: GREENLEE, Lorance, L. et al.; Greenlee, Winner and Sullivan, P.C., Suite 201, 5370 Manhattan Circle, Boulder, CO 80303 (US).		

(54) Title: MODIFIED FACTOR VIII

(57) Abstract

Specific amino acid loci of human factor VIII interact with inhibitory antibodies of hemophilia patients who have developed such antibodies after being treated with factor VIII. Modified factor VIII is disclosed in which the amino acid sequence is changed by a substitution at one or more of the specific loci. The modified factor VIII is not inhibited by inhibitory antibodies against the A2 or C2 domain epitopes. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory antibodies.

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5

**MODIFIED FACTOR VIII****CROSS REFERENCE TO RELATED APPLICATIONS**

10 This application claims priority from United States Patent Application No. 09/037,601 FILED March 10, 1998.

**ACKNOWLEDGEMENT OF FEDERAL RESEARCH SUPPORT**

15 The government has rights in this invention arising from National Institutes of Health Grant Nos. HL40921, HL46215, and HL36094 that partially funded the research leading to this invention.

**BACKGROUND OF THE INVENTION**

20 This invention relates generally to a hybrid factor VIII having human and animal factor VIII amino acid sequence or having human factor VIII and non-factor VIII amino acid sequence and methods of preparation and use thereof.

25 Blood clotting begins when platelets adhere to the cut wall of an injured blood vessel at a lesion site. Subsequently, in a cascade of enzymatically regulated reactions, soluble fibrinogen molecules are converted by the enzyme thrombin to insoluble strands of fibrin that hold the platelets together in a thrombus. At each step in the cascade, a protein precursor is converted to a protease that cleaves the next protein precursor in the series. Cofactors 30 are required at most of the steps.

35 Factor VIII circulates as an inactive precursor in blood, bound tightly and non-covalently to von Willebrand factor. Factor VIII is proteolytically activated by thrombin or factor

5           Xa, which dissociates it from von Willebrand factor and activates its procoagulant function in the cascade. In its active form, the protein factor VIIIa is a cofactor that increases the catalytic efficiency of factor IXa toward factor X activation by several orders of magnitude.

10           People with deficiencies in factor VIII or antibodies against factor VIII who are not treated with factor VIII suffer uncontrolled internal bleeding that may cause a range of serious symptoms, from inflammatory reactions in joints to early death. Severe hemophiliacs, who number about 10,000 in the United States, can be treated with infusion of human factor VIII, which will restore the blood's normal clotting ability if administered with sufficient frequency and concentration. The classic definition of factor VIII, in fact, is that substance present in normal blood plasma that corrects the clotting defect in plasma derived from individuals with hemophilia A.

20           The development of antibodies ("inhibitors" or "inhibitory antibodies") that inhibit the activity of factor VIII is a serious complication in the management of patients with hemophilia. Autoantibodies develop in approximately 20% of patients with hemophilia A in response to therapeutic infusions of factor VIII. In previously untreated patients with hemophilia A who develop inhibitors, the inhibitor usually develops within one year of treatment. Additionally, autoantibodies that inactivate factor VIII occasionally develop in individuals with previously normal factor VIII levels. If the inhibitor titer is low enough, patients can be managed by increasing the dose of factor VIII. However, often the inhibitor titer is so high that it cannot be overwhelmed by factor VIII. An alternative strategy is to bypass the need for factor VIII during normal hemostasis using factor IX complex preparations (for example, KONYNE®, Proplex®) or recombinant human factor VIIIa. Additionally, since porcine factor VIII usually has substantially less reactivity with

inhibitors than human factor VIII, a partially purified porcine factor VIII preparation (HYATE:C<sup>®</sup>) is used. Many patients who have developed inhibitory antibodies to human factor VIII have been successfully treated with porcine factor VIII and have tolerated such treatment for long periods of time. However, administration of porcine factor VIII is not a complete solution because inhibitors may develop to porcine factor VIII after one or more infusions.

Several preparations of human plasma-derived factor VIII of varying degrees of purity are available commercially for the treatment of hemophilia A. These include a partially-purified factor VIII derived from the pooled blood of many donors that is heat- and detergent-treated for viruses but contain a significant level of antigenic proteins; a monoclonal antibody-purified factor VIII that has lower levels of antigenic impurities and viral contamination; and recombinant human factor VIII, clinical trials for which are underway. Unfortunately, human factor VIII is unstable at physiologic concentrations and pH, is present in blood at an extremely low concentration (0.2 µg/ml plasma), and has low specific clotting activity.

Hemophiliacs require daily replacement of factor VIII to prevent bleeding and the resulting deforming hemophilic arthropathy. However, supplies have been inadequate and problems in therapeutic use occur due to difficulty in isolation and purification, immunogenicity, and the necessity of removing the AIDS and hepatitis infectivity risk. The use of recombinant human factor VIII or partially-purified porcine factor VIII will not resolve all the problems.

The problems associated with the commonly used, commercially available, plasma-derived factor VIII have stimulated significant interest in the development of a better factor VIII product. There is a need for a more potent factor VIII molecule so that more units of clotting activity can be

delivered per molecule; a factor VIII molecule that is stable at a selected pH and physiologic concentration; a factor VIII molecule that is less apt to cause production of inhibitory antibodies; and a factor VIII molecule that evades immune detection in patients who have already acquired antibodies to human factor VIII.

It is therefore an object of the present invention to provide a factor VIII that corrects hemophilia in a patient deficient in factor VIII or having inhibitors to factor VIII.

It is a further object of the present invention to provide methods for treatment of hemophiliacs.

It is still another object of the present invention to provide a factor VIII that is stable at a selected pH and physiologic concentration.

It is yet another object of the present invention to provide a factor VIII that has greater coagulant activity than human factor VIII.

It is an additional object of the present invention to provide a factor VIII against which less antibody is produced.

#### SUMMARY OF THE INVENTION

The present invention provides isolated, purified, hybrid factor VIII molecules and fragments thereof with coagulant activity including hybrid factor VIII having factor VIII amino acid sequence derived from human and pig or other non-human mammal (together referred to herein as "animal"); or in a second embodiment including a hybrid equivalent factor VIII having factor VIII amino acid sequence derived from human or animal or both and amino acid sequence having no known sequence identity to factor VIII ("non-factor VIII amino acid sequence"), preferably substituted in an antigenic and/or immunogenic region of the factor VIII, is described. One

skilled in the art will realize that numerous hybrid factor VIII constructs can be prepared including, but not limited to, human/animal factor VIII having greater coagulant activity than human factor VIII ("superior coagulant activity"); non-immunogenic human/equivalent factor VIII; non-antigenic human/equivalent or human/animal factor VIII; non-immunogenic human/animal or human/equivalent factor VIII having superior coagulant activity; non-antigenic human/animal or human/animal/equivalent factor VIII having superior coagulant activity; non-immunogenic, non-antigenic human/equivalent or human/equivalent/animal factor VIII; and non-immunogenic, non-antigenic human/animal/equivalent factor VIII having superior coagulant activity.

The hybrid factor VIII molecule is produced by isolation and recombination of human and animal factor VIII subunits or domains; or by genetic engineering of the human and animal factor VIII genes.

In a preferred embodiment, recombinant DNA methods are used to substitute elements of animal factor VIII for the corresponding elements of human factor VIII, resulting in hybrid human/animal factor VIII molecules. In a second preferred embodiment, recombinant DNA methods are used to replace one or more amino acids in the human or animal factor VIII or in a hybrid human/animal factor VIII with amino acids that have no known sequence identity to factor VIII, preferably a sequence of amino acids that has less immunoreactivity with naturally occurring inhibitory antibodies to factor VIII ("nonantigenic amino acid sequence") and/or is less apt to elicit the production of antibodies to factor VIII ("non-immunogenic amino acid sequence") than human factor VIII. An example of an amino acid sequence that can be used to replace immunogenic or antigenic sequence is a sequence of alanine residues.

In another embodiment, subunits of factor VIII are isolated and purified from human or animal plasma, and hybrid human/animal factor VIII is produced either by mixture of animal heavy chain subunits with human light chain subunits or by mixture of human heavy chain subunits with animal light chain subunits, thereby producing human light chain/animal heavy chain and human heavy chain/animal light chain hybrid molecules. These hybrid molecules are isolated by ion exchange chromatography.

Alternatively, one or more domains or partial domains of factor VIII are isolated and purified from human or animal plasma, and hybrid human/animal factor VIII is produced by mixture of domains or partial domains from one species with domains or partial domains of the second species. Hybrid molecules can be isolated by ion exchange chromatography.

Methods for preparing highly purified hybrid factor VIII are described having the steps of: (a) isolation of subunits of plasma-derived human factor VIII and subunits of plasma-derived animal factor VIII, followed by reconstitution of coagulant activity by mixture of human and animal subunits, followed by isolation of hybrid human/animal factor VIII by ion exchange chromatography; (b) isolation of domains or partial domains of plasma-derived human factor VIII and domains or partial domains of plasma-derived animal factor VIII, followed by reconstitution of coagulant activity by mixture of human and animal domains, followed by isolation of hybrid human/animal factor VIII by ion exchange chromatography; (c) construction of domains or partial domains of animal factor VIII by recombinant DNA technology, and recombinant exchange of domains of animal and human factor VIII to produce hybrid human/animal factor VIII with coagulant activity; (d) creation of hybrid human/animal factor VIII by replacement of specific amino acid residues of the factor VIII of one species with the corresponding unique amino acid residues of the factor VIII of the other species; or (e)

5

creation of a hybrid equivalent factor VIII molecule having human or animal amino acid sequence or both, in which specific amino acid residues of the factor VIII are replaced with amino acid residues having no known sequence identity to factor VIII by site-directed mutagenesis.

10

15

20

The determination of the entire DNA sequence encoding porcine factor VIII set forth herein has enabled, for the first time, the synthesis of full-length porcine factor VIII by expressing the DNA encoding porcine factor VIII in a suitable host cell. Purified recombinant porcine factor VIII is therefore an aspect of the present invention. The DNA encoding each domain of porcine factor VIII as well as any specified fragment thereof, can be similarly expressed, either by itself or in combination with DNA encoding human factor VIII to make the hybrid human/porcine factor VIII described herein. Furthermore, porcine fVIII having all or part of the B domain deleted (B-domainless porcine fVIII) is made available as part of the present invention, by expression DNA encoding porcine fVIII having a deletion of one or more codons of the B-domain.

25

30

Some embodiments of hybrid or hybrid equivalent factor VIII have specific activity greater than that of human factor VIII and equal to or greater than that of porcine factor VIII. Some embodiments of hybrid or hybrid equivalent factor VIII have equal or less immunoreactivity with inhibitory antibodies to factor VIII and/or less immunogenicity in humans or animals, compared to human or porcine factor VIII.

Also provided are pharmaceutical compositions and methods for treating patients having factor VIII deficiency comprising administering the hybrid or hybrid equivalent factor VIII.

35

## BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A-1H taken together provide an aligned sequence comparison of the human, pig and mouse factor VIII acid sequences.

5

## DETAILED DESCRIPTION OF THE INVENTION

Unless otherwise specified or indicated, as used herein, "factor VIII" denotes any functional factor VIII protein molecule from any animal, any hybrid factor VIII or modified factor VIII, "hybrid factor VIII" or "hybrid protein" denotes any functional factor VIII protein molecule or fragment thereof comprising factor VIII amino acid sequence from human, porcine, and/or non-human, non-porcine mammalian species. Such combinations include, but are not limited to, any or all of the following hybrid factor VIII molecules or fragments thereof: (1) human/porcine; (2) human/non-human, non-porcine mammalian, such as human/mouse; (3) porcine/non-human, non-porcine mammalian, such as mouse/dog. Such combinations also include hybrid factor VIII equivalent molecules or fragments thereof, as further defined below, comprising factor VIII amino acid sequence of hybrid, human, porcine, or non-human, non-porcine mammalian origin in which amino acid sequence having no known sequence identity to factor VIII is substituted. Such hybrid combinations also include hybrid factor VIII amino sequence derived from more than two species, such as human/pig/mouse, or from two or more species in which amino acid sequence having no known sequence identity to factor VIII is substituted. Unless otherwise indicated, "hybrid factor VIII" includes fragments of the hybrid factor VIII, which can be used, as described below in one exemplary embodiment, as probes for research purposes or as diagnostic reagents.

As used herein, "mammalian factor VIII" includes factor VIII with amino acid sequence derived from any non-human mammal, unless otherwise specified. "Animal", as used herein, refers to pig and other non-human mammals.

5        A "fusion protein" or "fusion factor VIII or fragment thereof", as used herein, is the product of a hybrid gene in which the coding sequence for one protein is extensively altered, for example, by fusing part of it to the coding sequence for a second protein from a different gene to produce a hybrid gene that encodes the fusion protein. As used herein, a fusion protein is a subset of the hybrid factor VIII protein described in this application.

10      A "corresponding" nucleic acid or amino acid or sequence of either, as used herein, is one present at a site in a factor VIII or hybrid factor VIII molecule or fragment thereof that has the same structure and/or function as a site in the factor VIII molecule of another species, although the nucleic acid or amino acid number may not be identical. A sequence "corresponding to" another factor VIII sequence substantially corresponds to such sequence, and hybridizes to the sequence of the designated SEQ ID NO. under stringent conditions. A sequence "corresponding to" another factor VIII sequence also includes a sequence that results in the expression of a factor VIII or claimed procoagulant hybrid factor VIII or fragment thereof and would hybridize to the designated SEQ ID NO. but for the redundancy of the genetic code.

25      A "unique" amino acid residue or sequence, as used herein, refers to an amino acid sequence or residue in the factor VIII molecule of one species that is different from the homologous residue or sequence in the factor VIII molecule of another species.

30      "Specific activity," as used herein, refers to the activity that will correct the coagulation defect of human factor VIII deficient plasma. Specific activity is measured in units of clotting activity per milligram total factor VIII protein in a standard assay in which the clotting time of human factor VIII deficient plasma is compared to that of normal human plasma. One unit of factor VIII activity is the

activity present in one milliliter of normal human plasma. In the assay, the shorter the time for clot formation, the greater the activity of the factor VIII being assayed. Hybrid human/porcine factor VIII has coagulation activity in a human factor VIII assay. This activity, as well as that of other hybrid or hybrid equivalent factor VIII molecules or fragments thereof, may be less than, equal to, or greater than that of either plasma-derived or recombinant human factor VIII.

The human factor VIII cDNA nucleotide and predicted amino acid sequences are shown in SEQ ID NOs:1 and 2, respectively. Factor VIII is synthesized as an approximately 300 kDa single chain protein with internal sequence homology that defines the "domain" sequence NH<sub>2</sub>-A1-A2-B-A3-C1-C2-COOH. In a factor VIII molecule, a "domain", as used herein, is a continuous sequence of amino acids that is defined by internal amino acid sequence identity and sites of proteolytic cleavage by thrombin. Unless otherwise specified, factor VIII domains include the following amino acid residues, when the sequences are aligned with the human amino acid sequence (SEQ ID NO:2): A1, residues Alal-Arg372; A2, residues Ser373-Arg740; B, residues Ser741-Arg1648; A3, residues Ser1690-Ile2032; C1, residues Arg2033-Asn2172; C2, residues Ser2173-Tyr2332. The A3-C1-C2 sequence includes residues Ser1690-Tyr2332. The remaining sequence, residues Glu1649-Arg1689, is usually referred to as the factor VIII light chain activation peptide. Factor VIII is proteolytically activated by thrombin or factor Xa, which dissociates it from von Willebrand factor, forming factor VIIIa, which has procoagulant function. The biological function of factor VIIIa is to increase the catalytic efficiency of factor IXa toward factor X activation by several orders of magnitude. Thrombin-activated factor VIIIa is a 160 kDa A1/A2/A3-C1-C2 heterotrimer that forms a complex with factor IXa and factor X on the surface of platelets or monocytes. A "partial domain" as used herein is a continuous sequence of amino acids forming part of a domain.

"Subunits" of human or animal factor VIII, as used herein, are the heavy and light chains of the protein. The heavy chain of factor VIII contains three domains, A1, A2, and B. The light chain of factor VIII also contains three domains, A3, C1, and C2.

The hybrid factor VIII or fragment thereof can be made  
5 (1) by substitution of isolated, plasma-derived animal  
subunits or human subunits (heavy or light chains) for  
10 corresponding human subunits or animal subunits; (2) by  
substitution of human domains or animal domains (A1, A2, A3,  
15 B, C1, and C2) for corresponding animal domains or human  
domains; (3) by substitution of parts of human domains or  
animal domains for parts of animal domains or human domains;  
20 (4) by substitution of at least one specific sequence  
including one or more unique human or animal amino acid(s) for  
the corresponding animal or human amino acid(s); or (5) by  
substitution of amino acid sequence that has no known sequence  
25 identity to factor VIII for at least one sequence including  
one or more specific amino acid residue(s) in human, animal,  
or hybrid factor VIII or fragments thereof. A "B-domainless"  
hybrid factor VIII, hybrid equivalent factor VIII, or fragment  
of either, as used herein, refers to any one of the hybrid  
factor VIII constructs described herein that lacks the B  
domain.

The terms "epitope", "antigenic site", and "antigenic  
determinant", as used herein, are used synonymously and are  
defined as a portion of the human, animal, hybrid, or hybrid  
30 equivalent factor VIII or fragment thereof that is  
specifically recognized by an antibody. It can consist of any  
number of amino acid residues, and it can be dependent upon  
the primary, secondary, or tertiary structure of the protein.  
In accordance with this disclosure, a hybrid factor VIII,  
35 hybrid factor VIII equivalent, or fragment of either that  
includes at least one epitope may be used as a reagent in the  
diagnostic assays described below. In some embodiments, the

hybrid or hybrid equivalent factor VIII or fragment thereof is not cross-reactive or is less cross-reactive with all naturally occurring inhibitory factor VIII antibodies than human or porcine factor VIII.

5

The term "immunogenic site", as used herein, is defined as a region of the human or animal factor VIII, hybrid or hybrid equivalent factor VIII, or fragment thereof that specifically elicits the production of antibody to the factor VIII, hybrid, hybrid equivalent, or fragment in a human or animal, as measured by routine protocols, such as immunoassay, e.g. ELISA, or the Bethesda assay, described herein. It can consist of any number of amino acid residues, and it can be dependent upon the primary, secondary, or tertiary structure of the protein. In some embodiments, the hybrid or hybrid equivalent factor VIII or fragment thereof is nonimmunogenic or less immunogenic in an animal or human than human or porcine factor VIII.

20

As used herein, a "hybrid factor VIII equivalent molecule or fragment thereof" or "hybrid equivalent factor VIII or fragment thereof" is an active factor VIII or hybrid factor VIII molecule or fragment thereof comprising at least one sequence including one or more amino acid residues that have no known identity to human or animal factor VIII sequence substituted for at least one sequence including one or more specific amino acid residues in the human, animal, or hybrid factor VIII or fragment thereof. The sequence of one or more amino acid residues that have no known identity to human or animal factor VIII sequence is also referred to herein as "non-factor VIII amino acid sequence". In a preferred embodiment, the amino acid(s) having no known sequence identity to factor VIII sequence are alanine residues. In another preferred embodiment, the specific factor VIII sequence for which the amino acid(s) having no known sequence identity to factor VIII sequence are substituted includes an antigenic site that is immunoreactive with naturally occurring

25

30

35

factor VIII inhibitory antibodies, such that the resulting hybrid factor VIII equivalent molecule or fragment thereof is less immunoreactive or not immunoreactive with factor VIII inhibitory antibodies. In yet another preferred embodiment, 5 the specific hybrid factor VIII sequence for which the amino acid(s) having no known sequence identity to factor VIII sequence are substituted includes an immunogenic site that elicits the formation of factor VIII inhibitory antibodies in an animal or human, such that the resulting hybrid factor VIII 10 equivalent molecule or fragment thereof is less immunogenic.

"Factor VIII deficiency," as used herein, includes deficiency in clotting activity caused by production of defective factor VIII, by inadequate or no production of 15 factor VIII, or by partial or total inhibition of factor VIII by inhibitors. Hemophilia A is a type of factor VIII deficiency resulting from a defect in an X-linked gene and the absence or deficiency of the factor VIII protein it encodes.

20 As used herein, "diagnostic assays" include assays that in some manner utilize the antigen-antibody interaction to detect and/or quantify the amount of a particular antibody that is present in a test sample to assist in the selection of medical therapies. There are many such assays known to those 25 of skill in the art. As used herein, however, the hybrid or hybrid equivalent factor VIII DNA or fragment thereof and protein expressed therefrom, in whole or in part, can be substituted for the corresponding reagents in the otherwise known assays, whereby the modified assays may be used to detect and/or quantify antibodies to factor VIII. It is the 30 use of these reagents, the hybrid or hybrid equivalent factor VIII DNA or fragment thereof or protein expressed therefrom, that permits modification of known assays for detection of antibodies to human or animal factor VIII or to hybrid 35 human/animal factor VIII. Such assays include, but are not limited to ELISAs, immunodiffusion assays, and immunoblots. Suitable methods for practicing any of these assays are known

to those of skill in the art. As used herein, the hybrid or hybrid equivalent factor VIII or fragment thereof that includes at least one epitope of the protein can be used as the diagnostic reagent. Examples of other assays in which the hybrid or hybrid equivalent factor VIII or fragment thereof can be used include the Bethesda assay and anticoagulation assays.

#### GENERAL DESCRIPTION OF METHODS

U.S. Serial No. 07/864,004 described the discovery of hybrid human/porcine factor VIII molecules having coagulant activity, in which elements of the factor VIII molecule of human or pig are substituted for corresponding elements of the factor VIII molecule of the other species. U.S. Serial No. 08/212,133 and PCT/US94/13200 describe procoagulant hybrid human/animal and hybrid equivalent factor VIII molecules, in which elements of the factor VIII molecule of one species are substituted for corresponding elements of the factor VIII molecule of the other species.

The present invention provides hybrid human/animal, animal/animal, and equivalent factor VIII molecules and fragments thereof, and the nucleic acid sequences encoding such hybrids, some of which have greater coagulant activity in a standard clotting assay when compared to highly-purified human factor VIII; and/or are less immunoreactive to inhibitory antibodies to human or porcine factor VIII than human or porcine factor VIII; and/or are less immunogenic in a human or animal than human or porcine factor VIII. These hybrid factor VIII molecules can be constructed as follows.

At least five types of active hybrid human/porcine or hybrid equivalent factor VIII molecules or fragments thereof, the nucleic acid sequences encoding these hybrid factor VIII molecules, and the methods for preparing them are disclosed herein: those obtained (1) by substituting a human or porcine subunit (i.e., heavy chain or light chain) for the

corresponding porcine or human subunit; (2) by substituting one or more human or porcine domain(s) (i.e., A1, A2, A3, B, C1, and C2) for the corresponding porcine or human domain(s); (3) by substituting a continuous part of one or more human or porcine domain(s) for the corresponding part of one or more porcine or human domain(s); (4) by substituting at least one specific sequence including one or more unique amino acid residue(s) in human or porcine factor VIII for the corresponding porcine or human sequence; and (5) by substituting at least one sequence including one or more amino acid residue(s) having no known sequence identity to factor VIII ("non-factor VIII amino acid sequence") for at least one specific sequence of one or more amino acids in human, porcine, or hybrid human/porcine factor VIII.

15

At least five types of active hybrid human/non-human, non-porcine mammalian or hybrid equivalent factor VIII molecules or fragments thereof, and the nucleic acid sequences encoding them, can also be prepared by the same methods: those obtained (1) by substituting a human or non-human, non-porcine mammalian subunit (i.e., heavy chain or light chain) for the corresponding non-human, non-porcine mammalian or human subunit; (2) by substituting one or more human or non-human, non-porcine mammalian domain(s) (i.e., A1, A2, A3, B, C1 and C2) for the corresponding non-human, non-porcine mammalian or human domain(s); (3) by substituting a continuous part of one or more human or non-human, non-porcine mammalian domain(s) for the corresponding part of one or more non-human, non-porcine mammalian or human domain(s); (4) by substituting at least one specific sequence including one or more unique amino acid residue(s) in human or non-human, non-porcine mammalian factor VIII for the corresponding non-human, non-porcine mammalian or human sequence; and (5) by substituting at least one sequence including one or more amino acid residue(s) having no known sequence identity to factor VIII ("non-factor VIII amino acid sequence") for at least one specific sequence of one or more amino acids in human, non-

20

25

30

35

human, non-porcine mammalian, or hybrid human/non-human, non-porcine mammalian factor VIII.

Further, one skilled in the art will readily recognize  
5 that the same methods can be used to prepare at least five  
types of active hybrid factor VIII molecules or fragments  
thereof, corresponding to types (1)-(5) in the previous two  
paragraphs, comprising factor VIII amino acid sequence from  
10 two or more non-human mammals, such as porcine/mouse, and  
further comprising non-factor VIII amino acid sequence.

Hybrid human/animal, animal/animal, and equivalent factor  
VIII proteins or fragments thereof listed above under groups  
15 (1)-(3) are made by isolation of subunits, domains, or  
continuous parts of domains of plasma-derived factor VIII,  
followed by reconstitution and purification. Hybrid  
human/animal, animal/animal, and equivalent factor VIII  
proteins or fragments thereof described under groups (3)-(5)  
20 above are made by recombinant DNA methods. The hybrid  
molecule may contain a greater or lesser percentage of human  
than animal sequence, depending on the origin of the various  
regions, as described in more detail below.

Since current information indicates that the B domain has  
25 no inhibitory epitope and has no known effect on factor VIII  
function, in some embodiments the B domain is deleted in the  
active hybrid or hybrid equivalent factor VIII molecules or  
fragments thereof ("B(-) factor VIII") prepared by any of the  
methods described herein.

It is shown in Example 4 that hybrid human/porcine factor  
VIII comprising porcine heavy chain and human light chain and  
corresponding to the first type of hybrid listed above has  
greater specific coagulant activity in a standard clotting  
35 assay compared to human factor VIII. The hybrid human/animal  
or equivalent factor VIII with coagulant activity, whether the  
activity is higher, equal to, or lower than that of human

factor VIII, can be useful in treating patients with inhibitors, since these inhibitors can react less with hybrid human/animal or equivalent factor VIII than with either human or porcine factor VIII.

5

Preparation of hybrid factor VIII molecules from isolated human and animal factor VIII subunits by reconstitution:

The present invention provides hybrid human/animal factor VIII molecules or fragments thereof, with subunit substitutions, the nucleic acid sequences encoding these hybrids, methods for preparing and isolating them, and methods for characterizing their procoagulant activity. One method, modified from procedures reported by Fay, P.J. et al. (1990) 10 *J. Biol. Chem.* 265:6197; and Lollar, J.S. et al. (1988) *J. Biol. Chem.* 263:10451, involves the isolation of subunits (heavy and light chains) of human and animal factor VIII, followed by recombination of human heavy chain and animal light chain or by recombination of human light chain and animal heavy chain. 15 20

Isolation of both human and animal individual subunits involves dissociation of the light chain/heavy chain dimer. This is accomplished, for example, by chelation of calcium 25 with ethylenediaminetetraacetic acid (EDTA), followed by monoS™ HPLC (Pharmacia-LKB, Piscataway, NJ). Hybrid human/animal factor VIII molecules are reconstituted from isolated subunits in the presence of calcium. Hybrid human light chain/animal heavy chain or animal light chain/human heavy chain factor VIII is isolated from unreacted heavy chains by monoS™ HPLC by procedures for the isolation of 30 porcine factor VIII, such as described by Lollar, J.S. et al. (1988) *Blood* 71:137-143.

These methods, used in one embodiment to prepare active hybrid human/porcine factor VIII, described in detail in the examples below, result in hybrid human light chain/porcine

heavy chain molecules with greater than six times the procoagulant activity of human factor VIII.

5        Other hybrid human/non-human, non-porcine mammalian factor VIII molecules can be prepared, isolated, and characterized for activity by the same methods. One skilled in the art will readily recognize that these methods can also be used to prepare, isolate, and characterize for activity hybrid animal/animal factor VIII, such as porcine/mouse, 10 comprising the light or heavy chain or one species is combined with the heavy or light chain of the other species.

15        Preparation of hybrid factor VIII molecules from isolated human and animal factor VIII domains by reconstitution:

20        The present invention provides hybrid human/animal factor VIII molecules or fragments thereof with domain substitutions, the nucleic acid sequences encoding them, methods for preparing and isolating them, and methods for characterizing their procoagulant activity. One method involves the isolation of one or more domains of human and one or more domains of animal factor VIII, followed by recombination of human and animal domains to form hybrid human/animal factor VIII with coagulant activity, as described by Lollar, P. et al. (Nov. 25, 1992) *J. Biol. Chem.* 267(33):23652-23657, for hybrid human/porcine factor VIII.

30        Specifically provided is a hybrid human/porcine factor VIII with substitution of the porcine A2 domain for the human A2 domain, which embodiment illustrates a method by which domain-substituted hybrid human/non-human, non-porcine mammalian factor VIII can be constructed. Plasma-derived non-human, non-porcine mammalian and human A1/A3-C1-C2 dimers are isolated by dissociation of the A2 domain from factor VIIa. 35 This is accomplished, for example, in the presence of NaOH, after which the mixture is diluted and the dimer is eluted using monoS™ HPLC (Pharmacia-LKB, Piscataway, NJ). The A2 domain is isolated from factor VIIa as a minor component in

the monoS™ HPLC. Hybrid human/animal factor VIII molecules are reconstituted by mixing equal volumes of the A2 domain of one species and the A1/A3-C1-C2 dimer of the other species.

5            Hybrid human/animal factor VIII or fragments thereof with one or more domain substitutions is isolated from the mixture of unreacted dimers and A2 by monoS™ HPLC by procedures for the isolation of porcine factor VIII, as described by Lollar, J.S. et al. (1988) *Blood* 71:137-143. Routine methods can also  
10          be used to prepare and isolate the A1, A3, C1, C2, and B domains of the factor VIII of one species, any one or more of which can be substituted for the corresponding domain in the factor VIII of the other species. One skilled in the art will readily recognize that these methods can also be used to  
15          prepare, isolate, and characterize for activity domain-substituted hybrid animal/animal factor VIII, such as porcine/mouse.

20          These methods, described in detail in the examples below, result in hybrid factor VIII molecules with procoagulant activity.

25          Preparation of hybrid factor VIII molecules by recombinant engineering of the sequences encoding human, animal, and hybrid factor VIII subunits, domains, or parts of domains:

30          Substitution of subunits, domains, continuous parts of domains:

35          The present invention provides active, recombinant hybrid human/animal and hybrid equivalent factor VIII molecules and fragments thereof with subunit, domain, and amino acid sequence substitutions, the nucleic acid sequences encoding these hybrids, methods for preparing and isolating them, and methods for characterizing their coagulant, immunoreactive, and immunogenic properties.

The human factor VIII gene was isolated and expressed in mammalian cells, as reported by Toole, J.J. et al. (1984) *Nature* 312:342-347 (Genetics Institute); Gitschier, J. et al. (1984) *Nature* 312:326-330 (Genentech); Wood, W.I. et al. (1984) *Nature* 312:330-337 (Genentech); Vehar, G.A. et al. (1984) *Nature* 312:337-342 (Genentech); WO 87/04187; WO 88/08035; WO 88/03558; U.S. Patent No. 4,757,006, and the amino acid sequence was deduced from cDNA. U.S. Patent No. 4,965,199 to Capon et al. discloses a recombinant DNA method for producing factor VIII in mammalian host cells and purification of human factor VIII. Human factor VIII expression on CHO (Chinese hamster ovary) cells and BHKC (baby hamster kidney cells) has been reported. Human factor VIII has been modified to delete part or all of the B domain (U.S. Patent No. 4,868,112), and replacement of the human factor VIII B domain with the human factor V B domain has been attempted (U.S. Patent No. 5,004,803). The cDNA sequence encoding human factor VIII and predicted amino acid sequence are shown in SEQ ID NOS:1 and 2, respectively.

Porcine factor VIII has been isolated and purified from plasma [Fass, D.N. et al. (1982) *Blood* 59:594]. Partial amino acid sequence of porcine factor VIII corresponding to portions of the N-terminal light chain sequence having homology to ceruloplasmin and coagulation factor V and largely incorrectly located were described by Church et al. (1984) *Proc. Natl. Acad. Sci. USA* 81:6934. Toole, J.J. et al. (1984) *Nature* 312:342-347 described the partial sequencing of the N-terminal end of four amino acid fragments of porcine factor VIII but did not characterize the fragments as to their positions in the factor VIII molecule. The amino acid sequence of the B and part of the A2 domains of porcine factor VIII were reported by Toole, J.J. et al. (1986) *Proc. Natl. Acad. Sci. USA* 83:5939-5942. The cDNA sequence encoding the complete A2 domain of porcine factor VIII and predicted amino acid

sequence and hybrid human/porcine factor VIII having substitutions of all domains, all subunits, and specific amino acid sequences were disclosed in U.S. Serial No. 07/864,004 entitled "Hybrid Human/Porcine factor VIII" filed April 7, 5 1992 by John S. Lollar and Marschall S. Runge, which issued as U.S. Patent No. 5,364,771 on November 15, 1994, and in WO 10 93/20093. The cDNA sequence encoding the A2 domain of porcine factor VIII having sequence identity to residues 373-740 in mature human factor VIII, as shown in SEQ ID NO:1, and the predicted amino acid sequence are shown in SEQ ID NOS:3 and 4, respectively. More recently, the nucleotide and corresponding 15 amino acid sequences of the A1 and A2 domains of porcine factor VIII and a chimeric factor VIII with porcine A1 and/or A2 domains substituted for the corresponding human domains were reported in WO 94/11503.

Both porcine and human factor VIII are isolated from plasma as a two subunit protein. The subunits, known as the heavy chain and light chain, are held together by a non-covalent bond that requires calcium or other divalent metal ions. The heavy chain of factor VIII contains three domains, 20 A1, A2, and B, which are linked covalently. The light chain of factor VIII also contains three domains, designated A3, C1, and C2. The B domain has no known biological function and can be removed from the molecule proteolytically or by recombinant 25 DNA technology methods without significant alteration in any measurable parameter of factor VIII. Human recombinant factor VIII has a similar structure and function to plasma-derived factor VIII, though it is not glycosylated unless expressed in 30 mammalian cells.

Both human and porcine activated factor VIII ("factor VIIIa") have three subunits due to cleavage of the heavy chain between the A1 and A2 domains. This structure is designated 35 A1/A2/A3-C1-C2. Human factor VIIIa is not stable under the conditions that stabilize porcine factor VIIIa, presumably because of the weaker association of the A2 subunit of human

factor VIIIa. Dissociation of the A2 subunit of human and porcine factor VIIIa is associated with loss of activity in the factor VIIIa molecule.

5       Using as probes the known sequence of parts of the porcine factor VIII molecule, the domains of the porcine factor VIII molecule that have not been sequenced to date can be sequenced by standard, established cloning techniques, such as those described in Weis, J.H., "Construction of recombinant 10 DNA libraries," in Current Protocols in Molecular Biology, F.M. Ausubel et al., eds. (1991); and Sambrook, J., et al., Molecular Cloning, A Laboratory Manual, so that full length hybrids can be constructed:

15       Specifically provided as an exemplary and a preferred embodiment is active recombinant hybrid human/porcine factor VIII having substituted A2 domain, the nucleic acid sequence encoding it, and the methods for preparing, isolating, and characterizing its activity. The methods by which this hybrid 20 construct is prepared can also be used to prepare active recombinant hybrid human/porcine factor VIII or fragments thereof having substitution of subunits, continuous parts of domains, or domains other than A2. One skilled in the art will recognize that these methods also demonstrate how other 25 recombinant hybrid human/non-human, non-porcine mammalian or animal/animal hybrid factor VIII molecules or fragments thereof can be prepared in which subunits, domains, or continuous parts of domains are substituted.

30       Recombinant hybrid human/porcine factor VIII is prepared starting with human cDNA (Biogen, Inc.) or porcine cDNA (described herein) encoding the relevant factor VIII sequence. In a preferred embodiment, the factor VIII encoded by the cDNA includes domains A1-A2-A3-C1-C2, lacking the entire B domain, and corresponds to amino acid residues 1-740 and 1649-35 2332 of single chain human factor VIII (see SEQ ID NO:2),

according to the numbering system of Wood et al. (1984) *Nature* 312:330-337.

5 Individual subunits, domains, or continuous parts of domains of porcine or human factor VIII cDNA can be and have been cloned and substituted for the corresponding human or porcine subunits, domains, or parts of domains by established mutagenesis techniques. For example, Lubin, I.M. et al. (1994) *J. Biol. Chem.* 269(12):8639-8641 describes techniques  
10 for substituting the porcine A2 domain for the human domain using convenient restriction sites. Other methods for substituting any arbitrary region of the factor VIII cDNA of one species for the factor VIII cDNA of another species include splicing by overlap extension ("SOE"), as described by  
15 Horton, R.M. et al. (1993) *Meth. Enzymol.* 217:270-279.

20 The hybrid factor VIII cDNA encoding subunits, domains, or parts of domains or the entire hybrid cDNA molecules are cloned into expression vectors for ultimate expression of active hybrid human/porcine factor VIII protein molecules in cultured cells by established techniques, as described by Selden, R.F., "Introduction of DNA into mammalian cells," in  
25 Current Protocols in Molecular Biology, F.M. Ausubel et al., eds (1991).

30 In a preferred embodiment, a hybrid human/porcine cDNA encoding factor VIII, in which the porcine sequence encodes a domain or part domain, such as the A2 domain or part domain, is inserted in a mammalian expression vector, such as ReNeo, to form a hybrid factor VIII construct. Preliminary characterization of the hybrid factor VIII is accomplished by insertion of the hybrid cDNA into the ReNeo mammalian expression vector and transient expression of the hybrid protein in COS-7 cells. A determination of whether active hybrid protein is expressed can then be made. The expression vector construct is used further to stably transfect cells in  
35

culture, such as baby hamster kidney cells, using methods that are routine in the art, such as liposome-mediated transfection (Lipofectin™, Life Technologies, Inc.). Expression of recombinant hybrid factor VIII protein can be confirmed, for example, by sequencing, Northern and Western blotting, or polymerase chain reaction (PCR). Hybrid factor VIII protein in the culture media in which the transfected cells stably expressing the protein are maintained can be precipitated, pelleted, washed, and resuspended in an appropriate buffer, and the recombinant hybrid factor VIII protein purified by standard techniques, including immunoaffinity chromatography using, for example, monoclonal anti-A2-Sepharose™.

In a further embodiment, the hybrid factor VIII comprising subunit, domain, or amino acid sequence substitutions is expressed as a fusion protein from a recombinant molecule in which sequence encoding a protein or peptide that enhances, for example, stability, secretion, detection, isolation, or the like is inserted in place adjacent to the factor VIII encoding sequence. Established protocols for use of homologous or heterologous species expression control sequences including, for example, promoters, operators, and regulators, in the preparation of fusion proteins are known and routinely used in the art. See Current Protocols in Molecular Biology (Ausubel, F.M., et al., eds), Wiley Interscience, N.Y.

The purified hybrid factor VIII or fragment thereof can be assayed for immunoreactivity and coagulation activity by standard assays including, for example, the plasma-free factor VIII assay, the one-stage clotting assay, and the enzyme-linked immunosorbent assay using purified recombinant human factor VIII as a standard.

Other vectors, including both plasmid and eukaryotic viral vectors, may be used to express a recombinant gene construct in eukaryotic cells depending on the preference and

judgment of the skilled practitioner (see, for example, Sambrook et al., Chapter 16). Other vectors and expression systems, including bacterial, yeast, and insect cell systems, can be used but are not preferred due to differences in, or lack of, glycosylation.

Recombinant hybrid factor VIII protein can be expressed in a variety of cells commonly used for culture and recombinant mammalian protein expression. In particular, a number of rodent cell lines have been found to be especially useful hosts for expression of large proteins. Preferred cell lines, available from the American Type Culture Collection, Rockville, MD, include baby hamster kidney cells, and chinese hamster ovary (CHO) cells which are cultured using routine procedures and media.

The same methods employed for preparing hybrid human/porcine factor VIII having subunit, domain, or amino acid sequence substitution can be used to prepare other recombinant hybrid factor VIII protein and fragments thereof and the nucleic acid sequences encoding these hybrids, such as human/non-human, non-porcine mammalian or animal/animal. Starting with primers from the known human DNA sequence, the murine and part of the porcine factor VIII cDNA have been cloned. Factor VIII sequences of other species for use in preparing a hybrid human/animal or animal/animal factor VIII molecule can be obtained using the known human and porcine DNA sequences as a starting point. Other techniques that can be employed include PCR amplification methods with animal tissue DNA, and use of a cDNA library from the animal to clone out the factor VIII sequence.

As an exemplary embodiment, hybrid human/mouse factor VIII protein can be made as follows. DNA clones corresponding to the mouse homolog of the human factor VIII gene have been isolated and sequenced and the amino acid sequence of mouse factor VIII protein predicted, as described in Elder, G., et

al. (1993) *Genomics* 16(2):374-379, which also includes a comparison of the predicted amino acid sequences of mouse, human, and part of porcine factor VIII molecules. The mouse factor VIII cDNA sequence and predicted amino acid sequence are shown in SEQ ID NO:5 and SEQ ID NO:8, respectively. In a preferred embodiment, the RNA amplification with transcript sequencing (RAWTS) methods described in Sarkar, G. et al. (1989) *Science* 244:331-334, can be used. Briefly, the steps are (1) cDNA synthesis with oligo(dT) or an mRNA-specific oligonucleotide primer; (2) polymerase chain reaction (PCR) in which one or both oligonucleotides contains a phage promoter attached to a sequence complementary to the region to be amplified; (3) transcription with a phage promoter; and (4) reverse transcriptase-mediated dideoxy sequencing of the transcript, which is primed with a nested (internal) oligonucleotide. In addition to revealing sequence information, this method can generate an *in vitro* translation product by incorporating a translation initiation signal into the appropriate PCR primer: and can be used to obtain novel mRNA sequence information from other species.

Substitution of amino acid(s):

The present invention provides active recombinant hybrid human/animal and animal/animal factor VIII molecules or fragments thereof comprising at least one sequence including one or more unique amino acids of one species substituted for the corresponding amino acid sequence of the other species or fragments thereof, nucleic acid sequences encoding these hybrids, methods for preparing and isolating them, and methods for characterizing their coagulant, immunogenic and immunoreactive properties.

The A2 domain is necessary for the procoagulant activity of the factor VIII molecule. Studies show that porcine factor VIII has six-fold greater procoagulant activity than human factor VIII (Lollar, P. et al. (1991) *J. Biol. Chem.*

266:12481-12486, and that the difference in coagulant activity between human and porcine factor VIII appears to be based on a difference in amino acid sequence between one or more residues in the human and porcine A2 domains (Lollar, P. et al. (1992) *J. Biol. Chem.* 267:23652-23657. Further, the A2 and C2 domains and possibly a third light chain region in the human factor VIII molecule are thought to harbor the epitopes to which most, if not all, inhibitory antibodies react, according to Hoyer (1994) *Semin. Hematol.* 31:1-5.

10

Recombinant hybrid human/animal, animal/animal, or equivalent factor VIII molecules or fragments thereof can be made by substitution of at least one specific sequence including one or more unique amino acids from the A2, C2, and/or other domains of the factor VIII of one species for the corresponding sequence of the other species, wherein the amino acid sequences differ, as illustrated in more detail below, between the molecules of the two species. In an exemplary preferred embodiment described herein, the present invention provides active recombinant hybrid human/porcine factor VIII comprising porcine amino acid sequence substituted for corresponding human amino acid sequence that includes an epitope, wherein the hybrid factor VIII has decreased or no immunoreactivity with inhibitory antibodies to factor VIII. In a further embodiment, active recombinant hybrid factor VIII molecules can also be made comprising amino acid sequence from more than one species substituted for the corresponding sequence in a third species. Recombinant hybrid equivalent molecules can also be made, comprising human, animal, or hybrid factor VIII including at least one sequence including one or more amino acids that have no known sequence identity to factor VIII, as further described below.

Any hybrid factor VIII construct having specific amino acid substitution as described can be assayed by standard procedures for coagulant activity and for reactivity with

35

inhibitory antibodies to factor VIII for identification of hybrid factor VIII molecules with enhanced coagulant activity and/or decreased antibody immunoreactivity. Hybrid molecules may also be identified that have reduced coagulant activity compared to human or porcine factor VIII but also have decreased antibody reactivity. One skilled in the art will recognize that hybrid factor VIII molecules or fragments thereof having less, equal, or greater coagulant activity, compared to human or porcine factor VIII, is useful for treating patients who have a factor VIII deficiency. The methods described herein to prepare active recombinant hybrid human/porcine factor VIII with substitution of specific amino acids can be used to prepare active recombinant hybrid human/non-human, non-porcine mammalian factor VIII protein, hybrid animal-1/animal-2 factor VIII, and hybrid equivalent factor VIII or fragments thereof.

Hybrid factor VIII molecules with altered coagulant activity:

The present invention provides procoagulant recombinant hybrid human/animal, animal/animal, or equivalent factor VIII molecules or fragments thereof comprising at least one specific sequence including one or more unique amino acids having procoagulant activity in the factor VIII of one species substituted for the corresponding amino acid sequence of the factor VIII of the other species, using established site-directed mutagenesis techniques as described herein. The specific sequences to be used in the substitution are selected and the hybrid constructs are prepared and assayed for coagulant activity, as follows. Specifically provided as a preferred and exemplary embodiment is a hybrid human/porcine factor VIII comprising amino acid substitutions in the A2 domain. It is understood that one skilled in the art can use these methods to prepare other hybrid human/animal, animal/animal, and equivalent factor VIII molecules or fragments thereof having altered coagulant activity,

preferably increased coagulant activity compared to human factor VIII.

5           The basis for the greater coagulant activity in porcine factor VIII appears to be the more rapid spontaneous dissociation of the A2 subunit of human factor VIIIa than porcine factor VIIIa, which leads to loss of activity, according to Lollar, P. et al. (1990) *J. Biol. Chem.* 265:1688-1692; Lollar, P. et al. (1992) *J. Biol. Chem.* 267:23652-23657; Fay, P.J. et al. (1992) *J. Biol. Chem.* 267:13246-13250.

10

15           A comparison of the alignment of the amino acid sequences of the human and porcine factor VIII A2 domains (residue numbering starts at position 373 with respect to the full length amino acid sequence of human factor VIII, SEQ ID NO:2) is shown in Figure 1C. For preparation of a hybrid human/porcine factor VIII molecule with altered coagulant activity, the initial target candidates for mutagenesis, which were revealed upon comparison of the human and porcine A2 20 amino acid sequences (SEQ ID NOS: 2 and 6, respectively) within the human A2 domain, are shown in Table I.

20

TABLE I. HUMAN AMINO ACID SEQUENCE TARGET CANDIDATES FOR MUTAGENESIS (SEQ ID NO:2)

25

	Sequence	Residues	Mismatches	Charge Changes
30	398-403	6	4	1
	434-444	10	4	3
	484-496	13	7	3
	598-603	6	4	2
	536-541	6	4	0
	713-722	10	6	2
35	727-737	11	6	2

40           Table I and the bold letters of Figures 1A-1B illustrate seven sequences in the human and pig A2 domain amino acid sequences (SEQ ID NOS:2 and 6, respectively) that constitute only 17 percent of the A2 domain but include 70 percent of the sequence differences between human and porcine A2 domains.

A recombinant hybrid human/porcine construct is described in which amino acids Ser373-Glu604 in the A2 domain (Ser373-Arg740) of human factor VIII have been replaced with the homologous porcine sequence. This construct does not react with A2 inhibitors and has the same coagulant activity as human B(-) factor VIII. A plasma-derived hybrid molecule is described that comprises a complete porcine A2 domain substitution in the human factor VIII that has increased coagulant activity compared to human factor VIII. Comparison of these constructs indicates that a region between residues Asp605 and Arg740 is responsible for the difference in activity between human and porcine factor VIII. This region can be defined more specifically by systematically making recombinant hybrid human/porcine factor VIII molecules with porcine substitutions in the region between Asp605 and Arg740 by using established site-directed mutagenesis techniques, for example, the "splicing by overlap extension" (SOE) method that has been used extensively to make hybrid factor VIII molecules containing porcine substitutions in the NH<sub>2</sub>-terminal region of A2. These molecules can be expressed in COS-7 cells and baby hamster kidney cells as described above. They can be purified to homogeneity using methods known in the art, such as heparin-Sepharose™ and immunoaffinity chromatography. Protein concentration can be estimated by absorption of ultraviolet light at A<sub>280</sub>, and the specific activity of the constructs can be determined by dividing coagulant activity (measured in units per ml by single stage clotting assay) by A<sub>280</sub>. Human factor VIII has a specific activity of approximately 3000-4000 U/A<sub>280</sub>, whereas porcine factor VIII has a specific activity of approximately 20,000 U/A<sub>280</sub>. In a preferred embodiment, the procoagulant recombinant hybrid human/porcine factor VIII has a specific activity of 20,000 U/A<sub>280</sub> and contains a minimal amount of porcine substitution in the A2 domain.

As described herein, site-directed mutagenesis techniques are used to identify hybrid protein with coagulant activity that can be enhanced, equal to, or reduced, compared to human

factor VIII, but preferably is enhanced. In the hybrid human/porcine embodiment, specific human sequences are replaced with porcine sequences, preferably using the splicing by overlap extension method (SOE), as described by Ho, S.N., et al., 77 Gene 51-59 (1994), and in Examples 7 and 8. Oligonucleotide-directed mutagenesis can also be used, as was done to loop out the amino acid sequence for part of the human A2 domain (see Example 7). As functional analysis of the hybrids reveals coagulant activity, the sequence can be further dissected and mapped for procoagulant sequence by standard point mutation analysis techniques.

The present invention contemplates that hybrid factor VIII cDNA and protein can be characterized by methods that are established and routine, such as DNA sequencing, coagulant activity assays, mass by ELISA and by UV absorbance at 280 nm of purified hybrid factor VIII, specific coagulant activity (U/mg), SDS-PAGE of purified hybrid factor VIII, and the like. Other known methods of testing for clinical effectiveness may be required, such as amino acid, carbohydrate, sulfate, or metal ion analysis.

A recombinant hybrid factor VIII having superior coagulant activity, compared to human factor VIII, may be less expensive to make than plasma-derived factor VIII and may decrease the amount of factor VIII required for effective treatment of factor VIII deficiency.

30 Hybrid factor VIII molecules with reduced immunoreactivity:

Epitopes that are immunoreactive with antibodies that inhibit the coagulant activity of factor VIII ("inhibitors" or "inhibitory antibodies") have been characterized based on known structure-function relationships in factor VIII. Presumably, inhibitors could act by disrupting any of the macromolecular interactions associated with the domain structure of factor VIII or its associations with von

Willebrand factor, thrombin, factor Xa, factor IXa, or factor X. However, over 90 percent of inhibitory antibodies to human factor VIII act by binding to epitopes located in the 40 kDa A2 domain or 20 kDa C2 domain of factor VIII, disrupting specific functions associated with these domains, as described by Fulcher et al. (1985) *Proc. Natl. Acad. Sci USA* 82:7728-7732; and Scandella et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:6152-6156. In addition to the A2 and C2 epitopes, there may be a third epitope in the A3 or C1 domain of the light chain of factor VIII, according to Scandella et al. (1993) *Blood* 82:1767-1775. The significance of this putative third epitope is unknown, but it appears to account for a minor fraction of the epitope reactivity in factor VIII.

Anti-A2 antibodies block factor X activation, as shown by Lollar et al. (1994) *J. Clin. Invest.* 93:2497-2504. Previous mapping studies by deletion mutagenesis described by Ware et al. (1992) *Blood Coagul. Fibrinolysis* 3:703-716, located the A2 epitope to within a 20 kDa region of the NH<sub>2</sub>-terminal end of the 40 kDa A2 domain. Competition immunoradiometric assays have indicated that A2 inhibitors recognize either a common epitope or narrowly clustered epitopes, as described by Scandella et al. (1992) *Throm. Haemostas* 67:665-671, and as demonstrated in Example 8.

The present invention provides active recombinant hybrid and hybrid equivalent factor VIII molecules or fragments thereof, the nucleic acid sequences encoding these hybrids, methods of preparing and isolating them, and methods for characterizing them. These hybrids comprise human/animal, animal/animal, or equivalent hybrid factor VIII molecules, further comprising at least one specific amino acid sequence including one or more unique amino acids of the factor VIII of one species substituted for the corresponding amino acid sequence of the factor VIII of the other species; or comprises

at least one sequence including one or more amino acids having no known sequence identity to factor VIII substituted for specific amino acid sequence in human, animal, or hybrid factor VIII. The resulting hybrid factor VIII has reduced or 5 no immunoreactivity to factor VIII inhibitory antibodies, compared to human or porcine factor VIII.

Using the approach described in the previous section for substitution of amino acids in the factor VIII molecule, mutational analysis is employed to select corresponding factor 10 VIII amino acid sequence of one species, preferably porcine, which is substituted for at least one sequence including one or more amino acids in the factor VIII of another species, preferably human, or for amino acid sequence of a hybrid equivalent factor VIII molecule, that includes one or more critical region(s) in the A2, C2, or any other domain to which inhibitory antibodies are directed. The methods are described 15 in more detail below. The resulting procoagulant recombinant hybrid construct has reduced or no immunoreactivity to inhibitory antibodies, compared to human factor VIII, using 20 standard assays. Through systematic substitution of increasingly smaller amino acid sequences followed by assay of the hybrid construct for immunoreactivity, as described below, the epitope in any domain of a factor VIII molecule is mapped, 25 substituted by amino acid sequence having less or no immunoreactivity, and a hybrid factor VIII is prepared.

It is understood that one skilled in the art can use this 30 approach combining epitope mapping, construction of hybrid factor VIII molecules, and mutational analysis of the constructs to identify and replace at least one sequence including one or more amino acids comprising an epitope in the A2, C2, and/or other domains to which inhibitory antibodies are directed and to construct procoagulant recombinant hybrid 35 human/animal, animal/animal, or equivalent factor VIII or fragments thereof having decreased or no immunoreactivity compared to human or porcine factor VIII. This approach is

5

used, as described in Example 8, to prepare a recombinant procoagulant hybrid human/porcine factor VIII having porcine amino acid substitutions in the human A2 domain and no antigenicity to anti-factor VIII antibodies as an exemplary embodiment.

10

15

20

25

30

35

Usually, porcine factor VIII has limited or no reaction with inhibitory antibodies to human factor VIII. The recombinant hybrid human/porcine factor VIII molecules having decreased or no reactivity with inhibitory antibodies based on amino acid substitution in the A2 domain are prepared, as an example of how hybrid factor VIII can be prepared using the factor VIII of other species and substitutions in domains other than A2, as follows. The porcine A2 domain is cloned by standard cloning techniques, such as those described above and in Examples 6, 7, and 8, and then cut and spliced within the A2 domain using routine procedures, such as using restriction sites to cut the cDNA or splicing by overlap extension (SOE). The resulting porcine amino acid sequence is substituted into the human A2 domain to form a hybrid factor VIII construct, which is inserted into a mammalian expression vector, preferably ReNeo, stably transfected into cultured cells, preferably baby hamster kidney cells, and expressed, as described above. The hybrid factor VIII is assayed for immunoreactivity, for example with anti-A2 antibodies by the routine Bethesda assay or by plasma-free chromogenic substrate assay. The Bethesda unit (BU) is the standard method for measuring inhibitor titers. If the Bethesda titer is not measurable (<0.7 BU/mg IgG) in the hybrid, then a human A2 epitope was eliminated in the region of substituted corresponding porcine sequence. The epitope is progressively narrowed, and the specific A2 epitope can thus be determined to produce a hybrid human/porcine molecule with as little porcine sequence as possible. As described herein, a 25-residue sequence corresponding to amino acids Arg484-Ile508 that is critical for inhibitory immunoreactivity has been identified and substituted in the human A2 domain. Within

this sequence are only nine differences between human and porcine factor VIII. This region can be further analyzed and substituted.

5        Hybrid human/porcine factor VIII molecules having decreased or no reactivity with inhibitory antibodies based on substitution of amino acid sequence in the C1, C2 or other domain, with or without substitution in the A2 domain, can also be prepared. The C2 epitope, for example can be mapped  
10      using the homolog scanning approach combined with site-directed mutagenesis. More specifically, the procedures can be the same or similar to those described herein for amino acids substitution in the A2 domain, including cloning the porcine C2 or other domain, for example by using RT-PCR or by  
15      probing a porcine liver cDNA library with human C2 or other domain DNA; restriction site techniques and/or successive SOE to map and simultaneously replace epitopes in the C2 or other domain; substitution for the human C2 or other domain in B(-) factor VIII; insertion into an expression vector, such as pBluescript; expression in cultured cells; and routine assay for immunoreactivity. For the assays, the reactivity of C2 hybrid factor VIII with a C2-specific inhibitor, MR [Scandella et al. (1992) *Thromb. Haemostasis* 67:665-671 and Lubin et al.  
20      (1994)], and/or other C2 specific antibodies prepared by  
25      affinity chromatography can be performed.

The C2 domain consists of amino acid residues 2173-2332 (SEQ ID NO:2). Within this 154 amino acid region, inhibitor activity appears to be directed to a 65 amino acid region between residues 2248 and 2312, according to Shima, M. et al. (1993) *Thromb. Haemostas* 69:240-246. If the C2 sequence of human and porcine factor VIII is approximately 85 percent identical in this region, as it is elsewhere in the functionally active regions of factor VIII, there will be approximately ten differences between human and porcine factor

VIII C2 amino acid sequence, which can be used as initial targets to construct hybrids with substituted C2 sequence.

5 It is likely that clinically significant factor VIII epitopes are confined to the A2 and C2 domains. However, if antibodies to other regions (A1, A3, B, or C1 domains) of factor VIII are identified, the epitopes can be mapped and eliminated by using the approach described herein for the nonantigenic hybrid human/porcine factor VIII molecules.

10 More specifically, mapping of the putative second light chain epitope and/or any other epitope in any other animal or human factor VIII domain can also be accomplished. Initially, determination of the presence of a third inhibitor epitope in the A3 or C1 domains can be made as follows. Using human ("H") and porcine ("p") factor VIII amino acid sequences as a model,  $A1_p$ - $A2_p$ - $A3_p$ - $C1_H$ - $C2_p$  and  $A1_p$ - $A2_p$ - $A3_H$ - $C1_p$ - $C2_p$ , B-domainless hybrids will be constructed. Inhibitor IgG from approximately 20 patient plasmas (from Dr. Dorothea Scandella, American Red Cross) who have low or undetectable titers against porcine factor VIII will be tested against the hybrids. If the third epitope is in the A3 domain, inhibitory IgG is expected to react with  $A1_p$ - $A2_p$ - $A3_H$ - $C1_p$ - $C2_p$  but not  $A1_p$ - $A2_p$ - $A3_p$ - $C1_H$ - $C2_p$ . Conversely, if the third epitope is in the C1 domain, then inhibitory IgG is expected to react with  $A1_p$ - $A2_p$ - $A3_p$ - $C1_H$ - $C2_p$  but not  $A1_p$ - $A2_p$ - $A3_H$ - $C1_p$ - $C2_p$ . If a third epitope is identified it will be characterized by the procedures described herein for the A2 and C2 epitopes.

30 For example, antibodies specific for the C1 or A3 domain epitope can be isolated from total patient IgG by affinity chromatography using the  $A1_p$ - $A2_p$ - $A3_H$ - $C1_p$ - $C2_p$  and  $A1_p$ - $A2_p$ - $A3_p$ - $C1_H$ - $C2_p$  hybrids, and by elimination of C2 specific antibodies by passage over recombinant factor VIII C2-Sepharaose™. The putative third epitope will be identified by SOE constructs in which, in a preferred embodiment, portions of the human factor

VIII A3 or C1 domain are systematically replaced with porcine sequence.

Hybrid factor VIII molecules with reduced immunogenicity:

5       A molecule is immunogenic when it can induce the production of antibodies in human or animal. The present invention provides a procoagulant recombinant hybrid human/animal or animal/animal factor VIII molecule, hybrid factor VIII equivalent molecule, or fragment of either that is  
10      less immunogenic than wild-type human porcine factor VIII in human or animal, comprising at least one specific amino acid sequence including one or more unique amino acids of the factor VIII of one species substituted for the corresponding amino acid sequence that has immunogenic activity of the factor VIII of the other species; or at least one amino acid sequence including one or more amino acids having no known  
15      identity to factor VIII substituted for amino acid sequence of the human, animal, or hybrid factor. This hybrid can be used to lower the incidence of inhibitor development in an animal or human and to treat factor VIII deficiency, and would be preferred in treating previously untreated patients with hemophilia. In a preferred embodiment, the hybrid factor VIII comprises human factor VIII amino acid sequence, further comprising one or more alanine residues substituted for human  
20      amino acid sequence having immunogenic activity, resulting in a procoagulant recombinant hybrid equivalent molecule or fragment thereof having reduced or no immunogenicity in human or animal.

25

30       The process described herein of epitope mapping and mutational analysis combined with substitution of non-antigenic amino acid sequence in a factor VIII molecule, using hybrid human/porcine factor VIII, produces hybrid molecules with low antigenicity. Using this model and the associated methods, any of the hybrid constructs described herein can be altered by site-directed mutagenesis techniques to remove as much of any functional epitope as possible to minimize the  
35

ability of the immune system to recognize the hybrid factor VIII, thereby decreasing its immunogenicity.

One method that can be used to further reduce the antigenicity and to construct a less immunogenic hybrid factor VIII is alanine scanning mutagenesis, described by Cunningham, B.C. et al. (1989) *Science* 244:1081-1085, of selected specific amino acid sequences in human, animal, or hybrid equivalent factor VIII. In alanine scanning mutagenesis, amino acid side chains that are putatively involved in an epitope are replaced by alanine residues by using site-directed mutagenesis. By comparing antibody binding of alanine mutants to wild-type protein, the relative contribution of individual side chains to the binding interaction can be determined. Alanine substitutions are likely to be especially useful, since side chain contributions to antibody binding are eliminated beyond the  $\beta$  carbon, but, unlike glycine substitution, main chain conformation is not usually altered. Alanine substitution does not impose major steric, hydrophobic or electrostatic effects that dominate protein-protein interactions.

In protein antigen-antibody interactions, there usually are about 15-20 antigen side chains in contact with the antibody. Side chain interactions, as opposed to main chain interactions, dominate protein-protein interactions. Recent studies have suggested that only a few (approximately 3 to 5) of these side chain interactions contribute most of the binding energy. See Clackson, T. et al. (1995) *Science* 267:383-386. An extensive analysis of growth hormone epitopes for several murine monoclonal antibodies revealed the following hierarchy for side chain contributions to the binding energy: Arg > Pro > Glu - Asp - Phe - Ile, with Trp, Ala, Gly, and Cys not tested [Jin, L. et al. (1992) *J. Mol. Biol.* 226:851-865]. Results with the A2 epitope described herein are consistent with this, since twelve of the 25

residues in the 484-508 A2 segment contain these side chains (Table 1).

The finding that certain amino acid residues are particularly well recognized by antibodies, indicates that elimination of these residues from a known epitope can decrease the ability of the immune system to recognize these epitopes, i.e., can make a molecule less immunogenic. In the case of the A2 epitope, immunogenic residues can be replaced without loss of factor VIII coagulant activity. For example, in HP9, Arg484 is replaced by Ser, Pro485 is replaced by Ala, Arg489 is replaced by Gly, Pro492 is replaced by Leu, and Phe501 is replaced by Met. Further, results from the patient plasmas used to test immunoreactivity in hybrid human/porcine factor VIII constructs, described in Example 8, indicate that antibodies from different patients recognize the same or a very similar structural region in the A2 domain and that the residues in the A2 domain that participate in binding A2 inhibitors appear to show little variation. Thus, the A2 epitope included in human factor VIII residues 484-508 is an immunodominant epitope in that it is recognized by the human immune system better than other structural regions of factor VIII. Replacing this structure by nonantigenic factor VIII sequence from another species or by non-factor VIII amino acid sequence, while retaining full procoagulant activity, is expected to alter recognition of hybrid or hybrid equivalent factor VIII by the immune system.

It is anticipated that site-directed mutagenesis to replace bulky and/or charged residues that tend to dominate epitopes with small, neutral side chains (e.g., alanine) may produce a less immunogenic region. It is expected that a molecule containing a few of these substitutions at each significant inhibitor epitope will be difficult for the immune system to fit by the lock-and-key mechanism that is typical of antigen-antibody interactions. Because of its low antigenicity, such a hybrid molecule could be useful in

treating factor VIII deficiency patients with inhibitors, and because of its low immunogenicity, it could be useful in treating previously untreated patients with hemophilia A.

5       A general result is that mutation of one of a few key residues is sufficient to decrease the binding constant for a given protein-protein interaction by several orders of magnitude. Thus, it appears likely that all factor VIII epitopes contain a limited number of amino acids that are critical for inhibitor development. For each epitope in factor VIII, alanine substitutions for at least one sequence including one or more specific amino acids having immunogenic activity, may produce an active molecule that is less immunogenic than wild-type factor VIII. In a preferred embodiment, the hybrid factor VIII is B-domainless.

10      The methods for preparing active recombinant hybrid or hybrid equivalent factor VIII with substitution of amino acid sequence having little or no immunogenic activity for amino acid sequence in the factor VIII having immunogenic activity are as follows, using hybrid human/porcine factor VIII with amino acid substitutions in the A2 domain as an exemplary embodiment. There are 25 residues in the human factor VIII region 484-508. Site-directed mutagenesis can be used to make single mutants in which any of these residues is replaced by any of the other 19 amino acids for a total of 475 mutants. Furthermore, hybrid molecules having more than one mutation can be constructed.

15      The hybrid constructs can be assayed for antigenicity by measuring the binding constant for inhibitor antibodies, as described by Friguet, B. et al. (1985) *J. Immunol. Methods* 77:305-319 (1985). In a preferred embodiment, the binding constant will be reduced by at least three orders of magnitude, which would lower the Bethesda titer to a level that is clinically insignificant. For example, the IC<sub>50</sub> (a

crude measure of the binding constant) of inhibition by A2 antibodies was reduced in hybrid human/porcine factor VIII constructs HP2, HP4, HP5, HP7, and HP9, described in Example 8, and this was associated with a reduction in Bethesda titer to an unmeasurable level. It is anticipated, for example, that a double or triple alanine mutant of human factor VIII (e.g., a human factor VIII Arg484->Ala, Arg489->Ala, Phe501->Ala triple mutant) will produce a molecule with sufficiently low antigenicity for therapeutic use. Similar mutations can be made in the C2 epitope and the putative third epitope. A preferred embodiment comprises two or three alanine substitutions into two or three factor VIII epitopes. Other substitutions into these regions can also be done.

In a preferred embodiment, hybrid equivalent factor VIII molecules will be identified that are less antigenic and/or immunogenic in human and animal than either human or porcine factor VIII. Such hybrid equivalent constructs can be tested in animals for their reduced antigenicity and/or immunogenicity. For example, control and factor VIII deficient rabbits, pigs, dogs, mice, primates, and other mammals can be used as animal models. In one experimental protocol, the hybrid or hybrid equivalent factor VIII can be administered systematically over a period of six months to one year to the animal, preferably by intravenous infusion, and in a dosage range between 5 and 50 Units/kg body weight, preferably 10-50 Units/kg, and most preferably 40 Units/kg body weight. Antibodies can be measured in plasma samples taken at intervals after the infusions over the duration of the testing period by routine methods, including immunoassay and the Bethesda assay. Coagulant activity can also be measured in samples with routine procedures, including a one-stage coagulation assay.

The hybrid equivalent factor VIII molecules can be tested in humans for their reduced antigenicity and/or immunogenicity

in at least two types of clinical trials. In one type of trial, designed to determine whether the hybrid or hybrid equivalent factor VIII is immunoreactive with inhibitory antibodies, hybrid or hybrid equivalent factor VIII is administered, preferably by intravenous infusion, to approximately 25 patients having factor VIII deficiency who have antibodies to factor VIII that inhibit the coagulant activity of therapeutic human or porcine factor VIII. The dosage of the hybrid or hybrid equivalent factor VIII is in a range between 5 and 50 Units/kg body weight, preferably 10-50 Units/kg, and most preferably 40 Units/kg body weight. Approximately 1 hour after each administration, the recovery of factor VIII from blood samples is measured in a one-stage coagulation assay. Samples are taken again approximately 5 hours after infusion, and recovery is measured. Total recovery and the rate of disappearance of factor VIII from the samples is predictive of the antibody titer and inhibitory activity. If the antibody titer is high, factor VIII recovery usually cannot be measured. The recovery results are compared to the recovery results in patients treated with plasma-derived human factor VIII, recombinant human factor VIII, porcine factor VIII, and other commonly used therapeutic forms of factor VIII or factor VIII substitutes.

In a second type of clinical trial, designed to determine whether the hybrid or hybrid equivalent factor VIII is immunogenic, i.e., whether patients will develop inhibitory antibodies, hybrid or hybrid equivalent factor VIII is administered, as described in the preceding paragraph, to approximately 100 previously untreated hemophiliac patients who have not developed antibodies to factor VIII. Treatments are given approximately every 2 weeks over a period of 6 months to 1 year. At 1 to 3 month intervals during this period, blood samples are drawn and Bethesda assays or other antibody assays are performed to determine the presence of inhibitory antibodies. Recovery assays can also be done, as described above, after each infusion. Results are compared to

hemophiliac patients who receive plasma-derived human factor VIII, recombinant human factor VIII, porcine factor VIII, or other commonly used therapeutic forms of factor VIII or factor VIII substitutes.

5

Preparation of hybrid factor VIII molecules using human and non-porcine, non-human mammalian factor VIII amino acid sequence:

10       The methods used to prepare hybrid human/porcine factor VIII with substitution of specific amino acids can be used to prepare recombinant hybrid human/non-human, non-porcine mammalian or animal/animal factor VIII protein that has, compared to human or porcine factor VIII, altered or the same coagulant activity and/or equal or reduced immunoreactivity and/or immunogenicity, based on substitution of one or more amino acids in the A2, C2, and/or other domains.

20       Similar comparisons of amino acid sequence identity can be made between human and non-human, non-porcine mammalian factor VIII proteins to determine the amino acid sequences in which procoagulant activity, anti-A2 and anti-C2 immunoreactivity, and or immunogenicity, or immunoreactivity and/or immunogenicity in other domains reside. Similar methods can then be used to prepare hybrid human/non-human, non-porcine mammalian factor VIII molecules. As described above, functional analysis of each hybrid will reveal those with decreased reactivity to inhibitory antibodies, and/or reduced immunogenicity, and/or increased coagulant activity, and the sequence can be further dissected by point mutation analysis.

35       For example, hybrid human/mouse factor VIII molecules can be prepared as described above. The amino acid sequence alignment of the A2 domain of human (SEQ ID NO:2) and mouse (SEQ ID NO:6) is shown in Figure 1C. As reported by Elder et al., the factor VIII protein encoded by the mouse cDNA (SEQ ID NO:5) has 2319 amino acids, with 74% sequence identity overall

to the human sequence (SEQ ID NO:2) (87 percent identity when the B domain is excluded from the comparison), and is 32 amino acids shorter than human factor VIII. The amino acid sequences in the mouse A and C domains (SEQ ID NO:6) are highly conserved, with 84-93 percent sequence identity to the human sequence (SEQ ID NO:2), while the B and the two short acidic domains have 42-70 percent sequence identity. Specifically, the A1, A2, and A3 mouse amino acid sequences (SEQ ID NO: 6) are 85, 85, and 90 percent identical to the corresponding human amino acid sequences (SEQ ID NO:2). The C1 and C2 mouse amino acid sequences are 93 and 84 percent identical to the corresponding human amino acid sequences. In the predicted mouse factor VIII amino acid sequence (SEQ ID NO: 6), the A1, A2, and A3 domains are homologous to human factor VIII amino acids 1-372, 373-740, and 1690-2032, respectively, using amino acid sequence identity for numbering purposes.

The thrombin/factor Xa and all but one activated protein C cleavage sites are conserved in mouse factor VIII. The tyrosine residue for von Willebrand factor binding is also conserved.

According to Elder et al., the nucleotide sequence (SEQ ID NO:5) of mouse factor VIII contains 7519 bases and has 67 percent identity overall with the human nucleotide sequence (SEQ ID NO:1). The 6957 base pairs of murine coding sequence have 82 percent sequence identity with the 7053 base pairs of coding sequence in human factor VIII. When the B domain is not included in the comparison, there is an 88 percent nucleotide sequence identity.

Elder et al. report that human and mouse factor VIII molecules are 74 percent identical overall, and that 95 percent of the human residues that lead to hemophilia when altered are identical in the mouse. These data support the application of the same techniques used to identify amino acid

sequence with coagulant activity and/or immunoreactivity to antibodies in the porcine factor VIII molecule to the mouse or other animal factor VIII to identify similar amino acid sequences and prepare hybrid molecules.

5                   Preparation of hybrid factor VIII molecules having reduced cross-reactivity using human and non-human, non-porcine mammalian factor VIII amino acid sequence and non-factor VIII amino acid sequence:

10                  Porcine factor VIII is used clinically to treat factor VIII deficiency patients who have inhibitory antibodies to human factor VIII. Cross-reactivity, in which human plasma reacts with porcine factor VIII, can be reduced by preparation  
15                  of hybrid porcine/non-human, non-porcine mammalian or hybrid equivalent factor VIII. In a preferred embodiment, a determination of whether human A2, C2, or other domain-specific inhibitors react with non-human, non-porcine mammalian ("other mammalian") factor VIII is made, using the routine Bethesda assay and the particular other mammalian plasma as the standard. Inhibitor titers are usually measured  
20                  in plasma, so purified other mammalian factor VIII is not necessary. If the inhibitors do not react with the other mammalian factor VIII, such as murine factor VIII, the sequence of which is known, then corresponding other mammalian sequence can be substituted into the porcine epitope region,  
25                  as identified by using human/porcine hybrids. Once the animal sequence is known, site directed mutagenesis techniques, such as oligonucleotide-mediated mutagenesis described by Kunkel,  
30                  T.A. et al. (1991) *Meth. Enzymol.* 204: 125-139, can be used to prepare the hybrid porcine/animal factor VIII molecule. If other animal plasmas are less reactive with A2, C2, or other factor VIII inhibitors than murine or porcine factor VIII, the animal sequence corresponding to the porcine epitope can be determined by routine procedures, such as RT-PCR, and a hybrid  
35                  human/animal or porcine/animal factor VIII constructed by site-directed mutagenesis. Also, hybrid human/animal or porcine/non-porcine mammalian factor VIII having reduced

cross-reactivity with human plasma compared to porcine factor VIII can be prepared that has corresponding amino acid sequence substitution from one or more other animals. In a further embodiment, cross-reactivity can be reduced by substitution of amino acid sequence having no known identity to factor VIII amino acid sequence, preferably alanine residues using alanine scanning mutagenesis techniques, for porcine epitope sequence.

After identification of clinically significant epitopes, recombinant hybrid factor VIII molecules will be expressed that have less than or equal cross-reactivity compared with porcine factor VIII when tested *in vitro* against a broad survey of inhibitor plasmas. Preferably these molecules will be combined A2/C2 hybrids in which immunoreactive amino acid sequence in these domains is replaced by other mammalian sequence. Additional mutagenesis in these regions may be done to reduce cross-reactivity. Reduced cross-reactivity, although desirable, is not necessary to produce a product that may have advantages over the existing porcine factor VIII concentrate, which produces side effects due to contaminant porcine proteins and may produce untoward effects due to the immunogenicity of porcine factor VIII sequences. A hybrid human/other mammalian or porcine/other mammalian factor VIII molecule will not contain foreign porcine proteins. Additionally, the extensive epitope mapping accomplished in the porcine A2 domain indicates that greater than 95% of the therapeutic hybrid human/porcine factor VIII sequence will be human.

30

Preparation of hybrid factor VIII equivalents:

The methods for amino acid substitution in factor VIII molecules described above and in the examples can also be used to prepare procoagulant recombinant hybrid factor VIII equivalent molecules or fragments thereof comprising at least one amino acid sequence including one or more amino acids

having no known amino acid sequence identity to factor VIII ("non-factor VIII sequence") substituted for at least one specific amino acid sequence that includes an antigenic and/or immunogenic site in human, animal, or hybrid factor VIII. The  
5 resulting active hybrid factor VIII equivalent molecule has equal or less reactivity with factor VIII inhibitory antibodies and/or less immunogenicity in human and animals than the unsubstituted human, animal, or hybrid factor VIII.

10 Suitable amino acid residues that can be substituted for those sequences of amino acids critical to coagulant and/or antigenic and/or immunogenic activity in human or animal factor VIII or hybrid human/animal factor VIII to prepare a hybrid equivalent factor VIII molecule include any amino acids  
15 having no known sequence identity to animal or human factor VIII amino acid sequence that has coagulant, antigenic, or immunogenic activity. In a preferred embodiment, the amino acids that can be substituted include alanine residues using alanine scanning mutagenesis techniques.  
20

Hybrid factor VIII equivalent molecules described herein also include those molecules in which amino acid residues having no known identity to animal factor VIII sequence are substituted for amino acid residues not critical to coagulant,  
25 antigenic, or immunogenic activity.

As described above, in one embodiment of a hybrid factor VIII equivalent molecule, the molecule has reduced cross-reactivity with inhibitor plasmas. One or more epitopes in the cross-reactive factor VIII are identified, as described above, and then replaced by non-factor VIII amino acid sequence, preferably alanine residues, using, for example, the alanine scanning mutagenesis method.  
30

35 In a preferred embodiment, a procoagulant recombinant hybrid factor VIII equivalent molecule is prepared comprising at least one sequence including one or more amino acids having

no known sequence identity to factor VIII, preferably alanine residues, substituted for at least one sequence including one or more amino acids including an epitope, and/or for at least one sequence including one or more amino acids including an immunogenic site, preferably in human factor VIII. The resulting hybrid equivalent factor VIII molecule or fragment thereof has reduced or no immunoreactivity with inhibitory antibodies to factor VIII and/or reduced or no immunogenicity in human or animals. The methods for identifying specific antigenic amino acid sequence in the A2 domain of human factor VIII for substitution by nonantigenic porcine unique amino acid sequence are described in Examples 7 and 8 and are exemplary for identifying antigenic sequence in the A2 and other domains of human and animal factor VIII and for using site-directed mutagenesis methods such as alanine scanning mutagenesis to substitute non-factor VIII amino acid sequence.

Since the human A2 epitope has been narrowed to 25 or few amino acids, as described in Example 8, alanine scanning mutagenesis can be performed on a limited number of hybrid factor VIII constructs having human amino acid sequence to determine which are procoagulant, non-immunoreactive and/or nonimmunogenic hybrid factor VIII constructs based on A2 amino acid substitutions. In the A2 domain, the most likely candidates for alanine substitutions to achieve both reduced antigenicity and immunogenicity in the hybrid construct are Arg484, Pro485, Tyr487, Ser488, Arg489, Pro492, Val495, Phe501, and Ile508. The binding affinity of a hybrid construct comprising each of these mutants for mAb413 and a panel of A2 specific patient IgGs will be determined by ELISA. Any mutant that is active and has a binding affinity for A2 inhibitors that is reduced by more than 2 orders of magnitude is a candidate for the A2 substituted factor VIII molecule. Constructs having more than one mutation will be selected, based on the assumption that the more the epitope is altered, the less immunogenic it will be. It is possible that there are other candidate residues in the region between Arg484-

Ile508, since there may be key residues for the epitope that are common to both human and porcine factor VIII. For example, charged residues are frequently involved in protein-protein interactions and, in fact, an alanine substitute for Arg490 produces a factor VIII procoagulated having only 0.2% of the reactivity to inhibitor of human factor VIII (Table VI). Similarly, an alanine substitution for Lys493 is a possible candidate.

This procedure will be carried out in the C2 epitope and the putative third epitope, which is thought to be in the A3 or C1 domains, as well as any other epitopes identified in factor VIII, to prepare hybrid equivalent factor VIII constructs.

Diagnostic Assays.

The hybrid human/animal, animal/animal, or equivalent factor VIII cDNA and/or protein expressed therefrom, in whole or in part, can be used in assays as diagnostic reagents for the detection of inhibitory antibodies to human or animal factor VIII or to hybrid human/animal factor or equivalent VIII in substrates, including, for example, samples of serum and body fluids of human patients with factor VIII deficiency. These antibody assays include assays such as ELISA assays, immunoblots, radioimmunoassays, immunodiffusion assays, and assay of factor VIII biological activity (e.g., by coagulation assay). Techniques for preparing these reagents and methods for use thereof are known to those skilled in the art. For example, an immunoassay for detection of inhibitory antibodies in a patient serum sample can include reacting the test sample with a sufficient amount of the hybrid human/animal factor VIII that contains at least one antigenic site, wherein the amount is sufficient to form a detectable complex with the inhibitory antibodies in the sample.

Nucleic acid and amino acid probes can be prepared based on the sequence of the hybrid human/porcine, human/non-human,

non-porcine mammalian, animal/animal, or equivalent factor VIII cDNA or protein molecule or fragments thereof. In some embodiments, these can be labeled using dyes or enzymatic, fluorescent, chemiluminescent, or radioactive labels that are commercially available. The amino acid probes can be used, for example, to screen sera or other body fluids where the presence of inhibitors to human, animal, or hybrid human/animal factor VIII is suspected. Levels of inhibitors can be quantitated in patients and compared to healthy controls, and can be used, for example, to determine whether a patient with a factor VIII deficiency can be treated with a hybrid human/animal or hybrid equivalent factor VIII. The cDNA probes can be used, for example, for research purposes in screening DNA libraries.

## Pharmaceutical Compositions.

20 Pharmaceutical compositions containing hybrid  
human/animal, porcine/non-human, non-porcine mammalian,  
animal-1/animal-2, or equivalent factor VIII, alone or in  
combination with appropriate pharmaceutical stabilization  
compounds, delivery vehicles, and/or carrier vehicles, are  
prepared according to known methods, as described in  
Remington's *Pharmaceutical Sciences* by E.W. Martin.

25 In one preferred embodiment, the preferred carriers or  
delivery vehicles for intravenous infusion are physiological  
saline or phosphate buffered saline.

In another preferred embodiment, suitable stabilization compounds, delivery vehicles, and carrier vehicles include but are not limited to other human or animal proteins such as albumin.

35 Phospholipid vesicles or liposomal suspensions are also preferred as pharmaceutically acceptable carriers or delivery vehicles. These can be prepared according to methods known to

those skilled in the art and can contain, for example, phosphatidylserine/-phosphatidylcholine or other compositions of phospholipids or detergents that together impart a negative charge to the surface, since factor VIII binds to negatively charged phospholipid membranes. Liposomes may be prepared by dissolving appropriate lipid(s) (such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container. An aqueous solution of the hybrid factor VIII is then introduced into the container. The container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.

15

The hybrid factor or hybrid equivalent factor VIII can be combined with other suitable stabilization compounds, delivery vehicles, and/or carrier vehicles, including vitamin K dependent clotting factors, tissue factor, and von Willebrand factor (vWF) or a fragment of vWF that contains the factor VIII binding site, and polysaccharides such as sucrose.

25

Hybrid or hybrid equivalent factor VIII can also be delivered by gene therapy in the same way that human factor VIII can be delivered, using delivery means such as retroviral vectors. This method consists of incorporation of factor VIII cDNA into human cells that are transplanted directly into a factor VIII deficient patient or that are placed in an implantable device, permeable to the factor VIII molecules but impermeable to cells, that is then transplanted. The preferred method will be retroviral-mediated gene transfer. In this method, an exogenous gene (e.g., a factor VIII cDNA) is cloned into the genome of a modified retrovirus. The gene is inserted into the genome of the host cell by viral machinery where it will be expressed by the cell. The retroviral vector is modified so that it will not produce virus, preventing viral infection of the host. The general

30

35

principles for this type of therapy are known to those skilled in the art and have been reviewed in the literature [e.g., Kohn, D.B. et al. (1989) *Transufusion* 29:812-820].

5            Hybrid factor VIII can be stored bound to vWF to increase the half-life and shelf-life of the hybrid molecule. Additionally, lyophilization of factor VIII can improve the yields of active molecules in the presence of vWF. Current methods for storage of human and animal factor VIII used by commercial suppliers can be employed for storage of hybrid factor VIII. These methods include: (1) lyophilization of factor VIII in a partially-purified state (as a factor VIII "concentrate" that is infused without further purification); (2) immunoaffinity-purification of factor VIII by the Zimmerman method and lyophilization in the presence of albumin, which stabilizes the factor VIII; (3) lyophilization of recombinant factor VIII in the presence of albumin.

20            Additionally, hybrid factor VIII has been indefinitely stable at 4° C in 0.6 M NaCl, 20 mM MES, and 5 mM CaCl<sub>2</sub>, at pH 6.0 and also can be stored frozen in these buffers and thawed with minimal loss of activity.

Methods of Treatment.

25            Hybrid or hybrid equivalent factor VIII is used to treat uncontrolled bleeding due to factor VIII deficiency (e.g., intraarticular, intracranial, or gastrointestinal hemorrhage) in hemophiliacs with and without inhibitory antibodies and in patients with acquired factor VIII deficiency due to the development of inhibitory antibodies. The active materials are preferably administered intravenously.

35            Additionally, hybrid or hybrid equivalent factor VIII can be administered by transplant of cells genetically engineered to produce the hybrid or by implantation of a device containing such cells, as described above.

5           In a preferred embodiment, pharmaceutical compositions of hybrid or hybrid equivalent factor VIII alone or in combination with stabilizers, delivery vehicles, and/or carriers are infused into patients intravenously according to the same procedure that is used for infusion of human or animal factor VIII.

10           The treatment dosages of hybrid or hybrid equivalent factor VIII composition that must be administered to a patient in need of such treatment will vary depending on the severity of the factor VIII deficiency. Generally, dosage level is adjusted in frequency, duration, and units in keeping with the severity and duration of each patient's bleeding episode. Accordingly, the hybrid factor VIII is included in the pharmaceutically acceptable carrier, delivery vehicle, or stabilizer in an amount sufficient to deliver to a patient a therapeutically effective amount of the hybrid to stop bleeding, as measured by standard clotting assays.

20           Factor VIII is classically defined as that substance present in normal blood plasma that corrects the clotting defect in plasma derived from individuals with hemophilia A. The coagulant activity *in vitro* of purified and partially-purified forms of factor VIII is used to calculate the dose of factor VIII for infusions in human patients and is a reliable indicator of activity recovered from patient plasma and of correction of the *in vivo* bleeding defect. There are no reported discrepancies between standard assay of novel factor VIII molecules *in vitro* and their behavior in the dog infusion model or in human patients, according to Lusher, J.M. et al. 328 *New Engl. J. Med.* 328:453-459; Pittman, D.D. et al. (1992) *Blood* 79:389-397; and Brinkhous et al. (1985) *Proc. Natl. Acad. Sci.* 82:8752-8755.

Usually, the desired plasma factor VIII level to be achieved in the patient through administration of the hybrid or hybrid equivalent factor VIII is in the range of 30-100% of normal. In a preferred mode of administration of the hybrid or hybrid equivalent factor VIII, the composition is given intravenously at a preferred dosage in the range from about 5 to 50 units/kg body weight, more preferably in a range of 10-50 units/kg body weight, and most preferably at a dosage of 20-40 units/kg body weight; the interval frequency is in the range from about 8 to 24 hours (in severely affected hemophiliacs); and the duration of treatment in days is in the range from 1 to 10 days or until the bleeding episode is resolved. See, e.g., Roberts, H.R., and M.R. Jones, "Hemophilia and Related Conditions - Congenital Deficiencies of Prothrombin (Factor II, Factor V, and Factors VII to XII)," Ch. 153, 1453-1474, 1460, in Hematology, Williams, W. J., et al., ed. (1990). Patients with inhibitors may require more hybrid or hybrid equivalent factor VIII, or patients may require less hybrid or hybrid equivalent factor VIII because of its higher specific activity than human factor VIII or decreased antibody reactivity or immunogenicity. As in treatment with human or porcine factor VIII, the amount of hybrid or hybrid equivalent factor VIII infused is defined by the one-stage factor VIII coagulation assay and, in selected instances, *in vivo* recovery is determined by measuring the factor VIII in the patient's plasma after infusion. It is to be understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.

Treatment can take the form of a single intravenous administration of the composition or periodic or continuous

administration over an extended period of time, as required. Alternatively, hybrid or hybrid equivalent factor VIII can be administered subcutaneously or orally with liposomes in one or several doses at varying intervals of time.

5

Hybrid or hybrid equivalent factor VIII can also be used to treat uncontrolled bleeding due to factor VIII deficiency in hemophiliacs who have developed antibodies to human factor VIII. In this case, coagulant activity that is superior to that of human or animal factor VIII alone is not necessary. Coagulant activity that is inferior to that of human factor VIII (i.e., less than 3,000 units/mg) will be useful if that activity is not neutralized by antibodies in the patient's plasma.

10

The hybrid or hybrid equivalent factor VIII molecule and the methods for isolation, characterization, making, and using it generally described above will be further understood with reference to the following non-limiting examples.

15

Example 1: Assay of porcine factor VIII and hybrid human/porcine factor VIII.

20

Porcine factor VIII has more coagulant activity than human factor VIII, based on specific activity of the molecule. These results are shown in Table III in Example 4. This conclusion is based on the use of appropriate standard curves that allow human porcine factor VIII to be fairly compared. Coagulation assays are based on the ability of factor VIII to shorten the clotting time of plasma derived from a patient with hemophilia A. Two types of assays were employed: the one-stage and the two stage assay.

25

30

35

In the one-stage assay, 0.1 ml hemophilia A plasma (George King Biomedical, Inc.) was incubated with 0.1 ml activated partial thromboplastin reagent (APTT) (Organon Teknika) and 0.01 ml sample or standard, consisting of

diluted, citrated normal human plasma, for 5 min at 37°C in a water bath. Incubation was followed by addition of 0.1 ml 20 mM CaCl<sub>2</sub>, and the time for development of a fibrin clot was determined by visual inspection.

5

A unit of factor VIII is defined as the amount present in 1 ml of citrated normal human plasma. With human plasma as the standard, porcine and human factor VIII activity were compared directly. Dilutions of the plasma standard or purified proteins were made into 0.15 M NaCl, 0.02 M HEPES, pH 7.4. The standard curve was constructed based on 3 or 4 dilutions of plasma, the highest dilution being 1/50, and on log<sub>10</sub> clotting time plotted against log<sub>10</sub> plasma concentration, which results in a linear plot. The units of factor VIII in an unknown sample were determined by interpolation from the standard curve.

The one-stage assay relies on endogenous activation of factor VIII by activators formed in the hemophilia A plasma, whereas the two-stage assay measures the procoagulant activity of preactivated factor VIII. In the two-stage assay, samples containing factor VIII that had been reacted with thrombin were added to a mixture of activated partial thromboplastin and human hemophilia A plasma that had been preincubated for 5 min at 37°C. The resulting clotting times were then converted to units/ml, based on the same human standard curve described above. The relative activity in the two-stage assay was higher than in the one-stage assay because the factor VIII had been preactivated.

30

*Example 2:* Characterization of the functional difference between human and porcine factor VIII.

35

The isolation of porcine and human plasma-derived factor VIII and human recombinant factor VIII have been described in the literature in Fulcher, C.A. et al. (1982) *Proc. Natl.*

Acad. Sci. USA 79:1648-1652; Toole et al. (1984) Nature 312:342-347 (Genetics Institute); Gitschier et al. (1984) Nature 312:326-330 (Genentech); Wood et al. (1984) Nature 312:330-337 (Genentech); Vehar et al. 312 Nature 312:337-342 (Genentech); Fass et al. (1982) Blood 59:594; Toole et al. (1986) Proc. Natl. Acad. Sci. USA 83:5939-5942. This can be accomplished in several ways. All these preparations are similar in subunit composition, although there is a functional difference in stability between human and porcine factor VIII.

10

For comparison of human recombinant and porcine factor VIII, preparations of highly-purified human recombinant factor VIII (Cutter Laboratories, Berkeley, CA) and porcine factor VIII [immunopurified as described in Fass et al. (1982) Blood 59:594] were subjected to high-pressure liquid chromatography (HPLC) over a Mono Q™ (Pharmacia-LKB, Piscataway, NJ) anion-exchange column (Pharmacia, Inc.). The purposes of the Mono Q™ HPLC step were elimination of minor impurities of exchange of human and porcine factor VIII into a common buffer for comparative purposes. Vials containing 1000-2000 units of factor VIII were reconstituted with 5 ml H<sub>2</sub>O. Hepes (2 M at pH 7.4) was then added to a final concentration of 0.02 M. Factor VIII was applied to a Mono Q™ HR 5/5 column equilibrated in 0.15 M NaCl, 0.02 M Hepes, 5mM CaCl<sub>2</sub>, at pH 7.4 (Buffer A plus 0.15 M NaCl); washed with 10 ml Buffer A + 0.15 M NaCl; and eluted with a 20 ml linear gradient, 0.15 M to 0.90 M NaCl in Buffer A at a flow rate of 1 ml/min.

15

20

25

30

For comparison of human plasma-derived factor VIII (purified by Mono Q™ HPLC) and porcine factor VIII, immunoaffinity-purified, plasma-derived porcine factor VIII was diluted 1:4 with 0.04 M Hepes, 5 mM CaCl<sub>2</sub>, 0.01% Tween-80, at pH 7.4, and subjected to Mono Q™ HPLC under the same conditions described in the previous paragraph for human

factor VIII. These procedures for the isolation of human and porcine factor VIII are standard for those skilled in the art.

Column fractions were assayed for factor VIII activity by a one-stage coagulation assay. The average results of the assays, expressed in units of activity per A<sub>280</sub> of material, are given in Table II, and indicate that porcine factor VIII has at least six times greater activity than human factor VIII when the one-stage assay is used.

10

TABLE II: COMPARISON OF HUMAN AND PORCINE FACTOR VIII COAGULANT ACTIVITY

	Activity (U/A <sub>280</sub> )
15	
	Porcine 21,300
	Human plasma-derived 3,600
	Human recombinant 2,400

20

Example 3: Comparison of the stability of human and porcine factor VIII.

The results of the one-stage assay for factor VIII reflect activation of factor VIII to factor VIIa in the sample and possibly loss of formed factor VIIa activity. A direct comparison of the stability of human and porcine factor VIII was made. Samples from Mono Q™ HPLC (Pharmacia, Inc., Piscataway, N.J.) were diluted to the same concentration and buffer composition and reacted with thrombin. At various times, samples were removed for two-stage coagulation assay. Typically, peak activity (at 2 min) was 10-fold greater for porcine than human factor VIIa, and the activities of both porcine and human factor VIIa subsequently decreased, with human factor VIIa activity decreasing more rapidly.

Generally, attempts to isolate stable human factor VIIa are not successful even when conditions that produce stable

porcine factor VIIIa are used. To demonstrate this, Mono Q™ HPLC-purified human factor VIII was activated with thrombin and subjected to Mono S™ cation-exchange (Pharmacia, Inc.) HPLC under conditions that produce stable porcine factor VIIIa, as described by Lollar et al. (1989) *Biochemistry* 28:666.

Human factor VIII, 43 µg/ml (0.2 µM) in 0.2 M NaCl, 0.01 M Hepes, 2.5 mM CaCl<sub>2</sub>, at pH 7.4, in 10 ml total volume, was reacted with thrombin (0.036 µM) for 10 min, at which time FPR-CH<sub>2</sub>Cl D-phenyl-prolyl-arginyl-chloromethyl ketone was added to a concentration of 0.2 µM for irreversible inactivation of thrombin. The mixture then was diluted 1:1 with 40 mM 2-(N-morpholino) ethane sulfonic acid (MES), 5 mM CaCl<sub>2</sub>, at pH 6.0, and loaded at 2 ml/min onto a Mono S™ HR 5/5 HPLC column (Pharmacia, Inc.) equilibrated in 5 mM MES, 5 mM CaCl<sub>2</sub>, at pH 6.0 (Buffer B) plus 0.1 M NaCl. Factor VIIIa was eluted without column washing with a 20 ml gradient from 0.1 M NaCl to 0.9 M NaCl in Buffer B at 1 ml/min.

The fraction with coagulant activity in the two-stage assay eluted as a single peak under these conditions. The specific activity of the peak fraction was approximately 7,500 U/A<sub>280</sub>. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of the Mono S™ factor VIIIa peak, followed by silver staining of the protein, revealed two bands corresponding to a heterodimeric (A3-C1-C2/A1) derivative of factor VIII. Although the A2 fragment was not identified by silver staining under these conditions because of its low concentration, it was identified as a trace constituent by <sup>125</sup>I-labeling.

In contrast to the results with human factor VIII, porcine factor VIIIa isolated by Mono S™ HPLC under the same conditions had a specific activity  $1.6 \times 10^6$  U/A<sub>280</sub>. Analysis of porcine factor VIIIa by SDS-PAGE revealed 3 fragments

corresponding to A1, A2, and A3-C1-C2 subunits, demonstrating that porcine factor VIIIa possesses three subunits.

The results of Mono S™ HPLC of human thrombin-activated factor VIII preparations at pH 6.0 indicate that human factor VIIIa is labile under conditions that yield stable porcine factor VIIIa. However, although trace amounts of A2 fragment were identified in the peak fraction, determination of whether the coagulant activity resulted from small amounts of heterotrimeric factor VIIIa or from heterodimeric factor VIIIa that has a low specific activity was not possible from this method alone.

A way to isolate human factor VIIIa before it loses its A2 subunit is desirable to resolve this question. To this end, isolation was accomplished in a procedure that involves reduction of the pH of the Mono S™ buffers to pH 5. Mono Q™-purified human factor VIII (0.5 mg) was diluted with H<sub>2</sub>O to give a final composition of 0.25 mg/ml (1 μm) factor VIII in 0.25 M NaCl, 0.01 M Hepes, 2.5 mM CaCl<sub>2</sub>, 0.005% Tween-80, at pH 7.4 (total volume 7.0 ml). Thrombin was added to a final concentration of 0.072 μm and allowed to react for 3 min. Thrombin was then inactivated with FPR-CH<sub>2</sub>Cl (0.2 μm). The mixture then was diluted 1:1 with 40 mM sodium acetate, 5 mM CaCl<sub>2</sub>, 0.01% Tween-80, at pH 5.0, and loaded at 2 ml/min onto a Mono S™ HR 5/5 HPLC column equilibrated in 0.01 M sodium acetate, 5 mM CaCl<sub>2</sub>, 0.01% Tween-80, at pH 5.0, plus 0.1 M NaCl. Factor VIIIa was eluted without column washing with a 20 ml gradient from 0.1 M NaCl to 1.0 M NaCl in the same buffer at 1 ml/min. This resulted in recovery of coagulant activity in a peak that contained detectable amounts of the A2 fragment as shown by SDS-PAGE and silver staining. The specific activity of the peak fraction was tenfold greater than that recovered at pH 6.0 (75,000 U/A<sub>280</sub> v. 7,500 U/A<sub>280</sub>). However, in contrast to porcine factor VIIIa isolated at pH 6.0, which is indefinitely stable at 4°C, human factor VIIIa activity decreased steadily over a period of several hours

5

after elution from Mono S™. Additionally, the specific activity of factor VIIIa purified at pH 5.0 and assayed immediately is only 5% that of porcine factor VIIIa, indicating that substantial dissociation occurred prior to assay.

10

These results demonstrate that both human and porcine factor VIIIa are composed of three subunits (A1, A2, and A3-C1-C2). Dissociation of the A2 subunit is responsible for the loss of activity of both human and porcine factor VIIIa under certain conditions, such as physiological ionic strength, pH, and concentration. The relative stability of porcine factor VIIIa under certain conditions is because of stronger association of the A2 subunit.

15

*Example 4: Preparation of hybrid human/porcine factor VIII by reconstitution with subunits.*

20

25

30

35

Porcine factor VIII light chains and factor VIII heavy chains were isolated as follows. A 0.5 M solution of EDTA at pH 7.4 was added to Mono Q™-purified porcine factor VIII to a final concentration of 0.05 M and was allowed to stand at room temperature for 18-24 h. An equal volume of 10 mM histidine-Cl, 10 mM EDTA, 0.2% v/v Tween 80, at pH 6.0 (Buffer B), was added, and the solution was applied at 1 ml/min to a Mono S™ HR 5/5 column previously equilibrated in Buffer A plus 0.25 M NaCl. Factor VIII heavy chains did not bind the resin, as judged by SDS-PAGE. Factor VIII light chain was eluted with a linear, 20 ml, 0.1-0.7 M NaCl gradient in Buffer A at 1 ml/min and was homogeneous by SDS-PAGE. Factor VIII heavy chains were isolated by mono Q™ HPLC (Pharmacia, Inc., Piscataway, N.J.) in the following way. Factor VIII heavy chains do not adsorb to mono S™ during the purification of factor VIII light chains. The fall-through material that contained factor VIII heavy chains was adjusted to pH 7.2 by addition of 0.5 M Hepes buffer, pH 7.4, and applied to a mono Q™ HR5/5 HPLC column (Pharmacia, Inc.) equilibrated in 0.1 M

5

NaCl, 0.02 M Hepes, 0.01% Tween-80, pH 7.4. The column was washed with 10 ml of this buffer, and factor VIII heavy chains were eluted with a 20 ml 0.1-1.0 M NaCl gradient in this buffer. Human light chains and heavy chains were isolated in the same manner.

10

15

20

25

30

35

Human and porcine light and heavy chains were reconstituted according to the following steps. Ten  $\mu$ l human or porcine factor VIII light chain, 100  $\mu$ g/ml, was mixed in 1 M NaCl, 0.02 M Hepes, 5 mM CaCl<sub>2</sub>, 0.01% Tween-80, pH 7.4, with (1) 25  $\mu$ l heterologous heavy chain, 60  $\mu$ g/ml, in the same buffer; (2) 10  $\mu$ l 0.02 M Hepes, 0.01% Tween-80, pH 7.4; (3) 5  $\mu$ l 0.6 M CaCl<sub>2</sub>, for 14 hr at room temperature. The mixture was diluted 1/4 with 0.02 M MES, 0.01% Tween-80, 5 mM CaCl<sub>2</sub>, pH 6 and applied to Mono S™ Hr5/5 equilibrated in 0.1 M NaCl, 0.02 M MES, 0.01% Tween-80, 5 mM CaCl<sub>2</sub>, pH 6.0. A 20 ml gradient was run from 0.1 - 1.0 M NaCl in the same buffer at 1 ml/min, and 0.5 ml fractions were collected. Absorbance was read at 280 nm of fractions, and fractions were assayed with absorbance for factor VIII activity by the one-stage clotting assay. Heavy chains were present in excess, because free light chain (not associated with heavy chain) also binds Mono S™; excess heavy chains ensure that free light chains are not part of the preparation. Reconstitution experiments followed by Mono S™ HPLC purification were performed with all four possible combinations of chains: human light chain/human heavy chain, human light chain/porcine heavy chain, porcine light chain/porcine heavy chain, porcine light chain/human heavy chain. Table III shows that human light chain/porcine heavy chain factor VIII has activity comparable to native porcine factor VIII (Table II), indicating that structural elements in the porcine heavy chain are responsible for the increased coagulant activity of porcine factor VIII compared to human factor VIII.

TABLE III: COMPARISON OF HYBRID HUMAN/PORCINE FACTOR VIII COAGULANT ACTIVITY WITH HUMAN AND PORCINE FACTOR VIII

	Activity (U/A <sub>280</sub> )
	Porcine light chain/porcine heavy chain 30,600
	Human light chain/porcine heavy chain 44,100
	Porcine light chain/human heavy chain 1,100
10	Human light chain/human heavy chain 1,000

Example 5: Preparation of active hybrid human/porcine factor VIII by reconstitution with domains.

The porcine A1/A3-C1-C2 dimer, the porcine A2 domain, the human A1/A3-C1-C2 dimer, and the human A2 domain were each isolated from porcine or human blood, according to the method described in Lollar et al. (1992) *J. Biol. Chem.* 267(33):23652-23657. For example, to isolate the porcine A1/A3-C1-C2 dimer, porcine factor VIIIa (140 µg) at pH 6.0 was raised to pH 8.0 by addition of 5 N NaOH for 30 minutes, producing dissociation of the A2 domain and 95 percent inactivation by clotting assay. The mixture was diluted 1:8 with buffer B (20 mM HEPES, 5 mM CaCl<sub>2</sub>, 0.01% Tween-80, pH 7.4) and applied to a monoS column equilibrated in buffer B. The A1/A3-C1-C2 dimer eluted as a single sharp peak at approximately 0.4 M NaCl by using a 0.1-1.0 M NaCl gradient in buffer B. To isolate the porcine A2 domain, porcine factor VIIIa was made according to the method of Lollar et al. (1989) *Biochem* 28:666-674, starting with 0.64 mg of factor VIII. Free porcine A2 domain was isolated as a minor component (50 µg) at 0.3 M NaCl in the MonoS™ chromatogram.

Hybrid human/porcine factor VIII molecules were reconstituted from the dimers and domains as follows. The concentrations and buffer conditions for the purified components were as follows: porcine A2, 0.63 µM in buffer A

(5 mM MES; 5 mM CaCl<sub>2</sub>, 0.01% Tween 80, pH 6.0) plus 0.3 M NaCl; porcine A1/A3-C1-C2, 0.27 μM in buffer B plus 0.4 M NaCl, pH 7.4; human A2, 1 μM in 0.3 M NaCl, 10 mM histidine-HCl, 5 mM CaCl<sub>2</sub>, 0.01% Tween 20, pH 6.0; human A1/A3-C1-C2, 0.18 μM in 0.5 M NaCl, 10 mM histidine-Cl, 2.5 mM CaCl<sub>2</sub>, 0.1% Tween-20, pH 6.0. Reconstitution experiments were done by mixing equal volumes of A2 domain and A1/A3-C1-C2 dimer. In mixing experiments with porcine A1/A3-C1-C2 dimer, the pH was lowered to 6.0 by addition of 0.5 M MES, pH 6.0, to 70 mM.

The coagulation activities of all four possible hybrid factor VIIIa molecules - [pA2/(hA1/A3-C1-C2)], [hA2/(pA1/A3-C1-C2)], [pA2/(pA1/pA3-C1-C2)], and [hA2/(hA1/A3-C1-C2)] - were obtained by a two-stage clotting assay at various times.

The generation of activity following mixing the A2 domains and A1/A3-C1-C2 dimers was nearly complete by one hour and was stable for at least 24 hours at 37°C. Table IV shows the activity of reconstituted hybrid factor VIIIa molecules when assayed at 1 hour. The two-stage assay, by which the specific activities of factor VIIIa molecules were obtained, differs from the one-stage assay, and the values cannot be compared to activity values of factor VIII molecules obtained by a one-stage assay.

TABLE IV: COMPARISON OF COAGULANT ACTIVITIES OF DOMAIN-SUBSTITUTED HYBRID HUMAN/PORCINE FACTOR VIIIa

	<u>Hybrid fVIIIa</u>	<u>Specific Activity (U/mg)</u>
30	Porcine A2 + Human A1/A3-C1-C2	140,000
35	Porcine A2 + Porcine A1/A3-C1-C2	70,000
40	Human A2 + Porcine A1/A3-C1-C2	40,000
	Human A2 + Human A1/A3-C1-C2	40,000

Table IV shows that the greatest activity was exhibited by the porcine A2 domain/human A1/A3-C1-C2 dimer, followed by the porcine A2 domain/porcine A1/A3-C1-C2 dimer.

5

Thus, when the A2 domain of porcine factor VIIIa was mixed with the A1/A3-C1-C2 dimer of human factor VIIIa, coagulant activity was obtained. Further, when the A2 domain of human factor VIIIa was mixed with the A1/A3-C1-C2 dimer of porcine factor VIIIa, coagulant activity was obtained. By themselves, the A2, A1, and A3-C1-C2 regions have no coagulant activity.

10

Example 6: *Isolation and sequencing of the A2 domain of porcine factor VIII.*

15

Only the nucleotide sequence encoding the B domain and part of the A2 domain of porcine factor VIII has been sequenced previously [Toole et al. (1986) *Proc. Natl. Acad. Sci. USA* 83:5939-5942]. The cDNA and predicted amino acid sequences (SEQ ID NOs: 3 and 4, respectively) for the entire porcine factor VIII A2 domain are disclosed herein.

20

The porcine factor VIII A2 domain was cloned by reverse transcription of porcine spleen total RNA and PCR amplification; degenerate primers based on the known human factor VIII cDNA sequence and an exact porcine primer based on a part of the porcine factor VIII sequence were used. A 1 kb PCR product was isolated and amplified by insertion into a Bluescript™ (Stratagene) phagemid vector.

25

The porcine A2 domain was completely sequenced by dideoxy sequencing. The cDNA and predicted amino acid sequences are as described in SEQ ID NOs: 3 and 4, respectively.

30

35

Example 7: Preparation of recombinant hybrid human/animal factor VIII

The nucleotide and predicted amino acid sequences (SEQ ID NOs: 1 and 2, respectively) of human factor VIII have been described in the literature [Toole et al. (1984) *Nature* 312:342-347 (Genetics Institute); Gitschier et al. *Nature* 312:326-330 (Genentech); Wood, et al. (1984) *Nature* 312:330-337 (Genentech); Vehar et al. *Nature* 312:337-342 (Genentech)].

10

Making recombinant hybrid human/animal factor VIII requires that a region of human factor VIII cDNA (Biogen Corp.) be removed and the animal cDNA sequence having sequence identity be inserted. Subsequently, the hybrid cDNA is expressed in an appropriate expression system. As an example, hybrid factor VIII cDNAs were cloned in which some or all of the porcine A2 domain was substituted for the corresponding human A2 sequences. Initially, the entire cDNA sequence corresponding to the A2 domain of human factor VIII and then a smaller part of the A2 domain was looped out by oligonucleotide-mediated mutagenesis, a method commonly known to those skilled in the art (see, e.g., Sambrook, J., E.F. Fritsch, and T. Maniatis, Molecular Cloning: A Laboratory Manual, Chapter 15, Cold Spring Harbor Press, Cold Spring Harbor, 1989). The steps were as follows.

15

20

25

Materials.

Methoxycarbonyl-D-cyclohexylglycyl-glycl-arginine-p-nitroanilide (Spectrozyme™ Xa) and anti-factor VIII monoclonal antibodies ESH4 and ESH8 were purchased from American Diagnostics (Greenwich, CT). Unilamellar phosphatidylcholine/phosphatidylserine (75/25, w/w) vesicles were prepared according to the method of Barenholz, Y., et al., 16 Biochemistry 2806-2810 (1977)). Recombinant desulfatohirudin was obtained from Dr. R. B. Wallis, Ciba-Geigy Pharmaceuticals (Cerritos, CA). Porcine factors IXa, X,

30

35

Xa, and thrombin were isolated according to the methods of Lollar et al. (1984) *Blood* 63:1303-1306, and Duffy, E.J. et al. (1992) *J. Biol. Chem.* 267:7621-7827. Albumin-free pure recombinant human factor VIII was obtained from Baxter-Biotech (Deerfield, IL).

5

Cloning of the porcine factor VIII A2 domain.

The cDNA encoding the porcine A2 domain was obtained following PCR of reverse-transcribed porcine spleen mRNA isolated as described by Chomczyneki et al. (1987) *Anal. Biochem.* 162:156-159. cDNA was prepared using the first-strand cDNA synthesis kit with random hexamers as primers (Pharmacia, Piscataway, N.J.). PCR was carried out using a 5'-terminal degenerate primer 5' AARCAYCCNAARACNTGGG 3' (SEQ ID NO:11), based on known limited porcine A2 amino acid sequence, and a 3'-terminal exact primer, 5' GCTCGCACTAGGGGTCTTGAATTC 3' (SEQ ID NO:12), based on known porcine DNA sequence immediately 3' of the porcine A2 domain. These oligonucleotides correspond to nucleotides 1186-1203 and 2289-2313 in the human sequence (SEQ ID NO:1). Amplification was carried out for 35 cycles (1 minute 94°C, 2 minutes 50°C, 2 minutes 72°C) using Taq DNA polymerase (Promega Corp., Madison, WI). The 1.1-kilobase amplified fragment was cloned into pBluescript II KS- (Stratagene) at the EcoRV site using the T-vector procedure, as described by Murchuk, D. et al. (1991) *Nucl. Acids Res.* 19:1154. *Escherichia coli* XL1-Blue-competent cells were transformed, and plasmid DNA was isolated. Sequencing was carried out in both directions using Sequenase™ version 2.0 (U.S. Biochemical Corp., a Division of Amersham LifeScience, Inc., Arlington Hts, IL). This sequence was confirmed by an identical sequence that was obtained by direct sequencing of the PCR product from an independent reverse transcription of spleen RNA from the same pig (CircumVent™, New England Biolabs, Beverly, MA). The region containing the epitope for

autoantibody RC was identified as 373-536 in human factor VIII (SEQ ID NO:2).

5                   Construction and expression of a hybrid human/porcine factor VIII cDNA.

B-domainless human factor VIII (HB<sup>-</sup>, from Biogen, Inc. Cambridge, MA), which lacks sequences encoding for amino acid residues 741-1648 (SEQ ID NO:2), was used as the starting material for construction of a hybrid human/porcine factor VIII. HB<sup>-</sup> was cloned into the expression vector ReNeo. To facilitate manipulation, the cDNA for factor VIII was isolated as a XbaI/HpaI fragment from ReNeo and cloned into XbaI/EcoRV digested pBlueScript II KS. An oligonucleotide, 5' CCTTCCTTATCCAAATACGTAGATCAAGAGGAAATTGAC 3' (SEQ ID NO:7), was used in a site-directed mutagenesis reaction using uracil-containing phage DNA, as described by Kunkel, T.A. et al. (1991) *Meth. Enzymol.* 204:125-139, to simultaneously loop-out the human A2 sequence (nucleotides 1169-2304 in SEQ ID NO:1) and introduce a SnaBI restriction site. The A2-domainless human factor VIII containing plasmid was digested with SnaBI followed by addition of ClaI linkers. The porcine A2 domain was then amplified by PCR using the phosphorylated 5' primer 5' GTAGCGTTGCCAAGAACCCCTAAGACG 3' (SEQ ID NO:8) and 3' primer 5' GAAGAGTAGTACGAGTTATTCTCTGGGTTCAATGAC 3' (SEQ ID NO:9), respectively. ClaI linkers were added to the PCR product followed by ligation into the human factor VIII-containing vector. The A1/A2 and A2/A3 junctions were corrected to restore the precise thrombin cleavage and flanking sequences by site-directed mutagenesis using the oligonucleotide shown in SEQ ID NO:8 and nucleotides 1-22 (5' GAA . . . TTC in SEQ ID NO:9) to correct the 5'- and 3'- terminal junctions, respectively. In the resulting construct, designated HP1, the human A2 domain was exactly substituted with the porcine A2 domain. A preliminary product contained an unwanted thymine at the A1-A2 junction as a result of the

PCR amplification of the porcine A2 domain. This single base was looped out by use of the mutagenic oligonucleotide 5' CCTTTATCCAAATACGTAGCGTTGCCAAGAAG 3' (SEQ ID NO:10). The resulting hybrid nucleotide sequence encoded active factor VIII having human A1, porcine A2 and human A3, C1 and C2 domains.

A region containing 63% of the porcine NH<sub>2</sub>-terminal A2 domain, which encompasses the putative A2 epitope, was substituted for the homologous human sequence of B-domainless cDNA by exchanging *SpeI/BamHI* fragments between the pBluescript plasmids containing human factor VIII and human/porcine A2 factor VIII cDNA. The sequence was confirmed by sequencing the A2 domain and splice sites. Finally, a *SpeI/ApaI* fragment, containing the entire A2 sequence, was substituted in place of the corresponding sequence in HB<sup>-</sup>, producing the HP2 construct.

Preliminary expression of HB<sup>-</sup> and HP2 in COS-7 cells was tested after DEAE-dextran-mediated DNA transfection, as described by Seldon, R.F., in Current Protocols in Molecular Biology (Ausubel, F.M., et al., eds), pp. 9.21-9.26, Wiley Interscience, N.Y. After active factor VIII expression was confirmed and preliminary antibody inhibition studies were done, HB<sup>-</sup> and HP2 DNA were then stably transfected into baby hamster kidney cells using liposome-mediated transfection (Lipofectin® Life Technologies, Inc., Gaithersburg, MD). Plasmid-containing clones were selected for G418 resistance in Dulbecco's modified Eagle's medium-F12, 10% fetal calf serum (DMEM-F12/10% fetal calf serum) containing 400 µg/ml G418, followed by maintenance in DMEM-F12/10% fetal calf serum containing 100 µg/ml G418. Colonies showing maximum expression of HB<sup>-</sup> and HP2 factor VIII activity were selected by ring cloning and expanded for further characterization.

HB<sup>-</sup> and HP2 factor VIII expression was compared by plasma-free factor VIII assay, one-stage clotting assay, and enzyme-linked immunosorbent assay using purified recombinant human factor VIII as a standard. Specific coagulant activities of 2600 and 2580 units/mg were obtained for HB<sup>-</sup> and HP2, respectively. HB<sup>-</sup> and HP2 produced 1.2 and 1.4 units/ml/48 hours/10<sup>7</sup> cells, respectively. This is identical to that of the wild type construct (2,600 ± 200 units/mg). The specific activities of HB<sup>-</sup> and HP2 were indistinguishable in the plasma-free factor VIII assay.

The biological activity of recombinant hybrid human/animal and equivalent factor VIII with A1, A2, A3, C1, and/or C2 domain substitutions can be evaluated initially by use of a COS-cell mammalian transient expression system. Hybrid human/animal and equivalent cDNA can be transfected into COS cells, and supernatants can be analyzed for factor VIII activity by use of one-stage and two-stage coagulation assays as described above. Additionally, factor VIII activity can be measured by use of a chromogenic substrate assay, which is more sensitive and allows analysis of larger numbers of samples. Similar assays are standard in the assay of factor VIII activity [Wood et al. (1984) *Nature* 312:330-337; Toole et al. (1984) *Nature* 312:342-347]. Expression of recombinant factor VIII in COS cells is also a standard procedure [Toole et al. (1984) *Nature* 312:342-347; Pittman et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:2429-2433].

The human factor VIII cDNA used as starting materials for the recombinant molecules described herein has been expressed in COS cells yielding a product with biological activity. This material, as described above, can be used as a standard to compare hybrid human/animal factor VIII molecules. The activity in the assays is converted to a specific activity for proper comparison of the hybrid molecules. For this, a measurement of the mass of factor VIII produced by the cells

is necessary and can be done by immunoassay with purified human and/or animal factor VIII as standards. Immunoassays for factor VIII are routine for those skilled in the art [See, e.g., Lollar et al. (1988) *Blood* 71:137-143].

5

*Example 8.* *Determination of inhibitory activity in hybrid human/animal and equivalent factor VIII.*

Sequences of human and animal factor VIII likely to be involved as epitopes (i.e., as recognition sites for inhibitory antibodies that react with factor VIII) can be determined using routine procedures, for example through use of assay with antibodies to factor VIII combined with site directed mutagenesis techniques such as splicing by overlap extension methods (SOE), as shown below. Sequences of animal factor VIII that are not antigenic compared to corresponding antigenic human sequences can be identified, and substitutions can be made to insert animal sequences and delete human sequences according to standard recombinant DNA methods. Sequences of amino acids such as alanine residues having no known sequence identity to factor VIII can also be substituted by standard recombinant DNA methods or by alanine scanning mutagenesis. Porcine factor VIII reacts less than human factor VIII with some inhibitory antibodies; this provides a basis for current therapy for patients with inhibitors. After the recombinant hybrids are made, they can be tested *in vitro* for reactivity with routine assays, including the Bethesda inhibitor assay. Those constructs that are less reactive than native human factor VIII and native animal factor VIII are candidates for replacement therapy.

The epitopes to which most, if not all, inhibitory antibodies reactive with human factor VIII are directed are thought to reside in two regions in the 2332 amino acid human factor VIII molecule, the A2 domain (amino acid residues 373-740) and the C2 domain (amino acid residues 2173-2332, both

sequences shown in SEQ ID NO:2). The A2 epitope has been eliminated by making a recombinant hybrid human-porcine factor VIII molecule in which part of the human A2 domain is replaced by the porcine sequence having sequence identity to the replaced human amino acid sequence. This was accomplished, as described in example 7, by cloning the porcine A2 domain by standard molecular biology techniques and then cutting and splicing within the A2 domain using restriction sites. In the resulting construct, designated HP2, residues 373-604 (SEQ ID NO:4) of porcine factor VIII were substituted into the human A2 domain. HP2 was assayed for immunoreactivity with anti-human factor VIII antibodies using the following methods.

15           Factor VIII enzyme-linked immunosorbent assay.

Microtiter plate wells were coated with 0.15 ml of 6 µg/ml ESH4, a human factor VIII light-chain antibody, and incubated overnight. After the plate was washed three times with H<sub>2</sub>O, the wells were blocked for 1 hour with 0.15 M NaCl, 20 10 mM sodium phosphate, 0.05% Tween 20, 0.05% nonfat dry milk, 0.05% sodium azide, pH 7.4. To increase sensitivity, samples containing factor VIII were activated with 30 nM thrombin for 15 minutes. Recombinant desulfatohirudin then was added at 100 nM to inhibit thrombin. The plate was washed again and 25 0.1 ml of sample or pure recombinant human factor VIII (10-600 ng/ml), used as the standard, were added. Following a 2 hour incubation, the plate was washed and 0.1 ml of biotinylated ESH8, another factor VIII light-chain antibody, was added to each well. ESH8 was biotinylated using the Pierce 30 sulfosuccinimidyl-6-(biotinamide)hexanoate biotinylation kit. After a 1 hour incubation, the plate was washed and 0.1 ml of strepavidin alkaline phosphatase was added to each well. The plate was developed using the Bio-Rad alkaline phosphatase 35 substrate reagent kit, and the resulting absorbance at 405 nm for each well was determined by using a Vmax microtiter plate reader (Molecular Devices, Inc., Sunnyville, CA). Unknown

factor VIII concentrations were determined from the linear portion of the factor VIII standard curve.

Factor VIII assays.

HB<sup>-</sup> and HP2 factor VIII were measured in a one-stage clotting assay, which was performed as described above [Bowie, E.J.W., and C.A. Owen, in Disorders of Hemostasis (Ratnoff and Forbes, eds) pp. 43-72, Grunn & Stratton, Inc., Orlando, FL (1984)], or by a plasma-free assay as follows. HB<sup>-</sup> or HP2 factor VIII was activated by 40 nM thrombin in 0.15 M NaCl, 20 nM HEPES, 5 mM CaCl<sub>2</sub>, 0.01% Tween 80, pH 7.4, in the presence of 10 nM factor IXa, 425 nM factor X, and 50 μM unilamellar phosphatidylserine/phosphatidylcholine (25/75, w/w) vesicles. After 5 minutes, the reaction was stopped with 0.05 M EDTA and 100 nM recombinant desulfatohirudin, and the resultant factor Xa was measured by chromogenic substrate assay, according to the method of Hill-Eubanks et al (1990) *J. Biol. Chem.* 265:17854-17858. Under these conditions, the amount of factor Xa formed was linearly proportional to the starting factor VIII concentration as judged by using purified recombinant human factor VIII (Baxter Biotech, Deerfield, IL) as the standard.

Prior to clotting assay, HB<sup>-</sup> or HP2 factor VIII were concentrated from 48 hour conditioned medium to 10-15 units/ml by heparin-Sepharose™ chromatography. HB<sup>-</sup> or HP2 factor VIII were added to hemophilia A plasma (George King Biomedical) to a final concentration of 1 unit/ml. Inhibitor titers in RC or MR plasma or a stock solution of mAb 413 IgG (4 μM) were measured by the Bethesda assay as described by Kasper, C.K. et al. (1975) *Thromb. Diath. Haemorrh.* 34:869-872. Inhibitor IgG was prepared as described by Leyte, A. et al. (1991) *J. Biol. Chem.* 266:740-746.

HP2 does not react with anti-A2 antibodies. Therefore, residues 373-603 must contain an epitope for anti-A2 antibodies.

5           Preparation of hybrid human-porcine factor VIII and assay by splicing by overlap extension (SOE).

Several more procoagulant recombinant hybrid human/porcine factor VIII B-domainless molecules with porcine amino acid substitutions in the human A2 region have been prepared to further narrow the A2 epitope. Besides restriction site techniques, the "splicing by overlap extension" method (SOE) as described by Ho et al. (1989) Gene 77:51-59, has been used to substitute any arbitrary region of porcine factor VIII cDNA. In SOE, the splice site is defined by overlapping oligonucleotides that can be amplified to produce the desired cDNA by PCR. Ten cDNA constructs, designated HP4 through HP13, have been made. They were inserted into the ReNeo expression vector, stably transfected into baby hamster kidney cells, and expressed to high levels [0.5-1 µg (approximately 3-6 units)/10<sup>7</sup> cells/24 hours] as described in Example 7. Factor VIII coagulant activity was determined in the presence and absence of a model murine monoclonal inhibitory antibody specific for the A2 domain, mAb413. In the absence of inhibitor, all of the constructs had a specific coagulant activity that was indistinguishable from B(-) human factor VIII.

30           The hybrid human/porcine factor VIII constructs were assayed for reactivity with the anti-A2 inhibitor mAb413 using the Bethesda assay [Kasper et al. (1975) *Thromb. Diath. Haemorrh.* 34:869-872]. The Bethesda unit (BU) is the standard method for measuring inhibitor titers. The results are shown in Table V, and are compared to recombinant human factor VIII.

TABLE V: COMPARISON OF IMMUNOREACTIVITY OF AMINO ACID-SUBSTITUTED HYBRID HUMAN/PORCINE FACTOR VIII

	Construct	Porcine Substitution	Inhibition mAb413 (BU/mg IgG)
5	Human B(-) fVIII	None	1470
	HP4	373-540	<0.7
10	HP5	373-508	<0.7
	HP6	373-444	1450
	HP7	445-508	<0.7
	HP8	373-483	1250
15	HP9	484-508	<0.7
	HP10	373-403	1170
	HP11	404-508	<0.7
	HP12	489-508	<0.7
	HP13	484-488	<0.7

The boundaries of porcine substitutions are defined by the first amino acids that differ between human and porcine factor VIII at the NH<sub>2</sub>-terminal and C-terminal ends of the insertion. As shown in Table V, if the Bethesda titer is not measurable (<0.7 BU/mg IgG), then an A2 epitope lies in the region of substituted porcine sequence. The epitope has been progressively narrowed to residues 484-509 (SEQ ID NO:2), consisting of only 25 residues, as exemplified by non-reactivity of mAb413 with HP9. Among constructs HP4 through HP11, HP9 was the most "humanized" construct that did not react with the inhibitor. This indicates that a critical region in the A2 epitope is located within the sequence Arg484-Ile508.

Based on a comparison between human and porcine factor VIII of the amino acid sequence in this critical region, two more constructs, HP12 and HP13, were made, in which corresponding porcine amino acid sequence was substituted for human amino acids 489-508 and 484-488, respectively. Neither reacts with mAb413. This indicates that residues on each side of the Arg488-Ser489 bond are important for reaction with A2 inhibitors. In HP12 only 5 residues are non-human, and in HP13 only 4 residues are non-human. The 484-508, 484-488, and 489-508 porcine substituted hybrids displayed decreased

inhibition by A2 inhibitors from four patient plasmas, suggesting that there is little variation in the structure of the A2 epitope according to the inhibitor population response.

5       The reactivity of the most humanized constructs, HP9, HP12, and HP13, with two anti-A2 IgG5 preparations prepared from inhibitor plasmas was determined. Like mAb413, these antibodies did not react with HP9, HP12, and HP13, but did react with the control constructs HP(-) and HP8.

10      The region between 484-508 can be further analyzed for final identification of the critical A2 epitope, using the same procedures.

15      The methods described in Examples 7 and 8 can be used to prepare other hybrid human/non-porcine mammalian factor VIII with amino acid substitution in the human A2 or other domains, hybrid human/animal or animal/animal factor VIII with amino acid substitution in any domain, or hybrid factor VII equivalent molecules or fragments of any of these, such hybrid factor VIII having reduced or absent immunoreactivity with anti-factor VIII antibodies.

20      Example 9.    *Elimination of human factor VIII A2 inhibitor reactivity by site-directed mutagenesis*

25      Example 8 showed that substitution of the porcine sequence bounded by residues 484 and 508 into the human factor VIII A2 domain yields a molecule that has markedly decreased reactivity with a panel of A2-specific factor VIII inhibitors [see also Healey et al. (1995) *J. Biol. Chem.* 270:14505-14509]. In this region, there are 9 amino acid differences between human and porcine factor VIII. These nine residues in human B-domainless factor VIII, R484, P485, Y487, P488, R489, P492, V495, F501, and I508 (using the single letter amino code), were individually changed to alanine by site-directed

5

mutagenesis. Additionally, *Mlu*1 and *Sac*2 restriction sites were placed in the factor VIII cDNA at sites 5' and 3' relative to the A2 epitope, without changing the amino acids corresponding to these sites, to facilitate cloning. The nine mutants were stably transfected into baby hamster kidney cells and expressed to high levels. All nine produced biologically active factor VIII. They were partially purified and concentrated by heparin-Sepharose chromatography as described by Healey et al.

10

15

20

25

The mutants have been characterized by their reactivity with the murine monoclonal inhibitor MAb413 as in Example 7. This inhibitor recognizes the same or a very closely clustered epitope in the A2 domain as all human inhibitors studied to date. Inhibitor reactivity was measured using the Bethesda assay. Briefly, the Bethesda titer of an inhibitor is the dilution of inhibitor that inhibits factor VIII by 50% in a standard one-stage factor VIII clotting assay. For example, if solution of antibody is diluted 1/420 and it inhibits the recombinant factor VIII test sample by 50%, the Bethesda titer is 420 U. In the case of a pure monoclonal like MAb413, the mass of antibody is known, so the results are expressed in Bethesda units (BU) per mg MAb413. To find the 50% inhibition point, a range of dilutions of MAb413 was made and 50% inhibition was found by a curve fitting procedure. The results are as follows:

Table VI

	<u>Mutation</u>	<u>MAb413 titer (BU/mg)</u>	<u>%</u>
	<u>Reactivity*</u>		
5	Wild-type, B(-)fVIII	9400	--
	484 → A	160	1.7
	P485 → A	4000	42
	Y487 → A	50	0.53
	P488 → A	3500	37
10	R489 → A	1.6	0.015
	R490 → A	<-->	<0.2>
	P492 → A	630	6.7
	V495 → A	10700	113
	F501 → A	11900	126
15	I508 → A	5620	60

\* Relative to wild-type

These results indicate that it is possible to reduce the antigenicity of factor VIII toward the model A2 inhibitor by over a factor of 10 by making alanine substitutions at positions 484, 487, 489, and 492. The reactivity of R489 → A is reduced by nearly 4 orders of magnitude. Any of these alanine substitutions can be therapeutically useful to reduce the antigenicity and the immunogenicity of factor VIII.

The results confirm the efficacy of alanine-scanning mutagenesis and further demonstrate that biological activity is retained even though the amino acid sequence has been altered within an epitope reactive to an inhibitory antibody. Five of the nine sites where the human and porcine sequences differ are also sites where the human and murine sequences differ. The factor VIIIs having alanine substitutions at these positions are therefore examples of a hybrid factor VIII equivalent molecule having a sequence with no known sequence identify with any presently known mammalian factor VIII.

Further modification, e.g. by combining two alanine substitutions, can also provide greatly reduced antigenicity for a wider range of patients, since polyclonal variant antibodies differing from patient to patient can react with variants of the factor VIII A2 epitope. In addition,

immunogenicity (the capacity to induce antibodies) is further reduced by incorporation of more than one amino acid substitution. Such substitutions can include both alanine, porcine-specific amino acids, or other amino acids known to have low immunogenic potential. The substitutions at positions 490, 495 and 501 are likely to be useful in reducing immunogenicity. In addition, these substitutions are likely to reduce reactivity to certain patient antibodies.

Other effective, antigenicity-reducing amino acid substitutions, besides alanine, can be made as long as care is taken to avoid those previously noted as being major contributors to antigen-antibody binding energy, or having bulky or charged side chains. Amino acids whose substitutions within an epitope reduce the antigenic reactivity thereof are termed "immunoreactivity-reducing" amino acids herein. Besides alanine, other immunoreactivity-reducing amino acids include, without limitation, methionine, leucine, serine and glycine. It will be understood that the reduction of immunoreactivity achievable by a given amino acid will also depend on any effects the substitution may have on protein conformation, epitope accessibility and the like.

*Example 10.*

Klenow fragment, phosphorylated ClaI linkers, NotI linkers, T4 ligase, and Taq DNA polymerase were purchased from Promega (Madison, Wisconsin). Polynucleotide kinase was purchased from Life Technologies, Inc., Gaithersburg, Maryland.  $\gamma^{32}\text{P}$ -ATP (Redivue, >5000Ci/mmol) was purchased from Amersham. pBluescript II KS- and *E. coli* Epicurean XL1-Blue cells were purchased from Stratagene (La Jolla, California). Synthetic oligonucleotides were purchased from Life Technologies, Inc. or Cruachem, Inc. 5'-phosphorylated primers were used when PCR products were produced for cloning purposes. Nucleotide (nt) numbering of oligonucleotides used as primers for polymerase chain reaction (PCR) amplification

of porcine fVIII cDNA or genomic DNA uses the human fVIII cDNA as reference (Wood et al. (1984) *supra*).

5           Porcine spleen total RNA was isolated by acid guanidinium thiocyanate-phenol-chloroform extraction [Chomczynski et al. (1987) *Anal. Biochem.* 162:156-159]. Porcine cDNA was prepared from total spleen RNA using Moloney murine leukemia virus reverse transcriptase (RT) and random hexamers to prime the reaction (First-Strand cDNA Synthesis Kit, Pharmacia Biotech) unless otherwise indicated. RT reactions contained 45 mM Tris-Cl, pH 8.3, 68 mM KCl, 15 mM DTT, 9 mM MgCl<sub>2</sub>, 0.08 mg/ml bovine serum albumin and 1.8 mM deoxynucleotide triphosphate (dNTP). Porcine genomic DNA was isolated from spleen using a standard procedure (Strauss, W.M. (1995) In Current Protocols in Molecular Biology, F. M. Ausubel et al., editors, John Wiley & Sons, pp. 2.2.1-2.2.3). Isolation of DNA from agarose gels was done using Geneclean II (Bio 101) or Quiex II Gel Extraction Kit (Qiagen).

20           PCR reactions were done using a Hybaid OmniGene thermocycler. For PCR reactions employing Taq DNA polymerase, reactions included 0.6 mM MgCl<sub>2</sub>, 0.2 mM dNTPs, 0.5 μM oligonucleotide primers, 50 U/ml polymerase and 0.1 volume of first strand cDNA reaction mix. Except where indicated otherwise, PCR products were gel purified, blunt-ended with Klenow fragment, precipitated with ethanol, and either ligated to the EcoRV site of dephosphorylated pBluescript II KS- or ligated with phosphorylated ClaI linkers using T4 ligase, digested with ClaI, purified by Sephadryl S400 chromatography, and ligated to ClaI-cut, dephosphorylated pBluescript II KS-. Ligations were done using T4 DNA ligase (Rapid DNA ligation kit, Boehringer Mannheim) except where indicated otherwise. Insert-containing pBluescript II KS- plasmids were used to transform *E. coli* Epicurean XL1-Blue cells.

Sequencing of plasmid DNA was done using an Applied Biosystems 373a automated DNA sequencer and the PRISM dye terminator kit or manually using Sequenase v. 2.0 sequencing kit (Amersham Corporation). Direct sequencing of PCR products, including <sup>32</sup>P-end labelling of oligonucleotides was done using a cycle sequencing protocol (dsDNA Cycle Sequencing System, Life Technologies).

10 Isolation of porcine fVIII cDNA clones containing 5' UTR sequence, signal peptide and A1 domain codons.

15 The porcine fVIII cDNA 5' to the A2 domain was amplified by nested RT-PCR of female pig spleen total RNA using a 5' rapid amplification of cDNA ends (5'-RACE) protocol (Marathon cDNA Amplification, Clontech, Version PR55453). This included first strand cDNA synthesis using a lock-docking oligo(dT) primer [Borson, N.D. et al. (1992) *PCR Methods Appl.* 2:144-148], second strand cDNA synthesis using *E. coli* DNA polymerase I, and ligation with a 5' extended double stranded 20 adaptor, SEQ ID NO:13

5'-CTA ATA CGA CTC ACT ATA GGG CTC GAG CGG CCG CCC GGG CAG GT-  
3'

3'-H<sub>2</sub>N-CCCGTCCA-PO<sub>4</sub>-5'

25 whose short strand was blocked at the 3' end with an amino group to reduce non-specific PCR priming and which was complementary to the 8 nucleotides at the 3' end (Siebert, P.D., et al. (1995) *Nucleic Acids. Res.* 23:1087-1088). The first round of PCR was done using an adaptor-specific oligonucleotide, SEQ ID NO:14 5'-CCA TCC TAA TAC GAC TCA CTA 30 TAG GGC-3' (designated AP1) as sense primer, and a porcine fVIII A2 domain specific oligonucleotide SEQ ID NO:15 5'-CCA TTG ACA TGA AGA CCG TTT CTC-3' (nt 2081-2104) as antisense primer. The second round of PCR was done using a nested, adaptor-specific oligonucleotide, SEQ ID NO:16 5'-ACT CAC TAT 35 AGG GCT CGA GCG GC-3' (designated AP2) as sense primer, and a nested, porcine A2 domain-specific oligonucleotide SEQ ID NO:17 5'-GGG TGC AAA GCG CTG ACA TCA GTG-3' (nt 1497-1520) as antisense primer. PCR was carried out using a commercial kit

(Advantage cDNA PCR core kit) which employs an antibody-mediated hot start protocol [Kellogg, D.E. et al. (1994) *BioTechniques* 16:1134-1137]. PCR conditions included denaturation at 94°C for 60 sec, followed by 30 cycles (first 5 PCR) or 25 cycles (second PCR) of denaturation for 30 sec at 94°C, annealing for 30 sec at 60°C and elongation for 4 min at 68°C using tube temperature control. This procedure yielded a prominent ≈1.6 kb product which was consistent with amplification of a fragment extending approximately 150 bp 10 into the 5' UTR. The PCR product was cloned into pBluescript using ClaI linkers. The inserts of four clones were sequenced in both directions.

The sequence of these clones included regions 15 corresponding to 137 bp of the 5' UTR, the signal peptide, the A1 domain and part of the A2 domain. A consensus was reached in at least 3 of 4 sites. However, the clones contained an average of 4 apparent PCR-generated mutations, presumably due to the multiple rounds of PCR required to generate a clonable 20 product. Therefore, we used sequence obtained from the signal peptide region to design a sense strand phosphorylated PCR primer, SEQ ID NO:18 5'-CCTCTC GAG CCA CCA TGT CGA GCC ACC ATG CAG CTA GAG CTC TCC ACC TG-3', designated RENEOPIGSP, for synthesis of another PCR product to confirm the sequence and 25 for cloning into an expression vector. The sequence in bold represents the start codon. The sequence 5' to this represents sequence identical to that 5' of the insertion site into the mammalian expression vector ReNeo used for expression of fVIII (Lubin et al. (1994) *supra*). This site includes an Xhol 30 cleavage site (underlined). RENEOPIGSP and the nt 1497-1520 oligonucleotide were used to prime a Taq DNA polymerase-mediated PCR reaction using porcine female spleen cDNA as a template. DNA polymerases from several other manufacturers failed to yield a detectable product. PCR conditions included 35 denaturation at 94°C for four min, followed by 35 cycles of denaturation for 1 min at 94°C, annealing for 2 min at 55°C

and elongation for 2 min at 72°C, followed by a final elongation step for 5 min at 72°C. The PCR product was cloned into pBluescript using ClaI linkers. The inserts of two of these clones were sequenced in both directions and matched the consensus sequence.

5

Isolation of porcine fVIII cDNA clones containing A3, C1 and 5' half of the C2 domain codons.

10       Initially, two porcine spleen RT-PCR products, corresponding to a B-A3 domain fragment (nt 4519-5571) and a C1-C2 domain fragment (nt 6405-6990) were cloned. The 3' end of the C2 domain that was obtained extended into the exon 26 region, which is the terminal exon in fVIII. The B-A3 product was made using the porcine-specific B domain primer, SEQ ID NO:19 5' CGC GCG GCC GCG CAT CTG GCA AAG CTG AGT T 3', where the underlined region corresponds to a region in porcine fVIII that aligns with nt 4519-4530 in human fVIII. The 5' region of the oligonucleotide includes a NotI site that was originally intended for cloning purposes. The antisense primer used in generating the B-A3 product, SEQ ID NO:20 5'-GAA ATA AGC CCA GGC TTT GCA GTC RAA-3' was based on the reverse complement of the human fVIII cDNA sequence at nt 5545-5571. The PCR reaction contained 50 mM KCl, 10 mM Tris-Cl, pH 9.0, 0.1% Triton X-100, 1.5 mM MgCl<sub>2</sub>, 2.5 mM dNTPs, 20 μM primers, 25 units/ml Taq DNA polymerase and 1/20 volume of RT reaction mix. PCR conditions were denaturation at 94°C for 3 min, followed by 30 cycles of denaturation for 1 min at 94°C, annealing for 2 min at 50°C and elongation for 2 min at 72°C. The PCR products were phosphorylated using T4 DNA kinase and NotI linkers were added. After cutting with NotI, the PCR fragments were cloned into the NotI site of BlueScript II KS- and transformed into XL1-Blue cells.

30       The C1-C2 product was made using the known human cDNA sequence to synthesize sense and antisense primers, SEQ ID NO:21 5'-AGG AAA TTC CAC TGG AAC CTT N-3' (nt 6405-6426) and

SEQ ID NO:22 5'-CTG GGG GTG AAT TCG AAG GTA GCG N-3' (reverse complement of nt 6966-6990), respectively. PCR conditions were identical to those used to generate the B-A2 product. The resulting fragment was ligated to the pNOT cloning vector 5 using the Prime PCR Cloner Cloning System (5 Prime-3 Prime, Inc., Boulder, Colorado) and grown in JM109 cells.

The B-A3 and C1-C2 plasmids were partially sequenced to make the porcine-specific sense and antisense 10 oligonucleotides, SEQ ID NO:23 5'-GAG TTC ATC GGG AAG ACC TGT TG-3' (nt 4551-4573) and SEQ ID NO:24 5'-ACA GCC CAT CAA CTC CAT GCG AAG-3' (nt 6541-6564), respectively. These 15 oligonucleotides were used as primers to generate a 2013 bp RT-PCR product using a Clontech Advantage cDNA PCR kit. This product, which corresponds to human nt 4551-6564, includes the region corresponding to the light chain activation peptide (nt 5002-5124), A3 domain (nt 5125-6114) and most of the C1 domain (nt 6115-6573). The sequence of the C1-C2 clone had 20 established that human and porcine cDNAs from nt 6565 to the 3' end of the C1 domain were identical. The PCR product cloned into the EcoRV site of pBluescript II KS-. Four clones were completely sequenced in both directions. A consensus was reached in at least 3 of 4 sites.

25 Isolation of porcine fVIII cDNA clones containing the 3'  
half of the C2 domain codons.

The C2 domain of human fVIII (nucleotides 6574-7053) is contained within exons 24-26 [Gitschier J. et al. (1984) 30 *Nature* 312:326-330]. Human exon 26 contains 1958 bp, corresponding nucleotides 6901-8858. It includes 1478 bp of 3' untranslated sequence. Attempts to clone the exon 26 cDNA corresponding to the 3' end of the C2 domain and the 3'UTR by 3' RACE [Siebert et al. (1995) *supra*], inverse PCR [Ochman, H. 35 et al. (1990) *Biotechnology (N.Y.)*. 8:759-760], restriction site PCR [Sarkar, G. et al. (1993) *PCR Meth. Appl.* 2:318-322], "unpredictably primed" PCR [Dominguez, O. et al. (1994)

Nucleic. Acids Res. 22:3247-3248] and by screening a porcine liver cDNA library failed. 3' RACE was attempted using the same adaptor-ligated double stranded cDNA library that was used to successfully used to clone the 5' end of the porcine fVIII cDNA. Thus, the failure of this method was not due to the absence of cDNA corresponding to exon 26.

A targeted gene walking PCR procedure [Parker, J.D. et al. (1991) Nucleic. Acids. Res. 19:3055-3060] was used to clone the 3' half of the C2 domain. A porcine-specific sense primer, SEQ ID NO:25 5'-TCAGGGCAATCAGGACTCC-3' (nt 6904-6924) was synthesized based on the initial C2 domain sequence and was used in a PCR reaction with nonspecific "walking" primers selected from oligonucleotides available in the laboratory. The PCR products were then targeted by primer extension analysis [Parker et al. (1991) BioTechniques 10:94-101] using a <sup>32</sup>P-end labelled porcine-specific internal primer, SEQ ID NO:26 5'-CCGTGGTGAACGCTCTGGACC-3' (nt 6932-6952). Interestingly, of the 40 nonspecific primers tested, only two yielded positive products on primer extension analysis and these two corresponded to an exact and a degenerate human sequence at the 3' end of the C2 domain: SEQ ID NO:27 5'-GTAGAGGT CCTGTGCCTCGCAGCC-3' (nt 7030-7053) and SEQ ID NO:28 5'-GTAGAGST S CTGKG C CT CRCAKCCYAG-3', (nt 7027-7053). These primers had initially been designed to yield a product by conventional RT-PCR but failed to yield sufficient product that could be visualized by ethidium bromide dye binding. However, a PCR product could be identified by the more sensitive primer extension method. This product was gel-purified and directly sequenced. This extended the sequence of porcine fVIII 3' to nt 7026.

Additional sequence was obtained by primer extension analysis of a nested PCR product generated using the adaptor-ligated double-stranded cDNA library used in the 5'-RACE protocol described previously. The first round reaction used

the porcine exact primer SEQ ID NO:29 5'-CTTCGCATGGAGTTGATGGGCTGT-3' (nt 6541-6564) and the AP1 primer. The second round reaction used SEQ ID NO:30 5'-AATCAGGACTCCTCCACCCCCG-3' (nt 6913-6934) and the AP2 primer.

5 Direct PCR sequencing extended the sequence 3' to the end of the C2 domain (nt 7053). The C2 domain sequence was unique except at nt 7045 near the 3' end of the C2 domain. Analysis of repeated PCR reactions yielded either A, G or a double read of A/G at this site.

10

Sequencing was extended into the 3'UTR using two additional primers, SEQ ID NO:31 5'-GGA TCC ACC CCA CGA GCT GG-3' (nt 6977-6996) and SEQ ID NO:32 5'-CGC CCT GAG GCT CGA GGT TCT AGG-3' (nt 7008-7031). Approximately 15 bp of 3' UTR sequence were obtained, although the sequence was unclear at several sites. Several antisense primers then were synthesized based on the best estimates of the 3' untranslated sequence. These primers included the reverse complement of the TGA stop codon at their 3' termini. PCR products were obtained from both porcine spleen genomic DNA and porcine spleen cDNA that were visualized by agarose gel electrophoresis and ethidium bromide staining using a specific sense primer SEQ ID NO:33 5'-AAT CAG GAC TCC TCC ACC CCC G-3' (nt 6913-6934) and the 3' UTR antisense primer, SEQ ID NO:34 5'-CCTTGCAGGAATTGATTCA-3'. To obtain sufficient quantities of material for cloning purposes, a second round of PCR was done using a nested sense primer, SEQ ID NO:35 5'-CCGTGGTGAACGCTCTGGACC-3' (nt 6932-6952) and the same antisense primer. The 141 bp PCR product was cloned into EcoRV-cut pBluescript II KS-. Sequence of three clones derived from genomic DNA and three clones derived from cDNA was obtained in both directions. The sequence was unambiguous except at nt 7045, where genomic DNA was always A and cDNA was always G.

35

Multiple DNA sequence alignments of human, porcine, and mouse fVIII (Fig. 1A-1H).

Alignments of the signal peptide, A1, A2, A3, C1, and C2 regions were done using the CLUSTALW program [Thompson, J.D. et al. (1994) *Nucleic Acids. Res.* **22**:4673-4680]. Gap open and gap extension penalties were 10 and 0.05 respectively. The alignments of the human, mouse, and pig B domains have been described previously [Elder et al. (1993) *supra*]. The human A2 sequence corresponds to amino acids 373-740 in SEQ ID NO:2. The porcine A2 amino acid sequence is given in SEQ ID NO:4, and the mouse A2 domain amino acid sequence is given in SEQ ID NO:6, amino acids 392-759.

Example 11. Expression of active, recombinant B-domainless porcine factor VIII (PB<sup>-</sup>)

Materials

Citrated hemophilia A and normal pooled human plasmas were purchased from George King Biomedical, Inc. Fetal bovine serum, geneticin, penicillin, streptomycin, DMEM/F12 medium and AIM-V medium were purchased from Life Technologies, Inc. Taq DNA polymerase was purchased from Promega. Vent DNA polymerase was purchased from New England Biolabs. Pfu DNA polymerase and the phagemid pBlueScript II KS<sup>-</sup> were purchased from Stratagene. Synthetic oligonucleotides were purchased from Life Technologies or Cruachem, Inc. Restriction enzymes were purchased from New England Biolabs or Promega. 5'-phosphorylated primers were used when PCR products were produced for cloning purposes. Nucleotide (nt) numbering of oligonucleotides used as primers for polymerase chain reaction (PCR) amplification of porcine fVIII cDNA or genomic DNA uses the human fVIII cDNA as reference [Wood et al. (1984) *Nature* **312**:330-337]. A fVIII expression vector, designated HB<sup>-</sup>/ReNeo, was obtained from Biogen, Inc. HB<sup>-</sup>/ReNeo contains ampicillin and geneticin resistance genes and a human fVIII cDNA that lacks the entire B domain, defined as the Ser741-Arg1648

cleavage fragment produced by thrombin. To simplify mutagenesis of fVIII C2 domain cDNA, which is at the 3' end of the fVIII insert in ReNeo, a *NotI* site was introduced two bases 3' to the stop codon of HB<sup>-</sup>/ReNeo by splicing-by-overlap extension (SOE) mutagenesis [Horton, R.M. et al. (1993) *Methods Enzymol.* 217:270-279]. This construct is designated HB<sup>-</sup>ReNeo/*NotI*.

Total RNA was isolated by acid guanidinium thiocyanate-phenol-chloroform extraction [Chomczynski, P. et al. (1987) *Anal. Biochem.* 162:156-159]. cDNA was synthesized from mRNA using Moloney murine leukemia virus reverse transcriptase (RT) and random hexamers according to instructions supplied by the manufacturer (First-Strand cDNA Synthesis Kit, Pharmacia Biotech). Plasmid DNA was purified using a Qiagen Plasmid Maxi Kit (Qiagen, Inc.). PCR reactions were done using a Hybaid OmniGene thermocycler using *Taq*, *Vent*, or *Pfu* DNA polymerases. PCR products were gel purified, precipitated with ethanol, and ligated into plasmid DNA using T4 DNA ligase (Rapid DNA ligation kit, Boehringer Mannheim). Insert-containing plasmids were used to transform *E. coli* Epicurean XL1-Blue cells. All novel fVIII DNA sequences generated by PCR were confirmed by dideoxy sequencing using an Applied Biosystems 373a automated DNA sequencer and the PRISM dye terminator kit.

Construction of a hybrid fVIII expression vector, HP20, containing the porcine C2 domain.

A porcine fVIII cDNA corresponding to the 3' end of the C1 domain and all of the C2 domain was cloned into pBluescript by RT-PCR from spleen total RNA using primers based on known porcine fVIII cDNA sequence [Healy, J.F. et al. (1996) *Blood* 88:4209-4214]. This construct and HB<sup>-</sup>/ReNeo were used as templates to construct a human C1-porcine C2 fusion product in pBlueScript by SOE mutagenesis. The C1-C2 fragment in this

plasmid was removed with *ApaI* and *NotI* and ligated into *ApaI/NotI*-cut *HB<sup>-</sup>/ReNeo/NotI* to produce *HP20/ReNeo/NotI*.

5                   Construction of B-domain deleted hybrid human/porcine fVIII containing the porcine light chain (HP18) -

10                  The human fVIII light chain consists of amino acid residues Asp1649-Tyr2332. The corresponding residues in the porcine fVIII cDNA were substituted for this region of *HB<sup>-</sup>* to produce a hybrid human/porcine fVIII molecule designated HP18. This was done by substituting a PCR product corresponding to porcine A2 region, the A3 domain, the C1 domain, and part of the C2 domain for the corresponding region in HP20. To facilitate constructions, a synonymous *AvrII* site was 15 introduced into nt 2273 at the junction of the A2 and A3 domains of HP20 by SOE mutagenesis.

20                  Construction of B-domain deleted hybrid human/porcine fVIII containing the porcine signal peptide, A1 domain and A2 domain (HP22) -

25                  The human fVIII signal peptide, A1 domain and A2 domains consist of amino acid residues Met(-19)-Arg740. The corresponding residues in the porcine fVIII cDNA were substituted for this region of *HB<sup>-</sup>* to produce a molecule designated HP22. Additionally, a synonymous *AvrII* site was introduced into nt 2273 at the junction of the A2 and A3 30 domains of HP22 by SOE mutagenesis. HP22 was constructed by fusion of a porcine signal peptide-A1-partial A2 fragment in pBlueScript [Healy et al. (1996) *supra*] with a B-domainless hybrid human/porcine fVIII containing the porcine A2 domain, designated HP1 [Lubin et al. (1994) *supra*].

35                  Construction of porcine B domainless fVIII-(PB<sup>-</sup>)

                      A *SpeI/NotI* fragment of HP18/BS (+ *AvrII*) was digested with *AvrII/NotI* and ligated into *AvrII/NotI*-digested HP22/BS (+ *AvrII*) to produce a construct *PB<sup>-</sup>/BS (+ AvrII)*, which

consists of the porcine fVIII lacking the entire B domain. PB<sup>-</sup> was cloned into ReNeo by ligating an Xba/NotI fragment of PB<sup>-</sup>/BS (+ AvrII) into HP22/ReNeo/NotI (+ AvrII).

5

Expression of recombinant fVIII molecules

PB<sup>-</sup>/ReNeo/NotI (+ AvrII) and HP22/ReNeo/NotI (+AvrII) were transiently transfected into COS cells and expressed as described previously [Lubin, I.M. et al. (1994) *J. Biol. Chem.* 10 269:8639-8641]. HB<sup>-</sup>/ReNeo/NotI and no DNA (mock) were transfected as a control.

The fVIII activity of PB<sup>-</sup>, HP22, and HB<sup>-</sup> were measured by a chromogenic assay as follows. Samples of fVIII in COS cell culture supernatants were activated by 40 nM thrombin in a 15 0.15 M NaCl, 20 mM HEPES, 5Mm cAC12, 0.01% Tween-80, pH 7.4 in the presence of 10 nM factor IXa, 425 nM factor X, and 50 μM unilamellar phosphatidylserine-[phosphatidylcholine (25/75 w/w) vesicles. After 5 min, the reaction was stopped with 0.05 M EDTA and 100 nM recombinant desulfatohirudin and the resultant 20 factor Xa was measured by chromogenic substrate assay. In the chromogenic substrate assay, 0.4 mM Spectrozyme Xa was added and the rate of para-nitroanilide release was measured by measuring the absorbance of the solution at 405 nm.

25

Results of independently transfected duplicate cell culture supernatants (absorbance at 405 nm per minute)

30

HB<sup>-</sup>: 13.9  
PB<sup>-</sup>: 139  
HP22: 100  
mock: <0.2

35

These results indicate that porcine B-domainless fVIII and a B-domainless fVIII consisting of the porcine A1 and A2 subunits are active and suggest that they have superior activity to human B-domainless fVIII.

PB<sup>-</sup> was partially purified and concentrated from the growth medium by heparin-Sepharose chromatography. Heparin-Sepharose (10 ml) was equilibrated with 0.075 M NaCl, 10 mM HEPES, 2.5 mM CaCl<sub>2</sub>, 0.005% Tween-80, 0.02% sodium azide, pH 7.40. Medium (100-200 ml) from expressing cells was applied to the heparin-Sepharose, which then was washed with 30 ml of equilibration buffer without sodium azide. PB<sup>-</sup> was eluted with 0.65 M NaCl, 20 mM HEPES, 5 mM CaCl<sub>2</sub>, 0.01% Tween-80, pH 7.40 and was stored at -80 °C. The yield of fVIII coagulant activity was typically 50-75%.

Stable expression of porcine B-domainless fVIII (PB<sup>-</sup>)

Transfected cell lines were maintained in Dulbecco's modified Eagle's medium-F12 containing 10% fetal bovine serum, 50 U/ml penicillin, 50 µg/ml streptomycin. Fetal bovine serum was heat inactivated at 50°C for one hour before use. HB<sup>-</sup>/ReNeo and PB<sup>-</sup>ReNeo/NotI (+ AvrII) were stably transfected into BHK cells and selected for geneticin resistance using a general protocol that has been described previously [Lubin et al. (1994) *Biol. Chem.* **269**:8639-8641] except that expressing cells were maintained in growth medium containing 600 µg/ml geneticin. Cells from Corning T-75 flasks grown to confluence were transferred to Nunc triple flasks in medium containing 600 µg/ml geneticin and grown to confluence. The medium was removed and replaced with serum-free, AIM-V medium (Life Technologies, Inc.) without geneticin. Factor VIII expression was monitored by one-stage factor VIII coagulant activity (*vide supra*) and 100-150 ml of medium was collected once daily for four to five days. Maximum expression levels in medium for HB<sup>-</sup> and PB<sup>-</sup> were 1-2 units per ml and 10-12 units per ml of factor VIII coagulant activity, respectively.

Purification of PB<sup>-</sup>

PB<sup>-</sup> was precipitated from culture supernatant using 60% saturated ammonium sulfate and then purified by W3-3 immunoaffinity chromatography and mono Q high pressure liquid

chromatography as described previously for the purification of plasma-derived porcine factor VIII [Lollar et al. (1993) Factor VIII/factor VIIIa. *Methods Enzymol.* 222:128-143]. The specific coagulant activity of PB<sup>-</sup> was measured by a one-stage 5 coagulation assay [Lollar et al. (1993) *supra*] and was similar to plasma-derived porcine factor VIII.

When analyzed by SDS-polyacrylamide gel electrophoresis, the PB<sup>-</sup> preparation contained three bands of apparent 10 molecular masses 160 kDa, 82 kDa, and 76 kDa. The 82 kDa and 76 kDa bands have been previously described as heterodimer containing the A1-A2 and ap-A3-C1-C2 domains (where ap refers to an activation peptide) [Toole et al. (1984) *Nature* 312:342-347]. The 160 kDa band was transferred to a polyvinylidene 15 fluoride membrane and subjected to NH<sub>2</sub>-terminal sequencing, which yielded Arg-Ile-Xx-Xx-Tyr (where Xx represents undermined) which is the NH<sub>2</sub>-terminal sequence of single chain factor VIII [Toole et al. (1984) *supra*]. Thus, PB<sup>-</sup> is partially processed by cleavage between the A2 and A3 domains, 20 such that it consists of two forms, a single chain A1-A2-ap-A3-C1-C2 protein and a A1-A2/ap-A3-C1-C2 heterodimer. Similar processing of recombinant HB<sup>-</sup> has been reported [Lind et al. (1995) *Eur. J. Biochem.* 232:19-27].

25 Characterization of Porcine factor VIII

We have determined the cDNA sequence of porcine fVIII corresponding to 137 bp of the 5' UTR, the signal peptide coding region (57 bp), and the A1 (1119 bp), A3 (990 bp), C1 30 (456 bp), and C2 (483 bp) domains. Along with previously published sequence of the B domain and light chain activation peptide regions [Toole et al. (1986) *supra*] and the A2 domain [Lubin et al. (1994) *supra*], the sequence reported here completes the determination of the porcine fVIII cDNA corresponding to the translated product. A fragment that 35 included the 5' UTR region, signal peptide, and A1 domain cDNA

was cloned using a 5'-RACE RT-PCR protocol. A primer based on human C2 sequence was successful in producing an RT-PCR product that led to cloning of the A3, C1, and 5' half of the C2 domain. The cDNA corresponding to the 3' half of the C2 domain and 3' UTR cDNA proved difficult to clone. The remainder of the C2 domain ultimately was cloned by a targeted gene walking PCR procedure [Parker et al. (1991) *supra*].

The sequence reported herein SEQ ID NO:36 was unambiguous except at nt 7045 near the 3' end of the C2 domain, which is either A or G as described hereinabove. The corresponding codon is GAC (Asp) or AAC (Asn). The human and mouse codons are GAC and CAG (Gln), respectively. Whether this represents a polymorphism or a reproducible PCR artifact is unknown. Recombinant hybrid human/porcine B-domainless fVIII cDNAs containing porcine C2 domain substitutions corresponding to both the GAC and AAC codons have been stably expressed with no detectable difference in procoagulant activity. This indicates that there is not a functional difference between these two C2 domain variants.

The alignment of the predicted amino acid sequence of full-length porcine fVIII SEQ ID NO:37 with the published human [Wood et al. (1984) *supra*] and murine [Elder et al. (1993) *supra*] sequences is shown in Fig. 1A-1H along with sites for post-translational modification, proteolytic cleavage, and recognition by other macromolecules. The degree of identity of the aligned sequences is shown in Table VII. As noted previously, the B domains of these species are more divergent than the A or C domains. This is consistent with the observation that the B domain has no known function, despite its large size [Elder et al. (1993) *supra*; Toole et al. (1986) *supra*]. The results of the present invention confirm that the B domain of porcine fVIII is not necessary for activity. Based on the sequence data presented herein, porcine fVIII having all or part of the B-domain deleted can

be synthesized by expressing the porcine fVIII coding DNA having deleted therefrom all or part of codons of the porcine B domain. There is also more divergence of sequences corresponding to the A1 domain APC/factor IXa cleavage peptide (residues 337-372) and the light chain activation peptide (Table VII). The thrombin cleavage site at position 336 to generate the 337-372 peptide is apparently lost in the mouse since this residue is glutamine instead of arginine [Elder et al. (1993) *supra*]. The relatively rapid divergence of thrombin cleavage peptides (or in mouse fVIII a possibly vestigial 337-372 activation peptide) has been previously noted for the fibrinopeptides [Creighton, T. E. (1993) In Proteins: Structures and Molecular Properties, W.H. Freeman, New York, pp. 105-138]. Lack of biological function of these peptides once cleaved has been cited as a possible reason for the rapid divergence. Arg562 in human fVIII has been proposed to be the more important cleavage site for activated protein C during the inactivation of fVIII and fVIIIA [Fay, P.J. et al. (1991) *J. Biol. Chem.* 266:20139-20145]. This site is conserved in human, porcine and mouse fVIII.

Potential N-linked glycosylation sites are also shown in bold in Fig. 1A-1H. There are eight conserved N-linked glycosylation sites: one in the A1 domain, one in the A2 domain, four in the B domain, one in the A3 domain, and one in the C1 domain. The 19 A and C domain cysteines are conserved, whereas there is divergence of B domain cysteines. Six of the seven disulfide linkages in fVIII are found at homologous sites in factor V and ceruloplasmin, and both C domain disulfide linkages are found in factor V [McMullen, B.A. et al. (1995) *Protein Sci.* 4:740-746]. Human fVIII contains sulfated tyrosines at positions 346, 718, 719, 723, 1664, and 1680 [Pittman, D.D. et al. (1992) *Biochemistry* 31:3315-3325; Michnick, D.A. et al. (1994) *J. Biol. Chem.* 269:20095-20102]. These residues are conserved in mouse fVIII and porcine fVIII.

(Fig. 1), although the CLUSTALW program failed to align the mouse tyrosine corresponding to Tyr346 in human fVIII.

5       Mouse and pig plasma can correct the clotting defect in  
human hemophilia A plasma, which is consistent with the level  
of conservation of residues in the A and C domains of these  
species. The procoagulant activity of porcine fVIII is  
superior to that of human fVIII [Lollar, P. et al. (1992) *J.  
Biol. Chem.* 267:23652-23657]. The recombinant porcine factor  
10      fVIII (B domain-deleted) expressed and purified as herein  
described also displays greater specific coagulant activity  
than human fVIII, being comparable to plasma-derived porcine  
fVIII. This may be due to a decreased spontaneous  
dissociation rate of the A2 subunit from the active A1/A2/A3-  
15      C1-C2 fVIIIa heterotrimer. Whether this difference in  
procoagulant activity reflects an evolutionary change in  
function as an example of species adaptation [Perutz, M.F.  
(1996) *Adv. Protein Chem.* 36:213-244] is unknown. Now that the  
porcine fVIII cDNA sequence corresponding to the translated  
20      product is complete, homolog scanning mutagenesis [Cunningham,  
B.C., et al. (1989) *Science* 243:1330-1336] may provide a way  
to identify structural differences between human and porcine  
fVIII that are responsible for the superior activity of the  
latter.

25       Porcine fVIII is typically less reactive with inhibitory  
antibodies that arise in hemophiliacs who have been transfused  
with fVIII or which arise as autoantibodies in the general  
population. This is the basis for using porcine fVIII  
30      concentrate in the management of patients with inhibitory  
antibodies [Hay and Lozier (1995) *supra*]. Most inhibitors are  
directed against epitopes located in the A2 domain or C2  
domain [Fulcher, C.A. et al. (1985) *Proc. Natl. Acad. Sci. USA*  
82:7728-7732; Scandella, D. et al. (1988) *Proc. Natl. Acad.*  
35      Sci. USA 85:6152-6156; Scandella, D. et al. (1989) *Blood*

74:1618-1626]. Additionally, an epitope of unknown significance has been identified that is in either the A3 or C1 domain [Scandella et al. (1989) *supra*; Scandella, D. et al. (1993) *Blood* 82:1767-1775; Nakai, H. et al. (1994) *Blood* 84:224a]. The A2 epitope has been mapped to residues 484-508 by homolog scanning mutagenesis [Healey et al. (1995) *supra*]. In this 25 residue segment, there is relatively low proportion of identical sequence (16/25 or 64%). It is interesting that this region, which appears to be functionally important based on the fact that antibodies to it are inhibitory, apparently has been subjected to relatively more rapid genetic drift. Alignment of the porcine A2 domain and A3 domains indicate that the A2 epitope shares no detectable homology with the corresponding region in the A3 domain.

15

The C2 inhibitor epitope of human fVIII has been proposed to be located to within residues 2248-2312 by deletion mapping [Scandella, D. et al. (1995) *Blood* 86:1811-1819]. Human and porcine fVIII are 83% identical in this 65 residue segment. However, homolog scanning mutagenesis of this region to characterize the C2 epitope has revealed that a major determinant of the C2 epitope was unexpectedly located in the region corresponding to human amino acids 2181-2243 (SEQ ID NO:2) and Fig. 1H.

25

Human-porcine hybrid factor VIII proteins were made in which various portions of the C2 domain of human factor VIII were replaced by the corresponding portions of porcine factor VIII, using the strategy herein described. (Example 8) The synthesis of the various C2-hybrid factor VIIIs was accomplished by constructing hybrid coding DNA, using the nucleotide sequence encoding the porcine C2 region given in SEQ ID NO.37. Each hybrid DNA was expressed in transfected cells, such that the hybrid factor VIIIs could be partially purified from the growth medium. Activity, in the absence of any inhibitor, was measured by the one-stage clotting assay.

A battery of five human inhibitors was used to test each hybrid factor VIII. The inhibitor plasmas containing anti factor VIII antibody had been previously shown to be directed against human C2 domain, based on the ability of recombinant human C2 domain to neutralize the inhibition. In all the test plasmas, the inhibitor titer was neutralized greater than 79% by C2 domain or light chain but less than 10% by recombinant human A2 domain. In addition the C2-hybrid factor VIIIs were tested against a murine monoclonal antibody, which binds the C2 domain, and like human C2 inhibitor antibodies, it inhibited the binding of factor VIII to phospholipid and to von Willebrand factor.

By comparing the antibody inhibitor titers against the C2-hybrid factor VIIIs, the major determinant of the human C2 inhibitor epitope was shown to be the region of residues 2181-2243 (SEQ ID NO:2, see also Fig. 1H). Anti-C2 antibodies directed to a region COOH-terminal to residue 2253 were not identified in four of the five patient sera. In comparing hybrids having porcine sequence corresponding to human amino acid residues numbers 2181-2199 and 2207-2243, it was apparent that both regions contribute to antibody binding. The porcine amino acid sequence corresponding to human residues 2181-2243 is numbered 1982-2044 in SEQ ID NO:37. The sequence of porcine DNA encoding porcine amino acids numbered 1982-2044 is nucleotides numbered 5944-6132 in SEQ ID NO:35.

Referring to Fig. 1H, it can be seen that in the region 2181-2243, there are 16 amino acid differences between the human and porcine sequences. The differences are found at residues 2181, 2182, 2188, 2195-2197, 2199, 2207, 2216, 2222, 2224-2227, 2234, 2238 and 2243. Amino acid replacement at one or more of these numbered residues can be carried out to make a modified human factor VIII non-reactive to human anti-C2 inhibitor antibodies. Alanine scanning mutagenesis provides a convenient method for generating alanine substitutions for naturally-occurring residues, as previously described. Amino

acids other than alanine can be substituted as well, as described herein. Alanine substitutions for individual amino acids, especially those which are non-identical between human/porcine or human/mouse or which are most likely to contribute to antibody binding, can yield a modified factor VIII with reduced reactivity to inhibitory antibodies.

In addition, the strategy of inserting amino acids with lower potential to be immunogenic in the defined region of residues 2181-2243 yields modified factor VIIIs having reduced immunogenicity. Reduced immunogenicity factor VIII is useful as a factor VIII supplement for treatment of hemophilia A patients in preference to natural-sequence factor VIII. Patients treated with reduced immunogenicity factor VIII are less likely to develop inhibitory antibodies, and are therefore less likely to suffer from reduced effectiveness of treatment over their lifetimes.

Figures 1A-1H taken together provide an aligned sequence comparison of the human, pig and mouse factor VIII amino acid sequences. Fig. 1A compares signal peptide regions (human, SEQ ID NO:40; porcine, SEQ ID NO:37, amino acids 1-19; murine, SEQ ID NO:6, amino acids 1-19). Note that the amino acids in Fig. 1A-1H are numbered at the first Alanine of the mature protein as number 1, with amino acids of the signal peptide assigned negative numbers. The Human fVIII sequence in SEQ ID NO:2 also begins with the first Alanine of the mature protein as amino acid number 1. In the amino acid sequences of mouse fVIII (SEQ ID NO:6) and porcine fVIII (SEQ ID No:37), the first amino acid (alanine) of the mature sequence is amino acid number 20. Fig. 1A-1H shows an alignment of the corresponding sequences of human, mouse and pig fVIII, such that the regions of greatest amino acid identity are juxtaposed. The amino acid numbers in Fig. 1A-1H apply to human fVIII only. Fig. 1B gives the amino acid sequences for the A1 domain of human (SEQ ID NO:2, amino acids 1-372),

porcine (SEQ ID NO:37, amino acids 20-391), and murine (SEQ ID NO:6, amino acids 20-391). Fig. 1C provides amino acid sequences for the Factor VIII A2 domains from human (SEQ ID NO:2, amino acids 373-740), pig (SEQ ID NO:37, amino acids 392-759) and mouse (SEQ ID NO:6, amino acids 392-759). Fig. 5 1D provides the amino acid sequences of B domains of human factor VIII (SEQ ID NO:2, amino acids 741-1648), pig (SEQ ID NO:37, amino acids 760-1449) and mouse (SEQ ID NO:6, amino acids 760-1640). Fig. 1E compares the amino acid sequences of 10 Factor VIII light chain activation peptides of human, pig and mouse (SEQ ID NO:2, amino acids 1649-1689; SEQ ID NO:37, amino acids 1450-1490; and SEQ ID NO:6, amino acids 1641-1678, respectively). Fig. 1F provides the sequence comparison for 15 human, pig and mouse Factor VIII A3 domains (SEQ ID NO:2, amino acids 1690-2019; SEQ ID NO:37, amino acids 1491-1820; and SEQ ID NO:6, amino acids 1679-2006, respectively. Fig. 1G provides the amino acid sequences of the Factor VIII C1 20 domains of human, pig and mouse (SEQ ID NO:2, amino acids 2020-2172; SEQ ID NO:37, amino acids 1821-1973; and SEQ ID NO:6, amino acids 2007-2159, respectively). Fig. 1H provides sequence data for the C2 domains of the Factor VIII C2 domains 25 of human, pig and mouse (SEQ ID NO:2, amino acids 2173-2332; SEQ ID NO:37, amino acids 1974-2133; and SEQ ID NO:6, amino acids 2160-2319, respectively).

The diamonds represent tyrosine sulfation sites, potential glycosylation sites are in bold type, proposed binding sites for Factor IXa, phospholipid and Protein C are double-underlined, and regions involved in binding anti-A2 and 30 anti-C2 inhibitory antibodies are italicized. Asterisks highlight amino acid sequences which are conserved. See also SEQ ID NO:36 (porcine factor VIII cDNA) and SEQ ID NO:37 (deduced amino acid sequence of porcine factor VIII). The human numbering system is used as the reference [Wood et al. 35 (1984) *supra*]. The A1, A2, and B domains are defined by thrombin cleavage sites at positions 372 and 740 and an

unknown protease cleavage site at 1648 as residues 1-372, 373-740, and 741-1648, respectively [Eaton, D.L. et al. (1986) *Biochemistry* 25:8343-8347]. The A3, C1, and C2 domains are defined as residues 1690-2019, 2020-2172, and 2173-2332, 5 respectively [Vehar et al. (1984) *supra*]. Cleavage sites for thrombin (factor IIa), factor IXa, factor Xa and APC [Fay et al. (1991) *supra*; Eaton, D. et al. (1986) *Biochemistry* 25:505-512; Lamphear, B.J. et al. (1992) *Blood* 80:3120-3128] are shown by placing the enzyme name over the reactive 10 arginine. An acidic peptide is cleaved from the fVIII light chain by thrombin or factor Xa at position 1689. Proposed binding sites for factor IXa [Fay, P.J. et al. (1994) *J. Biol. Chem.* 269:20522-20527; Lenting, P.J. et al. (1994) *J. Biol. Chem.* 269:7150-7155], phospholipid (Foster, P.A. et al. (1990) *Blood* 75:1999-2004) and protein C (Walker, F.J. et al. (1990) *J. Biol. Chem.* 265:1484-1489] are doubly underlined. Regions 15 involved in binding anti-A2 [Lubin et al. (1994) *supra*; Healey et al. (1995) *supra*]; and previously proposed for anti-C2 inhibitory antibodies are italicized. The C2 inhibitor 20 epitope identified as herein described (human amino acids 2181-2243) is shown by a single underline in Fig. 1H. Tyrosine sulfation sites [Pittman et al. (1992) *supra*; Michnick et al. (1994) *supra*] are shown by ♦. Recognition sequences for 25 potential N-linked glycosylation (NXS/T, where X is not proline) are shown in bold.

The nucleotide sequence encoding the factor VIII protein lacking the B domain is given in SEQ ID NO:38, and the corresponding deduced amino acid sequence is provided in SEQ 30 ID NO:39.

## CLAIMS

1. Isolated and purified DNA comprising a nucleotide sequence encoding the amino acid sequence of porcine factor VIII set forth in SEQ ID NO:37.
2. DNA of claim 1 comprising the nucleotide sequence set forth in SEQ ID NO:36.
3. Isolated and purified DNA comprising a nucleotide sequence encoding the A1 domain of porcine factor VIII as set forth in SEQ ID NO:37 from amino acids 20-391.
4. DNA of claim 3 comprising the nucleotide sequence set forth in SEQ ID NO:36 from positions 58-1173.
5. Isolated and purified DNA comprising a nucleotide sequence encoding the A3 domain of porcine factor VIII as set forth in SEQ ID NO:37 from amino acids 1491-1820.
6. DNA of claim 5 comprising the nucleotide sequence set forth in SEQ ID NO:36 from positions 4471-5460.
7. Isolated and purified DNA comprising a nucleotide sequence encoding the C1 domain of porcine factor VIII as set forth in SEQ ID NO:37 from amino acids 1821-1973.
8. DNA of claim 7 comprising the nucleotide sequence set forth in SEQ ID NO:36 from positions 5461-5919.
9. Isolated and purified DNA comprising a nucleotide sequence encoding the C2 domain of porcine factor VIII as set forth in SEQ ID NO:37 from amino acids 1974-2133.
10. DNA of claim 9 comprising the nucleotide sequence set forth in SEQ ID NO:36 from positions 5920-6399.

11. DNA of claim 1 wherein said nucleotide sequence encodes the amino acid sequence set forth in SEQ ID NO:39.
12. DNA of claim 11 comprising the nucleotide sequence set forth in SEQ ID NO:38.
13. DNA encoding human/porcine hybrid factor VIII comprising a substitution of porcine factor VIII coding DNA wherein nucleotide sequence encoding amino acids number 2181-2243 of human factor VIII is substituted by nucleotides encoding amino acids 1982-2044 of SEQ ID NO:37.
14. DNA according to claim 13 wherein the porcine factor VIII coding DNA is nucleotides 5944-6132 of SEQ ID NO:36.
15. DNA encoding porcine factor VIII comprising codons encoding amino acids 20-2133 of SEQ ID NO:37.
16. DNA according to claim 15 having the sequence of nucleotides 58-6399 of SEQ ID NO:36.
17. DNA encoding B-domainless porcine factor VIII comprising codons encoding amino acids 20-1443 of SEQ ID NO:39.
18. DNA according to claim 17 having the sequence of nucleotides 60-4331 of SEQ ID NO:38.
19. Isolated and purified protein expression product of the DNA of claim 17.
20. Isolated and purified protein expression product of the DNA of claim 18.
21. Modified human factor VIII comprising an amino acid substitution at one or more of position 2181-2243 according to SEQ ID NO:2, said substitution being insertion of an immunoreactivity-reducing amino acid for

the naturally-occurring amino acid, said modified factor VIII having procoagulant activity.

22. The modified factor VIII of claim 21 wherein the substitution is made at one or more of position 2181, 2182, 2195, 2196, 2197, 2199, 2207, 2216, 2222, 2224, 2225, 2226, 2227, 2228, 2234, 2238, or 2243 according to SEQ ID NO:2.
23. The modified factor VIII of claim 21 wherein the substitution is made at one or more of position 2181, 2195, 2196, 2207, 2226, 2227, 2228, and 2234.
24. A method for modifying a factor VIII such that reactivity to an inhibitory antibody is reduced and procoagulant activity is retained, comprising substituting an immunoreactivity-reducing amino acid for the naturally - occurring amino acid at at least one position within amino acids number 2181-2243 according to SEQ ID NO:2.
25. The method of claim 24 wherein an amino acid is substituted within amino acids number 2181-2243 according to SEQ ID NO:2, by expressing DNA encoding a modified factor VIII, the DNA having at least one codon modified to encode the amino acid substitution within said amino acids number 2181-2243.
26. The method of claim 24 wherein the immunoreactivity-reducing amino acid is alanine, methionine, lencine, serine or glycine.
27. The method of claim 26 wherein the immunoreactivity reducing amino acid is alanine.
28. The method of claim 24 wherein substitution of an immunoreactivity-reducing amino acid is made at at least one of positions number 2181, 2182, 2195, 2196, 2197,

2199, 2207, 2216, 2222, 2224, 2225, 2226, 2227, 2228, 2234, 2238 or 2243 according to SEQ ID NO:2.

29. A method of making porcine factor VIII comprising expressing DNA encoding the amino acid sequence set forth in SEQ ID NO:37 including at least amino acids 20-2133 in a suitable mammalian host cell in a culture medium and purifying the factor VIII protein from said cell or from said culture medium.
30. The method of claim 29 wherein the DNA has a nucleotide sequence essentially as set forth in SEQ ID NO:36, including at least nucleotides 58-6399.
31. The method of claim 29 wherein the DNA encodes the amino acid sequence set forth in SEQ ID NO:37.
32. The method of claim 31 wherein the DNA has the nucleotide sequence set forth in SEQ ID NO:36.
33. A method of making B-domainless porcine factor VIII comprising expressing a DNA encoding the amino acid sequence set forth in SEQ ID NO:39 including at least amino acids 20-1443 in a suitable mammalian host cell in a culture medium and purifying the factor VIII protein from said cell or from said culture medium.
34. The method of claim 33 wherein the DNA has a nucleotide sequence essentially as set forth in SEQ ID NO:38, including at least nucleotides 60-4331.
35. The method of claim 33 wherein the DNA encodes the amino acid sequence set forth in SEQ ID NO:39.
36. The method of claim 33 wherein the DNA has the nucleotide sequence set forth in SEQ ID NO:38 from nucleotide number 3 through nucleotide number 4331.

<b>Signal peptide</b>			
Human	-19	MQIELSTCFF	LCLLRFCFS
Pig		MQLELSTCVF	LCLLPLGFS
Mouse		MQIALFACFF	LSLFNFCSS

FIG. 1A

FIG. 1B

50 LFVEFTDHLF NIAKPRPPWM GLLGPTIQAЕ VYDTVVITLK NMASHPVSLH  
 VFVEFTDQLF SVARPRPPWM GLLGPTIQAЕ VYDTVVVTLK NMASHPVSLH  
 VFVEYKDQLF NIAKPRPPWM GLLGPTIWTE VHDTVVITLK NMASHPVSLH  
 \*\*\* \* \*\*\* \* \*\*\*\*\* \* \*\*\*\*\* \* \* \*\*\* \* \*\*\* \* \*\*\*\*\*

100 AVGSYWKAS EGAEYDDQTS QREKEDDKVF PPGSHTTYWQ VLKENGPMA  
AVGYSFWKSS EGAEYEDHTS QREKEDDKVL PGKSQTYYWQ VLKENGPTAS  
AVGSYWKAS EGDEYEDQTS QMEKEDDKVF PGESHTTYWQ VLKENGPMA  
\*\*\*\*\* \* \* \* \*\*\*\*\* \* \* \*\*\*\*\* \* \* \*\*\*\*\* \* \* \*\*\*\*\*

150 DPLCLTYSYL SHVOLVKDLN SGLIGALLVC REGSLAKEKT QTLHKFILLF  
DPPCLTYSYL SHVOLVKDLN SGLIGALLVC REGSLTRERT QNLHEFVLLF  
DPPCLTYSYM SHVOLVKDLN SGLIGALLVC KEGSLSKERT QMLYQFVLLF  
\*\*\*\*\*

200 AVFDEGKSHW SETKNLSMQD RDAASARAWP KMHTVNGYVN RSLPGLIGCH  
AVFOEGKSHW SARNDSWTRA MDPAPARAQP AMHTVNGYVN RSLPGLIGCH  
AVFDEGKSHW SETNDSYTQS MDSASARDWP KMHTVNGYVN RSLPGLIGCH  
\*\*\*\*\* \* \* \* \* \* \*\*\*\*\*

250 RKSVYWHVG MGTTPEVHSI FLEGHTFLVR NHRQASLEIS PITFLTAQTL  
KKSYYWHVG MGTSPEVHSI FLEGHTFLVR HHRQASLEIS PLTFLTAQTF  
RKSVYWHVG MGTTPEIHSI FLEGHTFFVR NHRQASLEIS PITFLTAQTL  
\*\*\*\*\* \* \*\*\*\*\* \*\*\*\*\* \* \*\*\*\*\* \*\*\*\*\*

350 LTDSEMDVVR FDDONSPSFI QIR  
LYDSDMDVVR LGDDDVSPFI QIR  
DDLYSEMDMF TLDYDSSPFI QIR  
\*\* \*\*\*

### A2 domain

Human	373	SVAKKHPKTW	VHYIAAEEEED	WDYAPVLAP	DORSYKSQYL	NNGPQRIGRK
Pig		SVAKKHPKTW	VHYISAEEEED	WDYAPAVPSP	DORSYKSLYL	NSGPQRIGRK
Mouse		SVAKKYPKTW	IHYISAEEEED	WDYAPSVPPTS	DNGSYKSQYL	SNGPHRIGRK
		*****	*****	*****	*****	*****

FIG. 1C

## A2 Inhibitor epitope

*F.IXa binding*  
APC

523 KSDPRCLTRY YSSFVNMERD LASGLIGPLL ICYKESVDQR GNOIMSOKRN  
KSDPRCLTRY YSSSINLEKD LASGLIGPLL ICYKESVDQR GNQSMSOKRN  
KSDPRCLTRY YSSFINPERD LASGLIGPLL ICYKESVDQR GNQSMSOKRN  
\*\*\*\*\*

573 VILFSVFDEN RSWYLTENIQ RFLPNPAGVQ LEDPEFQASN IMHSINGYVF  
VILFSVFDEN QSHYLAENIQ RFLPNPQGLQ PQDPFQASN IMHSINGYVF  
VILFSIFDEN QSHYITENMQ RFLPNAAKTQ PQDPGFQASN IMHSINGYVF  
\*\*\*\*\* \*\*\*\*\* \* \*\*\*\*\* \* \*\*\*\*\* \* \*\*\*\*\* \*\*\*\*\*

623 DSLQLSVLH EVAYWYILSI GAQTDFLSVF FSGYTFKHKM VYEDTLTLFP  
DSLQLSVLH EVAYWYILSV GAQTDFLSVF FSGYTFKHKM VYEDTLTLFP  
DSLELTVCVHLH EVAYWHILSV GAQTDFLSIF FSGYTFKHKM VYEDTLTLFP  
\*\*\*\*\* \* \*\*\*\*\* \* \*\*\*\*\* \* \*\*\*\*\* \* \*\*\*\*\* \* \*\*\*\*\*

673 FSGETVFM~~S~~ ENPGLWILGC HNSDFRN~~R~~G~~M~~ TALLK~~V~~SSCD KNTG~~D~~YYE~~D~~  
FSGETVFM~~S~~ ENPGLWVLGC HNSDLRN~~R~~G~~M~~ TALLK~~V~~SCD RDIG~~D~~YYD~~N~~  
FSGETVFM~~S~~ ENPGLWVLGC HNSDFRK~~R~~G~~M~~ TALLK~~V~~SSCD KSTS~~D~~YYE~~I~~  
\*\*\*\*\* \* \*\*\*\*\* \* \* \* \*\*\*\*\* \* \* \*

IIa/Xa/APC

723 YEDISAYLLS KNNAIEPR  
YEDIPGFLLS GKNVIEPR  
YEDIPTQLVN ENNVIDPR  
\*\*\*\*\* \* \* \* \*\*\*

## B domain

Human 741 SFSQNSRHPS TRQKQFNATT IPENDIEKTD PWFHARTPMP KIQMVSSSDL  
 Pig SFAQNSRPPS ASQKQFQTIT SPEDDOVE-LD PQSQERTQAL EELSVPSGOG  
 Mouse SFQNTNHPN TRKKKFKDST IPKNOMEKIE PQFEEIAEML KVQSVSVSDH  
 \*\*\* \* \* \* \* \* \* \* \* \* \* \* \*

FIG. 1D

791 LMLLRQS-PT PHGLSLSQLQ EAKYETFSDD PSPGAIDSNN SLSEMTHFRP  
 SMLLGQN-PA PHGSSSSDLQ EARNEA--DO YLPGARERNT APSAAARLRP  
 LMLLGQSHPT PHGLFLSDGQ EAIYEAIHOD HSPNAIDSNE GPSKVTQLRP  
 \*\*\* \* \*\*\* \* \* \* \* \* \* \* \* \* \*

840 QLHHSGDMVF TPESGLQLRL NEKLGTTAAT ELKKLDFKVS ST-SNNLIS-  
 ELHHSAERVL TPEP-----EK ELKKLDKMS SSSDLKKTSP  
 ESHHSEKIVF TPQPGLQLRS NKSLETTIEV KWKKLGLQVS SLPSNLMTT-  
 \*\*\* \* \*\*\*

888 TIPSDNLAAGT DNTSSLGPPS MPVHYDSQLD TTLFGKKSSP LTEGGPLSL  
 TIPSDTSLAET ERHSLGPPH PQVNFRSQLG AIVLGKNSH FIGAGVPLGS  
 TILSDNLKATF EKTDSGGFPD MPVHSSSKLS TTAFGKKAYS LVGSHVPLNA  
 \*\*\* \* \* \* \* \* \* \* \* \* \* \* \*

939 SEENHDSKLL ESGLMNSQES SWGKHNSSSTE SGRLFKGKRA HGPALLTKDN  
 TEED-----HES SLGENVSPVE SDGIFEKERA HGPASLTKEOD  
 SEENSDSNIL DSTLMYSQES LPRONILSIE NDRLREKRF HGIALLTKEOD  
 \*\* \*

989 ALFKVSISSL KTNKTSNNSA TNRKTHIDGP SLLIENSPSV WQNILESOTE  
 VLFKVNISLV KTNKARVYLK TNRKIHIODA ALLTENRAS-  
 TLFKDNYSLM KTHKTYHGST TNEKLHTESP TSIENSTTDL QDAILKVNSE  
 \*\*\* \* \*\*\* \* \* \* \*

1039 FKKVTPLIHD RMLMDKNTA LRLNHMSNKT TSSKNMEMVQ QKKEGPIPPO  
 -----ATFMOKNTTA SGLNHVSN-----  
 IQEVTLALIHD GTLLGKNTY LRLNHMLHRT TSTKNKDIFH RKDEDPPIPQD  
 \* \* \* \* \* \* \* \* \* \* \* \*

1089 AQNPDMSSFFK MLFLPESAPW IQRTHGKNSI NSGQGPSPKQ LVSLGPEKSV  
 -----W IKGPLGKNPL SSERGPSPTEL LTSSGSGKSV  
 EENTIMPF SK MLFLSESSNW FKKTNGNNSL NSEQEHSRKQ LYVLMFKKYV  
 \* \* \* \* \* \* \* \* \* \* \* \*

1139 EGQNFLSEKN KVVGKGEGFT KDVGKEMVF PSSRNLFLTN LDNLHENNT  
 KGQSSGQQGRI RVAVEEEELS KG---KEMML PNSELTFLTN SADVQGHDT  
 KNQSFLSEKN KVTVEQDGFT KNIGLKDMAF PHNMSIFLT T LSNVHENGHRH  
 \* \* \* \* \* \* \* \* \* \* \* \*

1189 NQEKKIQEEI EKKETLIQEN VVLPQIHTVT GTKNFMKNLF LLSTRQNV  
 SQGKKSREEM ERREKLVQFK VDLPQVYTAT GTKNFLRNIF HQSTEPSEVG  
 NQEKNIQEEI EK-EALIEEK VVLPQVHEAT GSKNFLKDIL ILGTRQNI--  
 \* \* \* \* \* \* \* \* \* \* \* \*

1433 HFLQAKKNN LSLAILTLEM TGQREVGSL GTSATNSVTY KKVENTVLPK  
PILQGAKRNN LSLPFLTLEM AGQQGKISAL GKSAAAGPLAS GKLEKAVLSS  
NFLKETKINN PSLAILPWNM FIDQGKFTSP GKSNTNSVTY KKRENIIFLK

**FIG. 1D**  
(cont.)

1483 PDLPKTSGKV ELLPKVHIYQ KDLFPTETSN GSPGHLDLVE GSLLQGTEGA  
 AGLSEASGKA EFLPKVRVHR EDLPLQKTSN VSCAHGDLGQ EIFLQKTRGP  
 PTLPEESGKI ELLPQVSIQE EEILPTETSH GSPGHLNLMK EVFLQKIQGP  
 \*\*\* \* \*\*\* \*

1533 IKWNEANRPG KVPFLRVATE SSAKTPSKLL DPLAWDNHYG TQIPKEEKWS  
VNLNKVNRPQ -----RTPSKLL -----G PPMPKE-WES  
TKWNKAKRHG ESIKGKTES- SKNTRSKLL NHHAWDYHYA AQIPKDMWKS  
\* \* \* \* \* \* \* \* \*

1633 ERLCSQNPPV LKRHQ<sup>R</sup>  
GRLGAPKPPV LRRHQ<sup>R</sup>  
QRTCSQIIPPY LKRHQ<sup>R</sup>  
\* \* \* \* \*

### Light chain activation peptide

IIa/Xa

Human 1649	EITRTTLQSDQEEIODYDOTISVEMKKEDFDFIYDEDENQNSPR						
Pig	DISLPTRQPEEOKMDYDDIFSTETKGEDFDFIYGEDENQNSPR						
Mouse	EL--SAFQSEQEATDYDOAITTET-IEDFDIYSEDIKQGPR						
*	*	*****	*	*****	**	*	***

FIG. 1E

### A3 domain

IXa Xa

1740 DGSFTQPLYR GELNEHLGLL GPYIRAEVED NIMVTFRNQA SRPYSFYSSL  
 DGSFTNPSYR GELNKHLGLL GPYIRAEVED NIMVTFKNQA SRPYSFYSSL  
 DGSFSQPLYR GELNEHLGLL GPYIRAEVED NIMVTFKNQA SRPYSFYSSL  
 \*\*\*\*\* \* \*\*\* \*\*\*\*\* \*\*\*\*\* \* \*\*\*\*\* \*\*\*\*\* \* \*\*\*\*\*

### Factor IXa binding

1790 I SYEEDOROG AEPRKNFVKP NETKTYFWKV QHHMAPTKDE FDCKAWAYS  
ISYPDQEQQ AEPRHNFVQP NETRTYFWKV QHHMAPTEDE FDCKAWAYS  
ISYKEDQR-G EEPRRNFKP NETKIYFWKV QHHMAPTEDE FDCKAWAYS  
\*\*\*\*\*

1840 DVLEKDVHS GLIGPLLVCH TNLNPAHGR QVTQEFALF FTIODETKW  
 DVLEKDVHS GLIGPLLICR ANTLNAAHGR QVTQEFALF FTIODETKW  
 DVLERDMHS GLIGPLLICH ANTLNPAHGR QVSQEFALL FTIODETKW  
 \*\*\*\*\* \* \*\*\* \*\*\*\*\* \* \*\*\*\*\* \* \*\*\*\*\* \* \*\*\*\*\* \* \*\*\*\*\*

1890 YFTENMERN C RAPCNIQMED PTFKENYRFH AINGYIMDTL PGLVMAQDQR  
YFTENVERNC RAPCHLQMED PTLKENYRFH AINGYVMDTL PGLVMAQNQR  
YFTENVKRNC KTPCNFQMED PTLKENYRFH AINGYVMDTL PGLVMAQDQR  
\*\*\*\*\* \* \*\*\*\*\* \* \*\*\*\*\* \* \*\*\*\*\* \* \*\*\*\*\* \* \*\*\*\*\* \* \*\*\*\*\*

1940 IRWYLLSMGS NENIHSIHFS GHVFVRKKE EYKMALYNLY PGVFETVEML  
IRWYLLSMGS NENIHSIHFS GHVFSRKKE EYKMAVYNLY PGVFETVEML  
IRWYLLSMGN NENIQSIHFS GHVFVRKKE EYKMAVYNLY PGVFETLEMI  
\*\*\*\*\*

### *Protein C binding*

1990 PSKAGIWRVE CLIGEHL~~HAG~~ MSTLFLVYSN  
PSKVG~~I~~WRIE CLIGEHLQAG MSTLFLVYSK  
PSRAGIWRVE CLIGEHLQAG MSTLFLVYSK  
\*\*\* \*\*\*\*\* \* \*\*\*\*\* \*\*\* \*\*\* \*\*\*

FIG. 1F

### C1 domain

Human	2020	KCQTPLGMAS	GHIROFQITA	SGQYQGWAPK	LARLHYSGSI	NAWSTKEPFS
Pig		ECQAPLGMAS	GRIROFQITA	SGQYQGWAPK	LARLHYSGSI	NAWSTKDOPHS
Mouse		QCQIPLGMAS	GSIROFQITA	SGHYQGWAPN	LARLHYSGSI	NAWSTKEPFS
		*****	*****	*****	*****	*****

FIG. 1G

2070 WIKV DLLAPM I IHG IKTQGA R QKF SLYIS QF I IMYSLDG K KWQTYRGNS  
WIKV DLLAPM I IHG INTQGA R QKF SLYIS QF I IMYSLDG R NWQSYRGNS  
WIKV DLLAPM IVH GIKTQGA R QKF SLYIS QF I IMYSLDG K KWLSYQGNS  
\*\*\*\*\* \* \*\*\*\*\* \* \*\*\*\*\* \* \*\*\*\*\* \* \*\*\*\*\* \* \* \* \*

## C2 domain

Human	2173	SCSMLPGM <b>E</b> S	KAI <b>D</b> AQITA	SSYFTNM <b>F</b> AT	WSPSKARLHL	QGRSNWRPQ
Pig		SCSMLGM <b>Q</b> N	KAI <b>D</b> SQITA	SSHLSNIFAT	WSPSQARLHL	QGRTNAWRP
Mouse		SCSIPLGM <b>E</b> S	KVI <b>T</b> OQTITA	SSYFTNM <b>F</b> AT	WSPSQARLHL	QGRTNAWRPQ
		*** * ***	* * ***	** * * ***	*****	*****

FIG. 1H

		C2	inhibitor
2223	VNNPKEWLQV DFQKTMKVVG VTTQGVKSLL TSMYVKEFLI SSSQDGHHWT		
	VSSAAEELQV DLQKTVKVVG ITTQGVKSLL SSMYYKEFLV SSSQDGRRWT		
	VNDPKQWLQV DLQKTMKVVG ITTQGVKSLSF TSMFVKEFLI SSSQDGHHWT		
*	*****	*****	*****

	<u>epitope</u>	<u>Phospholipid</u>
2273	LFFQNGKVKV FQGNQDSFTP VVNSLDPPLL LFLQDGHTKV FQGNQDSSTP VVNALDPPLF QILYNGKVKV FQGNQDSSTP MHNSLDPPLL	<u>TRYLRIHPOS WVHOIALRME</u> <u>TRYLRIHPTS WAHQHIALRLE</u> <u>TRYLRIHPPQI WEHQIALRLE</u>

*binding*  
2323 VLGCEAODLY  
V LGCEA QDLY  
I LGCEA QQQY  
\*\*\*\*\*

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

(i) APPLICANT: EMORY UNIVERSITY

(ii) TITLE OF INVENTION: Modified Factor VIII

(iii) NUMBER OF SEQUENCES: 40

## (iv) CORRESPONDENCE ADDRESS:

- (A) ADDRESSEE: Greenlee, Winner and Sullivan, P.C.
- (B) STREET: 5370 Manhattan Circle Suite 201
- (C) CITY: Boulder
- (D) STATE: Colorado
- (E) COUNTRY: USA
- (F) ZIP: 80303

## (v) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.30

## (vi) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER: WO Unassigned
- (B) FILING DATE: 10-MAR-1999
- (C) CLASSIFICATION:

## (vii) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: US 09/037,601
- (B) FILING DATE: 10-MAR-1998

## (viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: Greenlee, Lorance L.
- (B) REGISTRATION NUMBER: 27,894
- (C) REFERENCE/DOCKET NUMBER: 75-95G WO

## (ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: 303/499-8080
- (B) TELEFAX: 303/499-8089

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9009 base pairs
- (B) TYPE: nucleic acid

(C) STRANDEDNESS: double  
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens  
 (F) TISSUE TYPE: Liver

(ix) FEATURE:

(A) NAME/KEY: misc\_feature  
 (B) LOCATION: 5125..7053  
 (D) OTHER INFORMATION: /product= "Domain Structure"  
 /note= "Equivalent to the A3-C1-C2 domain"

(ix) FEATURE:

(A) NAME/KEY: misc\_feature  
 (B) LOCATION: 1..2277  
 (D) OTHER INFORMATION: /product= "Domain Structure"  
 /note= "Equivalent to the A1-A2 domain"

(ix) FEATURE:

(A) NAME/KEY: misc\_feature  
 (B) LOCATION: 1..2277  
 (D) OTHER INFORMATION: /product= "Domain"  
 /note= "cDNA encoding human factorVIII"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CAGTGGGTAA GTTCCTTAAA TGCTCTGCAA AGAAATTGGG ACTTTTCATT AAATCAGAAA	60
TTTTACTTTT TTCCCCCTCCT GGGAGCTAAA GATATTTAG AGAAGAATTA ACCTTTTGCT	120
TCTCCAGTTG AACATTTGTA GCAATAAGTC ATGCAAATAG AGCTCTCCAC CTGCTTCTTT	180
CTGTGCCTTT TGCGATTCTG CTTTAGTGCC ACCAGAAGAT ACTACCTGGG TGCAGTGGAA	240
CTGTCATGGG ACTATATGCA AAGTGATCTC GGTGAGCTGC CTGTGGACGC AAGATTTCT	300
CCTAGAGTGC CAAAATCTTT TCCATTCAAC ACCTCAGTCG TGTACAAAAA GACTCTGTTT	360
GTTAGAATTCA CGGTTCACCT TTTCAACATC GCTAAGCCAA GGCCACCCCTG GATGGGTCTG	420
CTAGGTCTTA CCATCCAGGC TGAGGTTTAT GATACAGTGG TCATTACACT TAAGAACATG	480
GCTTCCCCTAC CTGTCAGTCT TCATGCTGTT GGTGTATCCT ACTGGAAAGC TTCTGAGGGA	540
GCTGAATATG ATGATCAGAC CAGTCAAAGG GAGAAAGAAG ATGATAAAAGT CTTCCCTGGT	600
GGAAGCCATA CATATGTCTG GCAGGTCTG AAAGAGAATG GTCCAATGGC CTCTGACCCA	660

CTGTGCCTTA CCTACTCATA TCTTTCTCAT GTGGACCTGG TAAAAGACTT GAATTCAAGGC	720
CTCATTGGAG CCCTACTAGT ATGTAGAGAA GGGAGTCTGG CCAAGGAAAA GACACAGACC	780
TTGCACAAAT TTATACTACT TTTTGCTGTA TTTGATGAAG GGAAAAGTTG GCACTCAGAA	840
ACAAAGAACT CCTTGATGCA GGATAGGGAT GCTGCATCTG CTCGGCCTG GCCTAAAATG	900
CACACAGTCA ATGGTTATGT AAACAGGTCT CTGCCAGGTC TGATGGATG CCACAGGAAA	960
TCAGTCTATT GGATGTGAT TCCAATGGGC ACCACTCCTG AAGTGCACTC AATATTCCCTC	1020
GAAGGTCAACA CATTCTTGT GAGGAACCAT CGCCAGGCGT CCTTGGAAAT CTCGCCAATA	1080
ACTTTCTTAA CTGCTCAAAC ACTCTTGATG GACCTTGGAC AGTTCTACT GTTTGTCTAT	1140
ATCTCTTCCC ACCAACATGA TGGCATGGAA GCTTATGTCA AAGTAGACAG CTGTCAGAG	1200
GAACCCCAAC TACGAATGAA AAATAATGAA GAAGCGGAAG ACTATGATGA TGATCTTACT	1260
GATTCTGAAA TGGATGTGGT CAGGTTTGAT GATGACAAC TCTCTTCCTT TATCAAATT	1320
CGCTCAGTTG CCAAGAACCA TCCTAAACT TGGGTACATT ACATTGCTGC TGAAGAGGAG	1380
GACTGGGACT ATGCTCCCTT AGTCCTCGCC CCCGATGACA GAAGTTATAA AAGTCAATAT	1440
TTGAACAATG GCCCTCAGCG GATTGGTAGG AAGTACAAAA AAGTCCGATT TATGGCATAAC	1500
ACAGATGAAA CCTTTAAGAC TCGTGAAGCT ATTCAAGCATG AATCAAGGAAT CTTGGGACCT	1560
TTACTTTATG GGGAAAGTTGG AGACACACTG TTGATTATAT TTAAGAATCA AGCAAGCAGA	1620
CCATATAACA TCTACCCCTCA CGGAATCACT GATGTCCGTC CTTTGTATTC AAGGAGATTA	1680
CCAAAAGGTG TAAAACATTT GAAGGATTTT CCAATTCTGC CAGGAGAAAT ATTCAAATAT	1740
AAATGGACAG TGACTGTAGA AGATGGGCCA ACTAAATCAG ATCCTCGGTG CCTGACCCGC	1800
TATTACTCTA GTTTCGTTAA TATGGAGAGA GATCTAGCTT CAGGACTCAT TGGCCCTCTC	1860
CTCATCTGCT ACAAAAGAATC TGTAGATCAA AGAGGAAACC AGATAATGTC AGACAAGAGG	1920
AATGTCATCC TGTTTCTGT ATTTGATGAG AACCGAAGCT GGTACCTCAC AGAGAATATA	1980
CAACGTTTC TCCCCAATCC AGCTGGAGTG CAGCTTGAGG ATCCAGAGTT CCAAGCCTCC	2040
AACATCATGC ACAGCATCAA TGGCTATGTT TTTGATAGTT TGCAGTTGTC AGTTTGTGTT	2100
CATGAGGTGG CATACTGGTA CATTCTAAGC ATTGGAGCAC AGACTGACTT CTTTCTGTC	2160
TTCTTCTCTG GATATAACCTT CAAACACAAA ATGGTCTATG AAGACACACT CACCCTATT	2220
CCATTCTCAG GAGAAACTGT CTTCATGTGCG ATGGAAAACC CAGGTCTATG GATTCTGGGG	2280
TGCCACAACT CAGACTTTCG GAACAGAGGC ATGACCGCCT TACTGAAGGT TTCTAGTTGT	2340

GACAAGAACAA	CTGGTGATTA	TTACGAGGAC	AGTTATGAAG	ATATTCAGC	ATACTTGCTG	2400
AGTAAAAAACAA	ATGCCATTGA	ACCAAGAACG	TTCTCCCAGA	ATTCAAGACA	CCCTAGCACT	2460
AGGCAAAAGC	AATTTAATGC	CACCACAAATT	CCAGAAAATG	ACATAGAGAA	GACTGACCCCT	2520
TGGTTTGCAC	ACAGAACACC	TATGCCTAAA	ATACAAAATG	TCTCCTCTAG	TGATTTGTTG	2580
ATGCTCTTGC	GACAGAGTCC	TACTCCACAT	GGGCTATCCT	TATCTGATCT	CCAAGAACGCC	2640
AAATATGAGA	CTTTTCTGA	TGATCCATCA	CCTGGAGCAA	TAGACAGTAA	TAACAGCCTG	2700
TCTGAAATGA	CACACTTCAG	GCCACAGCTC	CATCACAGTG	GGGACATGGT	ATTTACCCCT	2760
GAGTCAGGCC	TCCAATTAAG	ATTAATGAG	AAACTGGGGA	CAAATGCAGC	AACAGAGTTG	2820
AAGAAACTTG	ATTCAAAGT	TTCTAGTACA	TCAAATAATC	TGATTCAAC	AATTCCATCA	2880
GACAATTGG	CAGCAGGTAC	TGATAATACA	AGTTCCCTAG	GACCCCCAAG	TATGCCAGTT	2940
CATTATGATA	GTCAATTAGA	TACCACTCTA	TTTGGCAAAA	AGTCATCTCC	CCTTACTGAG	3000
TCTGGTGGAC	CTCTGAGCTT	GAGTGAAGAA	AATAATGATT	CAAAGTTGTT	AGAATCAGGT	3060
TTAATGAATA	GCCAAGAACG	TTCATGGGGA	AAAAATGTAT	CGTCAACAGA	GAGTGGTAGG	3120
TTATTTAAAG	GGAAAAGAGC	TCATGGACCT	GCTTTGTTGA	CTAAAGATAA	TGCCTTATTC	3180
AAAGTTAGCA	TCTCTTGTT	AAAGACAAAC	AAAACTTCCA	ATAATTCAAGC	AACTAATAGA	3240
AAGACTCACA	TTGATGGCCC	ATCATTATTA	ATTGAGAATA	GTCCATCAGT	CTGGCAAAAT	3300
ATATTAGAAA	GTGACACTGA	GTTTAAAAAA	GTGACACCTT	TGATTCATGA	CAGAATGCTT	3360
ATGGACAAAAA	ATGCTACAGC	TTTGAGGCTA	AATCATATGT	CAAATAAAAC	TACTTCATCA	3420
AAAAACATGG	AAATGGTCCA	ACAGAAAAAA	GAGGGCCCCA	TTCCACCAGA	TGCACAAAAT	3480
CCAGATATGT	CGTTCTTAA	GATGCTATT	TTGCCAGAAT	CAGCAAGGTG	GATAACAAAGG	3540
ACTCATGGAA	AGAACTCTCT	GAACCTCTGGG	CAAGGCCCCA	GTCCAAAGCA	ATTAGTATCC	3600
TTAGGACCAG	AAAAATCTGT	GGAAAGTCAG	AATTCTTGT	CTGAGAAAAA	CAAAGTGGTA	3660
GTAGGAAAGG	GTGAATTAC	AAAGGACGTA	GGACTCAAAG	AGATGGTTT	TCCAAGCAGC	3720
AGAAACCTAT	TTCTTACTAA	CTTGGATAAT	TTACATGAAA	ATAATACACA	CAATCAAGAA	3780
AAAAAAATTC	AGGAAGAAAT	AGAAAAGAAG	GAAACATTAA	TCCAAGAGAA	TGTAGTTTG	3840
CCTCAGATAAC	ATACAGTGAC	TGGCACTAAG	AATTCATGA	AGAACCTTTT	CTTACTGAGC	3900
ACTAGGCAAA	ATGTAGAAGG	TTCATATGAG	GGGGCATATG	CTCCAGTACT	TCAAGATTTT	3960
AGGTCATTAA	ATGATTCAAC	AAATAGAACAA	AAGAAACACA	CAGCTCATTT	CTCAAAAAAA	4020

GGGGAGGAAG AAAACTTGGG ACGCTTGGG AATCAAACCA AGCAAATTGT AGAGAAATAT	4080
GCATGCACCA CAAGGATATC TCCTAATACA AGCCAGCAGA ATTTTGTAC GCAACGTAGT	4140
AAGAGAGCTT TGAAACAATT CAGACTCCC CTAGAAGAAA CAGAACTTGA AAAAAGGATA	4200
ATTGTGGATG ACACCTCAAC CCAGTGGTCC AAAAACATGA AACATTTGAC CCCGAGCACC	4260
CTCACACAGA TAGACTACAA TGAGAAGGAG AAAGGGCAG TTACTCAGTC TCCCTTATCA	4320
GATTGCCTTA CGAGGAGTCA TAGCATCCCT CAAGCAAATA GATCTCCATT ACCCATTGCA	4380
AAGGTATCAT CATTCCATC TATTAGACCT ATATATCTGA CCAGGGTCCT ATTCCAAGAC	4440
AACTCTTCTC ATCTTCCAGC AGCATCTTAT AGAAAGAAA ATTCTGGGT CCAAGAAAGC	4500
AGTCATTCT TACAAGGAGC CAAAAAAAAT AACCTTTCTT TAGCCATTCT AACCTTGGAG	4560
ATGACTGGTG ATCAAAGAGA GGTTGGCTCC CTGGGGACAA GTGCCACAAA TTCAGTCACA	4620
TACAAGAAAAG TTGAGAACAC TGTTCTCCCG AAACAGACT TGCCAAAAC ATCTGGCAA	4680
GTTGAATTGC TTCCAAAAGT TCACATTTAT CAGAAGGACC TATTCCCTAC GGAAACTAGC	4740
AATGGGTCTC CTGGCCATCT GGATCTCGTG GAAGGGAGCC TTCTTCAGGG AACAGAGGGA	4800
GCGATTAAGT GGAATGAAGC AACAGACCT GGAAAGTTTC CCTTTCTGAG AGTAGCAACA	4860
GAAAGCTCTG CAAAGACTCC CTCCAAGCTA TTGGATCCTC TTGCTTGGGA TAACCACTAT	4920
GGTACTCAGA TACCAAAAGA AGAGTGGAAA TCCCAAGAGA AGTCACCAGA AAAAACAGCT	4980
TTTAAGAAAA AGGATACCAT TTTGTCCCTG AACGCTTGTG AAAGCAATCA TGCAATAGCA	5040
GCAATAATG AGGGACAAAA TAAGCCGAA ATAGAAGTCA CCTGGGCAAA GCAAGGTAGG	5100
ACTGAAAGGC TGTGCTCTCA AAACCCACCA GTCTTGAAAC GCCATCAACG GGAAATAACT	5160
CGTACTACTC TTCAGTCAGA TCAAGAGGAA ATTGACTATG ATGATACCAT ATCAGTTGAA	5220
ATGAAGAAGG AAGATTTGA CATTATGAT GAGGATGAAA ATCAGAGCCC CCGCAGCTTT	5280
CAAAAGAAAA CACGACACTA TTTTATTGCT GCAGTGGAGA GGCTCTGGGA TTATGGATG	5340
AGTAGCTCCC CACATGTTCT AAGAACAGG GCTCAGAGTG GCAGTGTCCC TCAGTTCAAG	5400
AAAGTTGTTT TCCAGGAATT TACTGATGGC TCCTTTACTC AGCCCTTATA CCGTGGAGAA	5460
CTAAATGAAC ATTTGGGACT CCTGGGGCCA TATATAAGAG CAGAAGTTGA AGATAATATC	5520
ATGGTAACCT TCAGAAATCA GGCCTCTCGT CCCTATTCT TCTATTCTAG CCTTATTCT	5580
TATGAGGAAG ATCAGAGGCA AGGAGCAGAA CCTAGAAAAA ACTTTGTCAA GCCTAATGAA	5640
ACCAAAACTT ACTTTGGAA AGTGCAACAT CATATGGCAC CCACTAAAGA TGAGTTTGAC	5700

TGCAAAGCCT	GGGCTTATTT	CTCTGATGTT	GACCTGGAAA	AAGATGTGCA	CTCAGGCCTG	5760
ATTGGACCCC	TTCTGGTCTG	CCACACTAAC	ACACTGAACC	CTGCTCATGG	GAGACAAGTG	5820
ACAGTACAGG	AATTTGCTCT	GTTCCTCACC	ATCTTTGATG	AGACCAAAAG	CTGGTACTTC	5880
ACTGAAAATA	TGGAAAGAAA	CTGCAGGGCT	CCCTGCAATA	TCCAGATGGA	AGATCCCACT	5940
TTTAAAGAGA	ATTATCGCTT	CCATGCAATC	AATGGCTACA	TAATGGATAC	ACTACCTGGC	6000
TTAGTAATGG	CTCAGGATCA	AAGGATTCGA	TGGTATCTGC	TCAGCATGGG	CAGCAATGAA	6060
AACATCCATT	CTATTCAATT	CAGTGGACAT	GTGTTCACTG	TACGAAAAAA	AGAGGAGTAT	6120
AAAATGGCAC	TGTACAATCT	CTATCCAGGT	GTTCCTGAGA	CAGTGGAAAT	GTTACCATCC	6180
AAAGCTGGAA	TTTGGCGGGT	GGAATGCCCTT	ATTGGCGAGC	ATCTACATGC	TGGGATGAGC	6240
ACACTTTTC	TGGTGTACAG	CAATAAGTGT	CAGACTCCCC	TGGGAATGGC	TTCTGGACAC	6300
ATTAGAGATT	TTCAGATTAC	AGCTTCAGGA	CAATATGGAC	AGTGGGCC	AAAGCTGGCC	6360
AGACTTCATT	ATTCCGGATC	AATCAATGCC	TGGAGCACCA	AGGAGCCCTT	TTCTGGATC	6420
AAGGTGGATC	TGTTGGCACC	AATGATTATT	CACGGCATCA	AGACCCAGGG	TGCCCGTCAG	6480
AAGTTCTCCA	GCCTCTACAT	CTCTCAGTTT	ATCATCATGT	ATAGTCTTGA	TGGGAAGAAG	6540
TGGCAGACTT	ATCGAGGAAA	TTCCACTGGA	ACCTTAATGG	TCTTCTTTGG	CAATGTGGAT	6600
TCATCTGGGA	AAAAACACAA	TATTTTAAC	CCTCCAATT	TTGCTCGATA	CATCCGTTG	6660
CACCCAACTC	ATTATAGCAT	TCGCAGCACT	CTTCGCATGG	AGTTGATGGG	CTGTGATTAA	6720
AATAGTTGCA	GCATGCCATT	GGGAATGGAG	AGTAAAGCAA	TATCAGATGC	ACAGATTACT	6780
GCTTCATCCT	ACTTTACCAA	TATGTTGCC	ACCTGGTCTC	CTTCAAAAGC	TCGACTTCAC	6840
CTCCAAGGGA	GGAGTAATGC	CTGGAGACCT	CAGGTGAATA	ATCCAAAAGA	GTGGCTGCAA	6900
GTGGACTTCC	AGAAGACAAT	GAAAGTCACA	GGAGTAACTA	CTCAGGGAGT	AAAATCTCTG	6960
CTTACCAAGCA	TGTATGTGAA	GGAGTTCTC	ATCTCCAGCA	GTCAAGATGG	CCATCAGTGG	7020
ACTCTCTTTT	TTCAGAATGG	CAAAGTAAAG	GTTCCTCAGG	GAAATCAAGA	CTCCTTCACA	7080
CCTGTGGTGA	ACTCTCTAGA	CCCACCGTTA	CTGACTCGCT	ACCTTCGAAT	TCACCCCCAG	7140
AGTTGGGTGC	ACCAGATTGC	CCTGAGGATG	GAGGTTCTGG	GCTGCGAGGC	ACAGGACCTC	7200
TACTGAGGGT	GGCCACTGCA	GCACCTGCCA	CTGCCGTAC	CTCTCCCTCC	TCAGCTCCAG	7260
GGCAGTGTCC	CTCCCTGGCT	TGCCTTCTAC	CTTGTGCTA	AATCCTAGCA	GACACTGCCT	7320
TGAAGCCTCC	TGAATTAACT	ATCATCAGTC	CTGCATTCT	TTGGTGGGGG	GCCAGGAGGG	7380

TGCATCCAAT TTAACCTAAC TCTTACCTAT TTTCTGCAGC TGCTCCCAGA TTACTCCTTC	7440
CTTCCAATAT AACTAGGCAA AAAGAAAGTGA GGAGAAACCT GCATGAAAGC ATTCTTCCCT	7500
GAAAAGTTAG GCCTCTCAGA GTCACCACCT CCTCTGTTGT AGAAAAACTA TGTGATGAAA	7560
CTTGAAAAAA GATATTATG ATGTTAACAT TTCAGGTTAA GCCTCATACG TTTAAAATAA	7620
AACTCTCAGT TGTGTTATTAT CCTGATCAAG CATGGAACAA AGCATGTTTC AGGATCAGAT	7680
CAATACAATC TTGGAGTCAA AAGGCAAATC ATTTGGACAA TCTGCAAAT GGAGAGAATA	7740
CAATAACTAC TACAGTAAAG TCTGTTCTG CTTCCCTACA CATAGATATA ATTATGTTAT	7800
TTAGTCATTA TGAGGGGCAC ATTCTTATCT CCAAAACTAG CATTCTTAAA CTGAGAATTA	7860
TAGATGGGGT TCAAGAATCC CTAAGTCCCC TGAAATTATA TAAGGCATTC TGTATAAATG	7920
CAAATGTGCA TTTTCTGAC GAGTGTCCAT AGATATAAAG CCATTGGTCT TAATTCTGAC	7980
CAATAAAAAA ATAAGTCAGG AGGATGCAAT TGTTGAAAGC TTTGAAATAA AATAACATGT	8040
CTTCTTGAAA TTTGTGATGG CCAAGAAAGA AAATGATGAT GACATTAGGC TTCTAAAGGA	8100
CATACATTAA ATATTTCTGT GGAAATATGA GGAAATCCA TGGTTATCTG AGATAGGAGA	8160
TACAAACTTT GTAATTCTAA TAATGCACTC AGTTTACTCT CTCCCTCTAC TAATTTCTG	8220
CTGAAAATAA CACAACAAAA ATGTAACAGG GGAAATTATA TACCGTGACT GAAAACATGA	8280
GTCCTACTTA CATAGTTGAA ATATCAAGGA GGTCAGAAGA AAATTGGACT GGTGAAAACA	8340
GAAAAAACAC TCCAGTCTGC CATATCACCA CACAATAGGA TCCCCCTTCT TGCCCTCCAC	8400
CCCCATAAGA TTGTGAAGGG TTTACTGCTC CTTCCATCTG CCTGCACCCC TTCACTATGA	8460
CTACACAGAA CTCTCCTGAT AGTAAAGGG GCTGGAGGCA AGGATAAGTT ATAGAGCAGT	8520
TGGAGGAAGC ATCCAAAGAC TGCAACCCAG GGCAAAATGGA AAACAGGAGA TCCTAATATG	8580
AAAGAAAAAT GGATCCAAT CTGAGAAAAG GCAAAAGAAT GGCTACTTTT TTCTATGCTG	8640
GAGTATTTTC TAATAATCCT GCTTGACCCCT TATCTGACCT CTTTGGAAAC TATAACATAG	8700
CTGTCACAGT ATAGTCACAA TCCACAAATG ATGCAGGTGC AAATGGTTA TAGCCCTGTG	8760
AAGTTCTTAA AGTTTAGAGG CTAACCTACA GAAATGAATA AGTTGTTTG TTTTATAGCC	8820
CGGTAGAGGA GTTAACCCCA AAGGTGATAT GGTTTATTT CCTGTTATGT TTAACCTTGAT	8880
AATCTTATTAT TGGCATTCTT TTCCCATGGA CTATATACAT CTCTATTCT CAAATGTTCA	8940
TGGAACTAGC TCTTTATTT TCCTGCTGGT TTCTTCAGTA ATGAGTTAAA TAAAACATTG	9000
ACACATACA	9009

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 2332 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

(vi) ORIGINAL SOURCE:  
(A) ORGANISM: Homo sapiens  
(F) TISSUE TYPE: Liver

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Ala Thr Arg Arg Tyr Tyr Leu Gly Ala Val Glu Leu Ser Trp Asp Tyr  
1 5 10 15

Met Gln Ser Asp Leu Gly Glu Leu Pro Val Asp Ala Arg Phe Pro Pro  
20 25 30

Arg Val Pro Lys Ser Phe Pro Phe Asn Thr Ser Val Val Tyr Lys Lys  
35 40 45

Thr Leu Phe Val Glu Phe Thr Val His Leu Phe Asn Ile Ala Lys Pro  
50 55 60

Arg Pro Pro Trp Met Gly Leu Leu Gly Pro Thr Ile Gln Ala Glu Val  
65 70 75 80

Tyr Asp Thr Val Val Ile Thr Leu Lys Asn Met Ala Ser His Pro Val  
85 90 95

Ser Leu His Ala Val Gly Val Ser Tyr Trp Lys Ala Ser Glu Gly Ala  
100 105 110

Glu Tyr Asp Asp Gln Thr Ser Gln Arg Glu Lys Glu Asp Asp Lys Val  
115 120 125

Phe Pro Gly Gly Ser His Thr Tyr Val Trp Gln Val Leu Lys Glu Asn  
130 135 140

Gly Pro Met Ala Ser Asp Pro Leu Cys Leu Thr Tyr Ser Tyr Leu Ser  
145 150 155 160

His Val Asp Leu Val Lys Asp Leu Asn Ser Gly Leu Ile Gly Ala Leu  
165 170 175

Leu Val Cys Arg Glu Gly Ser Leu Ala Lys Glu Lys Thr Gln Thr Leu  
180 185 190

His Lys Phe Ile Leu Leu Phe Ala Val Phe Asp Glu Gly Lys Ser Trp  
195 200 205

His Ser Glu Thr Lys Asn Ser Leu Met Gln Asp Arg Asp Ala Ala Ser  
210 215 220

Ala Arg Ala Trp Pro Lys Met His Thr Val Asn Gly Tyr Val Asn Arg  
225 230 235 240

Ser Leu Pro Gly Leu Ile Gly Cys His Arg Lys Ser Val Tyr Trp His  
245 250 255

Val Ile Gly Met Gly Thr Thr Pro Glu Val His Ser Ile Phe Leu Glu  
260 265 270

Gly His Thr Phe Leu Val Arg Asn His Arg Gln Ala Ser Leu Glu Ile  
275 280 285

Ser Pro Ile Thr Phe Leu Thr Ala Gln Thr Leu Leu Met Asp Leu Gly  
290 295 300

Gln Phe Leu Leu Phe Cys His Ile Ser Ser His Gln His Asp Gly Met  
305 310 315 320

Glu Ala Tyr Val Lys Val Asp Ser Cys Pro Glu Glu Pro Gln Leu Arg  
325 330 335

Met Lys Asn Asn Glu Glu Ala Glu Asp Tyr Asp Asp Asp Leu Thr Asp  
340 345 350

Ser Glu Met Asp Val Val Arg Phe Asp Asp Asp Asn Ser Pro Ser Phe  
355 360 365

Ile Gln Ile Arg Ser Val Ala Lys Lys His Pro Lys Thr Trp Val His  
370 375 380

Tyr Ile Ala Ala Glu Glu Glu Asp Trp Asp Tyr Ala Pro Leu Val Leu  
385 390 395 400

Ala Pro Asp Asp Arg Ser Tyr Lys Ser Gln Tyr Leu Asn Asn Gly Pro  
405 410 415

Gln Arg Ile Gly Arg Lys Tyr Lys Lys Val Arg Phe Met Ala Tyr Thr  
420 425 430

Asp Glu Thr Phe Lys Thr Arg Glu Ala Ile Gln His Glu Ser Gly Ile  
435 440 445

Leu Gly Pro Leu Leu Tyr Gly Glu Val Gly Asp Thr Leu Leu Ile Ile  
450 455 460

Phe Lys Asn Gln Ala Ser Arg Pro Tyr Asn Ile Tyr Pro His Gly Ile  
465 470 475 480

Thr Asp Val Arg Pro Leu Tyr Ser Arg Arg Leu Pro Lys Gly Val Lys  
485 490 495

His Leu Lys Asp Phe Pro Ile Leu Pro Gly Glu Ile Phe Lys Tyr Lys  
500 505 510

Trp Thr Val Thr Val Glu Asp Gly Pro Thr Lys Ser Asp Pro Arg Cys  
515 520 525

Leu Thr Arg Tyr Tyr Ser Ser Phe Val Asn Met Glu Arg Asp Leu Ala  
530 535 540

Ser Gly Leu Ile Gly Pro Leu Leu Ile Cys Tyr Lys Glu Ser Val Asp  
545 550 555 560

Gln Arg Gly Asn Gln Ile Met Ser Asp Lys Arg Asn Val Ile Leu Phe  
565 570 575

Ser Val Phe Asp Glu Asn Arg Ser Trp Tyr Leu Thr Glu Asn Ile Gln  
580 585 590

Arg Phe Leu Pro Asn Pro Ala Gly Val Gln Leu Glu Asp Pro Glu Phe  
595 600 605

Gln Ala Ser Asn Ile Met His Ser Ile Asn Gly Tyr Val Phe Asp Ser  
610 615 620

Leu Gln Leu Ser Val Cys Leu His Glu Val Ala Tyr Trp Tyr Ile Leu  
625 630 635 640

Ser Ile Gly Ala Gln Thr Asp Phe Leu Ser Val Phe Phe Ser Gly Tyr  
645 650 655

Thr Phe Lys His Lys Met Val Tyr Glu Asp Thr Leu Thr Leu Phe Pro  
660 665 670

Phe Ser Gly Glu Thr Val Phe Met Ser Met Glu Asn Pro Gly Leu Trp  
675 680 685

Ile Leu Gly Cys His Asn Ser Asp Phe Arg Asn Arg Gly Met Thr Ala  
690 695 700

Leu Leu Lys Val Ser Ser Cys Asp Lys Asn Thr Gly Asp Tyr Tyr Glu  
705 710 715 720

Asp Ser Tyr Glu Asp Ile Ser Ala Tyr Leu Leu Ser Lys Asn Asn Ala  
725 730 735

Ile Glu Pro Arg Ser Phe Ser Gln Asn Ser Arg His Pro Ser Thr Arg  
740 745 750

Gln Lys Gln Phe Asn Ala Thr Thr Ile Pro Glu Asn Asp Ile Glu Lys  
755 760 765

Thr Asp Pro Trp Phe Ala His Arg Thr Pro Met Pro Lys Ile Gln Asn  
770 775 780

Val Ser Ser Ser Asp Leu Leu Met Leu Leu Arg Gln Ser Pro Thr Pro  
 785                    790                    795                    800  
  
 His Gly Leu Ser Leu Ser Asp Leu Gln Glu Ala Lys Tyr Glu Thr Phe  
 805                    810                    815  
  
 Ser Asp Asp Pro Ser Pro Gly Ala Ile Asp Ser Asn Asn Ser Leu Ser  
 820                    825                    830  
  
 Glu Met Thr His Phe Arg Pro Gln Leu His His Ser Gly Asp Met Val  
 835                    840                    845  
  
 Phe Thr Pro Glu Ser Gly Leu Gln Leu Arg Leu Asn Glu Lys Leu Gly  
 850                    855                    860  
  
 Thr Thr Ala Ala Thr Glu Leu Lys Leu Asp Phe Lys Val Ser Ser  
 865                    870                    875                    880  
  
 Thr Ser Asn Asn Leu Ile Ser Thr Ile Pro Ser Asp Asn Leu Ala Ala  
 885                    890                    895  
  
 Gly Thr Asp Asn Thr Ser Ser Leu Gly Pro Pro Ser Met Pro Val His  
 900                    905                    910  
  
 Tyr Asp Ser Gln Leu Asp Thr Thr Leu Phe Gly Lys Lys Ser Ser Pro  
 915                    920                    925  
  
 Leu Thr Glu Ser Gly Gly Pro Leu Ser Leu Ser Glu Glu Asn Asn Asp  
 930                    935                    940  
  
 Ser Lys Leu Leu Glu Ser Gly Leu Met Asn Ser Gln Glu Ser Ser Trp  
 945                    950                    955                    960  
  
 Gly Lys Asn Val Ser Ser Thr Glu Ser Gly Arg Leu Phe Lys Gly Lys  
 965                    970                    975  
  
 Arg Ala His Gly Pro Ala Leu Leu Thr Lys Asp Asn Ala Leu Phe Lys  
 980                    985                    990  
  
 Val Ser Ile Ser Leu Leu Lys Thr Asn Lys Thr Ser Asn Asn Ser Ala  
 995                    1000                    1005  
  
 Thr Asn Arg Lys Thr His Ile Asp Gly Pro Ser Leu Leu Ile Glu Asn  
 1010                    1015                    1020  
  
 Ser Pro Ser Val Trp Gln Asn Ile Leu Glu Ser Asp Thr Glu Phe Lys  
 1025                    1030                    1035                    1040  
  
 Lys Val Thr Pro Leu Ile His Asp Arg Met Leu Met Asp Lys Asn Ala  
 1045                    1050                    1055  
  
 Thr Ala Leu Arg Leu Asn His Met Ser Asn Lys Thr Thr Ser Ser Lys  
 1060                    1065                    1070  
  
 Asn Met Glu Met Val Gln Gln Lys Lys Glu Gly Pro Ile Pro Pro Asp  
 1075                    1080                    1085

Ala Gln Asn Pro Asp Met Ser Phe Phe Lys Met Leu Phe Leu Pro Glu  
1090                    1095                    1100

Ser Ala Arg Trp Ile Gln Arg Thr His Gly Lys Asn Ser Leu Asn Ser  
1105                    1110                    1115                    1120

Gly Gln Gly Pro Ser Pro Lys Gln Leu Val Ser Leu Gly Pro Glu Lys  
1125                    1130                    1135

Ser Val Glu Gly Gln Asn Phe Leu Ser Glu Lys Asn Lys Val Val Val  
1140                    1145                    1150

Gly Lys Gly Glu Phe Thr Lys Asp Val Gly Leu Lys Glu Met Val Phe  
1155                    1160                    1165

Pro Ser Ser Arg Asn Leu Phe Leu Thr Asn Leu Asp Asn Leu His Glu  
1170                    1175                    1180

Asn Asn Thr His Asn Gln Glu Lys Lys Ile Gln Glu Glu Ile Glu Lys  
1185                    1190                    1195                    1200

Lys Glu Thr Leu Ile Gln Glu Asn Val Val Leu Pro Gln Ile His Thr  
1205                    1210                    1215

Val Thr Gly Thr Lys Asn Phe Met Lys Asn Leu Phe Leu Leu Ser Thr  
1220                    1225                    1230

Arg Gln Asn Val Glu Gly Ser Tyr Glu Gly Ala Tyr Ala Pro Val Leu  
1235                    1240                    1245

Gln Asp Phe Arg Ser Leu Asn Asp Ser Thr Asn Arg Thr Lys Lys His  
1250                    1255                    1260

Thr Ala His Phe Ser Lys Lys Gly Glu Glu Asn Leu Glu Gly Leu  
1265                    1270                    1275                    1280

Gly Asn Gln Thr Lys Gln Ile Val Glu Lys Tyr Ala Cys Thr Thr Arg  
1285                    1290                    1295

Ile Ser Pro Asn Thr Ser Gln Gln Asn Phe Val Thr Gln Arg Ser Lys  
1300                    1305                    1310

Arg Ala Leu Lys Gln Phe Arg Leu Pro Leu Glu Glu Thr Glu Leu Glu  
1315                    1320                    1325

Lys Arg Ile Ile Val Asp Asp Thr Ser Thr Gln Trp Ser Lys Asn Met  
1330                    1335                    1340

Lys His Leu Thr Pro Ser Thr Leu Thr Gln Ile Asp Tyr Asn Glu Lys  
1345                    1350                    1355                    1360

Glu Lys Gly Ala Ile Thr Gln Ser Pro Leu Ser Asp Cys Leu Thr Arg  
1365                    1370                    1375

Ser His Ser Ile Pro Gln Ala Asn Arg Ser Pro Leu Pro Ile Ala Lys  
1380                    1385                    1390

Val Ser Ser Phe Pro Ser Ile Arg Pro Ile Tyr Leu Thr Arg Val Leu  
 1395 1400 1405  
  
 Phe Gln Asp Asn Ser Ser His Leu Pro Ala Ala Ser Tyr Arg Lys Lys  
 1410 1415 1420  
  
 Asp Ser Gly Val Gln Glu Ser Ser His Phe Leu Gln Gly Ala Lys Lys  
 1425 1430 1435 1440  
  
 Asn Asn Leu Ser Leu Ala Ile Leu Thr Leu Glu Met Thr Gly Asp Gln  
 1445 1450 1455  
  
 Arg Glu Val Gly Ser Leu Gly Thr Ser Ala Thr Asn Ser Val Thr Tyr  
 1460 1465 1470  
  
 Lys Lys Val Glu Asn Thr Val Leu Pro Lys Pro Asp Leu Pro Lys Thr  
 1475 1480 1485  
  
 Ser Gly Lys Val Glu Leu Leu Pro Lys Val His Ile Tyr Gln Lys Asp  
 1490 1495 1500  
  
 Leu Phe Pro Thr Glu Thr Ser Asn Gly Ser Pro Gly His Leu Asp Leu  
 1505 1510 1515 1520  
  
 Val Glu Gly Ser Leu Leu Gln Gly Thr Glu Gly Ala Ile Lys Trp Asn  
 1525 1530 1535  
  
 Glu Ala Asn Arg Pro Gly Lys Val Pro Phe Leu Arg Val Ala Thr Glu  
 1540 1545 1550  
  
 Ser Ser Ala Lys Thr Pro Ser Lys Leu Leu Asp Pro Leu Ala Trp Asp  
 1555 1560 1565  
  
 Asn His Tyr Gly Thr Gln Ile Pro Lys Glu Glu Trp Lys Ser Gln Glu  
 1570 1575 1580  
  
 Lys Ser Pro Glu Lys Thr Ala Phe Lys Lys Asp Thr Ile Leu Ser  
 1585 1590 1595 1600  
  
 Leu Asn Ala Cys Glu Ser Asn His Ala Ile Ala Ala Ile Asn Glu Gly  
 1605 1610 1615  
  
 Gln Asn Lys Pro Glu Ile Glu Val Thr Trp Ala Lys Gln Gly Arg Thr  
 1620 1625 1630  
  
 Glu Arg Leu Cys Ser Gln Asn Pro Pro Val Leu Lys Arg His Gln Arg  
 1635 1640 1645  
  
 Glu Ile Thr Arg Thr Thr Leu Gln Ser Asp Gln Glu Glu Ile Asp Tyr  
 1650 1655 1660  
  
 Asp Asp Thr Ile Ser Val Glu Met Lys Lys Glu Asp Phe Asp Ile Tyr  
 1665 1670 1675 1680  
  
 Asp Glu Asp Glu Asn Gln Ser Pro Arg Ser Phe Gln Lys Lys Thr Arg  
 1685 1690 1695

His Tyr Phe Ile Ala Ala Val Glu Arg Leu Trp Asp Tyr Gly Met Ser  
 1700 1705 1710  
  
 Ser Ser Pro His Val Leu Arg Asn Arg Ala Gln Ser Gly Ser Val Pro  
 1715 1720 1725  
  
 Gln Phe Lys Lys Val Val Phe Gln Glu Phe Thr Asp Gly Ser Phe Thr  
 1730 1735 1740  
  
 Gln Pro Leu Tyr Arg Gly Glu Leu Asn Glu His Leu Gly Leu Leu Gly  
 1745 1750 1755 1760  
  
 Pro Tyr Ile Arg Ala Glu Val Glu Asp Asn Ile Met Val Thr Phe Arg  
 1765 1770 1775  
  
 Asn Gln Ala Ser Arg Pro Tyr Ser Phe Tyr Ser Ser Leu Ile Ser Tyr  
 1780 1785 1790  
  
 Glu Glu Asp Gln Arg Gln Gly Ala Glu Pro Arg Lys Asn Phe Val Lys  
 1795 1800 1805  
  
 Pro Asn Glu Thr Lys Thr Tyr Phe Trp Lys Val Gln His His Met Ala  
 1810 1815 1820  
  
 Pro Thr Lys Asp Glu Phe Asp Cys Lys Ala Trp Ala Tyr Phe Ser Asp  
 1825 1830 1835 1840  
  
 Val Asp Leu Glu Lys Asp Val His Ser Gly Leu Ile Gly Pro Leu Leu  
 1845 1850 1855  
  
 Val Cys His Thr Asn Thr Leu Asn Pro Ala His Gly Arg Gln Val Thr  
 1860 1865 1870  
  
 Val Gln Glu Phe Ala Leu Phe Phe Thr Ile Phe Asp Glu Thr Lys Ser  
 1875 1880 1885  
  
 Trp Tyr Phe Thr Glu Asn Met Glu Arg Asn Cys Arg Ala Pro Cys Asn  
 1890 1895 1900  
  
 Ile Gln Met Glu Asp Pro Thr Phe Lys Glu Asn Tyr Arg Phe His Ala  
 1905 1910 1915 1920  
  
 Ile Asn Gly Tyr Ile Met Asp Thr Leu Pro Gly Leu Val Met Ala Gln  
 1925 1930 1935  
  
 Asp Gln Arg Ile Arg Trp Tyr Leu Leu Ser Met Gly Ser Asn Glu Asn  
 1940 1945 1950  
  
 Ile His Ser Ile His Phe Ser Gly His Val Phe Thr Val Arg Lys Lys  
 1955 1960 1965  
  
 Glu Glu Tyr Lys Met Ala Leu Tyr Asn Leu Tyr Pro Gly Val Phe Glu  
 1970 1975 1980  
  
 Thr Val Glu Met Leu Pro Ser Lys Ala Gly Ile Trp Arg Val Glu Cys  
 1985 1990 1995 2000

Leu Ile Gly Glu His Leu His Ala Gly Met Ser Thr Leu Phe Leu Val  
2005 2010 2015

Tyr Ser Asn Lys Cys Gln Thr Pro Leu Gly Met Ala Ser Gly His Ile  
2020 2025 2030

Arg Asp Phe Gln Ile Thr Ala Ser Gly Gln Tyr Gly Gln Trp Ala Pro  
2035 2040 2045

Lys Leu Ala Arg Leu His Tyr Ser Gly Ser Ile Asn Ala Trp Ser Thr  
2050 2055 2060

Lys Glu Pro Phe Ser Trp Ile Lys Val Asp Leu Leu Ala Pro Met Ile  
2065 2070 2075 2080

Ile His Gly Ile Lys Thr Gln Gly Ala Arg Gln Lys Phe Ser Ser Leu  
2085 2090 2095

Tyr Ile Ser Gln Phe Ile Ile Met Tyr Ser Leu Asp Gly Lys Lys Trp  
2100 2105 2110

Gln Thr Tyr Arg Gly Asn Ser Thr Gly Thr Leu Met Val Phe Phe Gly  
2115 2120 2125

Asn Val Asp Ser Ser Gly Ile Lys His Asn Ile Phe Asn Pro Pro Ile  
2130 2135 2140

Ile Ala Arg Tyr Ile Arg Leu His Pro Thr His Tyr Ser Ile Arg Ser  
2145 2150 2155 2160

Thr Leu Arg Met Glu Leu Met Gly Cys Asp Leu Asn Ser Cys Ser Met  
2165 2170 2175

Pro Leu Gly Met Glu Ser Lys Ala Ile Ser Asp Ala Gln Ile Thr Ala  
2180 2185 2190

Ser Ser Tyr Phe Thr Asn Met Phe Ala Thr Trp Ser Pro Ser Lys Ala  
2195 2200 2205

Arg Leu His Leu Gln Gly Arg Ser Asn Ala Trp Arg Pro Gln Val Asn  
2210 2215 2220

Asn Pro Lys Glu Trp Leu Gln Val Asp Phe Gln Lys Thr Met Lys Val  
2225 2230 2235 2240

Thr Gly Val Thr Thr Gln Gly Val Lys Ser Leu Leu Thr Ser Met Tyr  
2245 2250 2255

Val Lys Glu Phe Leu Ile Ser Ser Gln Asp Gly His Gln Trp Thr  
2260 2265 2270

Leu Phe Phe Gln Asn Gly Lys Val Lys Val Phe Gln Gly Asn Gln Asp  
2275 2280 2285

Ser Phe Thr Pro Val Val Asn Ser Leu Asp Pro Pro Leu Leu Thr Arg  
2290 2295 2300

Tyr Leu Arg Ile His Pro Gln Ser Trp Val His Gln Ile Ala Leu Arg  
 2305                    2310                    2315                    2320

Met Glu Val Leu Gly Cys Glu Ala Gln Asp Leu Tyr  
 2325                    2330

## (2) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1130 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Porcine
- (F) TISSUE TYPE: blood

(ix) FEATURE:

- (A) NAME/KEY: misc\_feature
- (B) LOCATION: 1..1130
- (D) OTHER INFORMATION: /product= "region"

/note= "cDNA encoding A2 domain of porcine factorVIII"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TAAGCACCCCT AAGACGTGGG TGCACTACAT CTCTGCAGAG GAGGAGGACT GGGACTACGC	60
CCCCGCGGTC CCCAGCCCCA GTGACAGAAAG TTATAAAAGT CTCTACTTGA ACAGTGGTCC	120
TCAGCGAATT GGTAGGAAAT ACAAAAAAGC TCGATTGTC GCTTACACGG ATGTAACATT	180
TAAGACTCGT AAAGCTATTTC CGTATGAATC AGGAATCCTG GGACCTTTAC TTTATGGAGA	240
AGTTGGAGAC ACACTTTGA TTATATTAA GAATAAAGCG AGCCGACCAC ATAACATCTA	300
CCCTCATGGA ATCACTGATG TCAGCGCTTT GCACCCAGGG AGACTTCTAA AAGGTTGGAA	360
ACATTTGAAA GACATGCCAA TTCTGCCAGG AGAGACTTTC AAGTATAAAT GGACAGTGAC	420
TGTGGAAGAT GGGCCAACCA AGTCCGATCC TCGGTGCCCTG ACCCGCTACT ACTCGAGCTC	480
CATTAATCTA GAGAAAGATC TGGCTTCGGG ACTCATTGGC CCTCTCCTCA TCTGCTACAA	540
AGAATCTGTA GACCAAAGAG GAAACCGAGAT GATGTCAGAC AAGAGAAACG TCATCCTGTT	600
TTCTGTATTC GATGAGAATC AAAGCTGGTA CCTCGCAGAG AATATTCAAGC GCTTCCTCCC	660
CAATCCGGAT GGATTACAGC CCCAGGATCC AGAGTTCCAA GCTTCTAACCA TCATGCACAG	720

CATCAATGGC TATGTTTTG ATAGCTTGCA GCTGTCGGTT TGTTTGCACG AGGTGGCATA	780
CTGGTACATT CTAAGTGGT GAGCACAGAC GGACTTCCTC TCCGTCTTCT TCTCTGGCTA	840
CACCTTCAAA CACAAAATGG TCTATGAAGA CACACTCACC CTGTTCCCCT TCTCAGGAGA	900
AACGGTCTTC ATGTCAATGG AAAACCCAGG TCTCTGGTC CTAGGGTGCC ACAACTCAGA	960
CTTGCAGAAC AGAGGGATGA CAGCCTTACT GAAGGTGTAT AGTTGTGACA GGGACATTGG	1020
TGATTATTAT GACAACACTT ATGAAGATAT TCCAGGCTTC TTGCTGAGTG GAAAGAATGT	1080
CATTGAACCC AGAAGCTTG CCCAGAATTG AAGACCCCT AGTGCAGCA	1130

## (2) INFORMATION FOR SEQ ID NO:4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 368 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Porcine
- (F) TISSUE TYPE: spleen

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..368

(D) OTHER INFORMATION: /note= "Predicted amino acid sequence of porcine factor VIII A2 domain, defined as residues homologous to human factor VIII, amino acids 373-740. Residues 1-4 are from known porcine amino acid sequence."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Ser Val Ala Lys Lys His Pro Lys Thr Trp Val His Tyr Ile Ser Ala			
1	5	10	15

Glu Glu Glu Asp Trp Asp Tyr Ala Pro Ala Val Pro Ser Pro Ser Asp		
20	25	30

Arg Ser Tyr Lys Ser Leu Tyr Leu Asn Ser Gly Pro Gln Arg Ile Gly		
35	40	45

Arg Lys Tyr Lys Lys Ala Arg Phe Val Ala Tyr Thr Asp Val Thr Phe		
50	55	60

Lys Thr Arg Lys Ala Ile Pro Tyr Glu Ser Gly Ile Leu Gly Pro Leu  
 65 70 75 80  
 Leu Tyr Gly Glu Val Gly Asp Thr Leu Leu Ile Ile Phe Lys Asn Lys  
 85 90 95  
 Ala Ser Arg Pro Tyr Asn Ile Tyr Pro His Gly Ile Thr Asp Val Ser  
 100 105 110  
 Ala Leu His Pro Gly Arg Leu Leu Lys Gly Trp Lys His Leu Lys Asp  
 115 120 125  
 Met Pro Ile Leu Pro Gly Glu Thr Phe Lys Tyr Lys Trp Thr Val Thr  
 130 135 140  
 Val Glu Asp Gly Pro Thr Lys Ser Asp Pro Arg Cys Leu Thr Arg Tyr  
 145 150 155 160  
 Tyr Ser Ser Ser Ile Asn Leu Glu Lys Asp Leu Ala Ser Gly Leu Ile  
 165 170 175  
 Gly Pro Leu Leu Ile Cys Tyr Lys Glu Ser Val Asp Gln Arg Gly Asn  
 180 185 190  
 Gln Met Met Ser Asp Lys Arg Asn Val Ile Leu Phe Ser Val Phe Asp  
 195 200 205  
 Glu Asn Gln Ser Trp Tyr Leu Ala Glu Asn Ile Gln Arg Phe Leu Pro  
 210 215 220  
 Asn Pro Asp Gly Leu Gln Pro Gln Asp Pro Glu Phe Gln Ala Ser Asn  
 225 230 235 240  
 Ile Met His Ser Ile Asn Gly Tyr Val Phe Asp Ser Leu Gln Leu Ser  
 245 250 255  
 Val Cys Leu His Glu Val Ala Tyr Trp Tyr Ile Leu Ser Val Gly Ala  
 260 265 270  
 Gln Thr Asp Phe Leu Ser Val Phe Phe Ser Gly Tyr Thr Phe Lys His  
 275 280 285  
 Lys Met Val Tyr Glu Asp Thr Leu Thr Leu Phe Pro Phe Ser Gly Glu  
 290 295 300  
 Thr Val Phe Met Ser Met Glu Asn Pro Gly Leu Trp Val Leu Gly Cys  
 305 310 315 320  
 His Asn Ser Asp Leu Arg Asn Arg Gly Met Thr Ala Leu Leu Lys Val  
 325 330 335  
 Tyr Ser Cys Asp Arg Asp Ile Gly Asp Tyr Tyr Asp Asn Thr Tyr Glu  
 340 345 350  
 Asp Ile Pro Gly Phe Leu Leu Ser Gly Lys Asn Val Ile Glu Pro Arg  
 355 360 365

## (2) INFORMATION FOR SEQ ID NO:5:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7493 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Mus musculus*

(ix) FEATURE:

- (A) NAME/KEY: repeat\_unit
- (B) LOCATION: 1..407
- (D) OTHER INFORMATION: /rpt\_type= "terminal"

/note= "5' UTR"

(ix) FEATURE:

- (A) NAME/KEY: misc\_feature
- (B) LOCATION: 7471..7476
- (D) OTHER INFORMATION: /function= "polyA signal"

(ix) FEATURE:

- (A) NAME/KEY: repeat\_unit
- (B) LOCATION: 7368..7493
- (D) OTHER INFORMATION: /rpt\_type= "terminal"

/note= "3' UTR"

(ix) FEATURE:

- (A) NAME/KEY: misc\_feature
- (B) LOCATION: 408..7367
- (D) OTHER INFORMATION: /product= "coagulation factor VIII"

## (x) PUBLICATION INFORMATION:

- (A) AUTHORS: Elder, F.  
Lakich, D.  
Gitschier, J.
- (B) TITLE: Sequence of the murine Factor VIII cDNA
- (C) JOURNAL: Genomics
- (D) VOLUME: 16
- (F) PAGES: 374-379
- (G) DATE: 1993

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

TCTAGAGTTT CTTTGCTACA GGTACCAAGG AACAGTCCTT TAGAATAGGC TAGGAATTAA

60

AATACACCTG AACGCCCTC CTCAGTATTG TGTTCCCTTT CTTAAGGATT CAAACTTGTT

120

AGGATGCACC CAGCAGGAAA TGGGTTAACG CTTAGCTCAG CCACCTCTCC TATTCCAGTT	180
TTCCTGTGCC TGCTTCCTAC TACCCAAAAG GAAGTAATCC TTCAGATCTG TTTTGTGCTA	240
ATGCTACTTT CACTCACAGT AGATAAAACTT CCAGAAAATC CTCTGCAAAA TATTTAGGAC	300
TTTTTACTAA ATCATTACAT TTCTTTTG TCTTAAAAGC TAAAGTTATT TTAGAGAAGA	360
GTAAATTTT CATTCTTTA GTTGAACATT TTCTAGTAAT AAAAGCCATG CAAATAGCAC	420
TCTTCGCTTG CTTCTTCTG AGCCTTTCA ATTTCTGCTC TAGTGCCATC AGAAGATACT	480
ACCTTGGTGC AGTGGAAATIG TCCTGGAACAT ATATTCAAGAG TGATCTGCTC AGTGTGCTGC	540
ATACAGACTC AAGATTTCTT CCTAGAACATGT CAACATCTT TCCATTCAAC ACCTCCATCA	600
TGTATAAAAA GACTGTGTT GTAGAGTACA AGGACCAGCT TTTCAACATT GCCAAGCCCA	660
GGCCACCCCTG GATGGGTTTG CTAGGTCTA CCATTGGAC TGAGGTTCAT GACACAGTGG	720
TCATTACACT TAAAAACATG GCTTCTCATC CTGTCAGTCT TCATGCTGTT GGTGTGCTC	780
ACTGGAAAGC TTCTGAGGGA GATGAATATG AAGATCAGAC AAGCCAAATG GAGAAGGAAG	840
ATGATAAAAGT TTTCCCTGGT GAAAGTCATA CTTATGTTTG GCAAGTCCTG AAAGAGAATG	900
GTCCAATGGC CTCTGACCCCT CCATGTCTCA CTTACTCATA TATGTCTCAT GTGGATCTGG	960
TGAAAGATTT GAATTCAAGGC CTCATTGGAG CTCTGCTAGT ATGTAAGAA GGCACTCTCT	1020
CCAAAGAAAG AACACAGATG TTGTACCAAT TTGTACTGCT TTTTGCTGTA TTTGATGAAG	1080
GGAAGAGCTG GCACTCAGAA ACAAACGACT CTTATACACA GTCTATGGAT TCTGCATCTG	1140
CTAGAGACTG GCCTAAAATG CACACAGTCA ATGGCTATGT AAACAGGTCT CTTCCAGGTC	1200
TGATTGGATG CCATAGGAAA TCAGTCTACT GGCACGTGAT TGGAATGGGC ACCACTCCTG	1260
AAATACACTC AATATTCCCTC GAAGGTACACA CATTGTTGT GAGGAACCAC CGTCAAGCTT	1320
CATTGGAGAT ATCACCAATA ACTTTCTTA CTGCTCAAAC ACTCTTGATA GATCTTGGGC	1380
AGTCCTACT ATTTGTCAT ATCTCTTCCC ATAAACATGA TGGCATGGAA GCTTATGTCA	1440
AAGTAGATAG CTGCCCTGAG GAATCCAAT GGCAAAAGAA AAATAATAAT GAGGAAATGG	1500
AAGATTATGA TGATGATCTT TATTCAAGAAA TGGATATGTT CACATTGGAT TATGACAGCT	1560
CTCCTTTAT CCAAATTCGC TCGGTTGCTA AAAAGTACCC TAAAACCTGG ATACATTATA	1620
TTTCTGCTGA GGAGGAAGAC TGGGACTATG CACCTTCAGT TCCTACCTCG GATAATGGAA	1680
GTTATAAAAG CCAGTATCTG AGCAATGGTC CTCATCGGAT TGGTAGGAAA TATAAAAAG	1740
TCAGATTTAT AGCATAACACA GATGAAACCT TTAAGACTCG TGAAACTATT CAGCATGAAT	1800

CAGGACTCTT	GGGACCTTA	CTTTATGGAG	AAGTTGGAGA	CACACTGTTG	ATTATTTTA	1860
AGAACATCAAGC	AAGCCGACCA	TATAACATTT	ACCCCTCATGG	AATCACTGAT	GTCAGTCCTC	1920
TACATGCAAG	GAGATTGCCA	AGAGGTATAA	AGCACGTGAA	GGATTTGCCA	ATTCATCCAG	1980
GAGAGATATT	CAAGTACAAG	TGGACAGTTA	CAGTAGAAGA	TGGACCAACT	AAATCAGATC	2040
CACGGTGCCT	GACCCGCTAT	TATTCAAGTT	TCATTAACCC	TGAGAGAGAT	CTAGCTTCAG	2100
GACTGATTGG	CCCTCTTCTC	ATCTGCTACA	AAGAATCTGT	AGATCAAAGG	GGAAACCAGA	2160
TGATGTCAGA	CAAAAGAAAT	GTCATCCTGT	TTTCTATATT	TGATGAGAAC	CAAAGCTGGT	2220
ACATCACAGA	GAACATGCAA	CGCTTCCTCC	CCAATGCAGC	AAAAACACAG	CCCCAGGACC	2280
CTGGGTTCCA	GGCCTCCAAAC	ATCATGCACA	GCATCAATGG	CTATGTTTTT	GATAGCTTGG	2340
AGTTGACAGT	TTGTTTGCAT	GAGGTGGCAT	ACTGGCACAT	TCTCAGTGTT	GGAGCACAGA	2400
CAGACTTCTT	ATCTATCTTC	TTCTCTGGAT	ATACTTTCAA	ACACAAAATG	GTCTATGAAG	2460
ATACACTTAC	CCTGTTCCA	TTCTCAGGAG	AAACTGTCTT	TATGTCGATG	AAAAACCCAG	2520
GTCTATGGGT	CTTGGGGTGT	CATAATTCA	ACTTTCGGAA	GAGAGGTATG	ACAGCATTGC	2580
TGAAAGTTTC	TAGTTGTGAC	AAGAGCACTA	GTGATTATTA	TGAAGAAATA	TATGAAGATA	2640
TTCCAACACA	GTTGGTGAAT	GAGAACATG	TCATTGATCC	CAGAAGCTTC	TTCCAGAATA	2700
CAAATCATCC	TAATACTAGG	AAAAAGAAAT	TCAAAGATT	CACAATTCCA	AAAAATGATA	2760
TGGAGAAGAT	TGAGCCTCAG	TTTGAAGAGA	TAGCAGAGAT	GCTTAAAGTA	CAGAGTGTCT	2820
CAGTTAGTGA	CATGTTGATG	CTCTGGGAC	AGAGTCATCC	TACTCCACAT	GGCTTATTTT	2880
TATCAGATGG	CCAAGAACCC	ATCTATGAGG	CTATTCA	TGATCATTCA	CCAAATGCAA	2940
TAGACAGCAA	TGAAGGCCA	TCTAAAGTGA	CCCAACTCAG	GCCAGAATCC	CATCACAGTG	3000
AGAAAATAGT	ATTTACTCCT	CAGCCGGCC	TCCAGTTAAG	ATCCAATAAA	AGTTTGGAGA	3060
CAACTATAGA	AGTAAAGTGG	AAGAAACTTG	GTGCAAGT	TTCTAGTTG	CCAAGTAATC	3120
TAATGACTAC	AAACAATTCTG	TCAGACAATT	TGAAAGCAAC	TTTGAAAAG	ACAGATTCTT	3180
CAGGATTTC	AGATATGCCA	GTTCACTCTA	GTAGTAAATT	AACTACTACT	GCATTTGGTA	3240
AGAAAGCATA	TTCCCTTGT	GGGTCTCATG	TACCTTTAAA	CGCGAGTGAA	AAAAATAGTG	3300
ATTCCAACAT	ATTGGATTCA	ACTTTAATGT	ATAGTCAAGA	AAGTTTACCA	AGAGATAATA	3360
TATTATCAAT	AGAGAAATGAT	AGATTACTCA	GAGAGAAGAG	GTTTCATGGA	ATTGCTTTAT	3420
TGACCAAAGA	TAATACTTTA	TTCAAAGACA	ATGTCTCCTT	AATGAAAACA	AAACAAACAT	3480

ATAATCATTC AACAACTAAT GAAAAACTAC ACACGTGAGAG CCCAACATCA ATTGAGAATA	3540
GTACAACAGA CTTGCAAGAT GCCATATTAA AGGTCAATAG TGAGATTCAA GAAGTAACAG	3600
CTTGATTCA TGATGGAACA CTTTAGGCA AAAATTCTAC ATATTTGAGA CTAACCATA	3660
TGCTAAATAG AACTACCTCA ACAAAAAATA AAGACATATT TCATAGAAAA GATGAAGATC	3720
CTATTCCACA AGATGAAGAG AATACAATCA TGCCATTTC CAAGATGTTG TTCTTGTCA	3780
AATCTCAAA TTGGTTAAA AAGACCAATG GAAATAATT CTTGAACCT GAGCAAGAAC	3840
ATAGTCAAA GCAATTAGTA TATTTAATGT TTAAAAAATA TGTAAAAAT CAAAGTTCT	3900
TGTCAGAGAA AAATAAGTC ACAGTAGAAC AGGATGGATT TACAAAGAAC ATAGGACTTA	3960
AAGACATGGC TTTTCCACAT AATATGAGCA TATTTCTTAC CACTTGTCT AACGTACATG	4020
AAAATGGTAG GCACAATCAA GAAAAAATA TTCAGGAAGA GATAGAGAAC GAAGCACTAA	4080
TTGAAGAGAA AGTAGTTTG CCCCAGGTGC ACGAAGCAAC TGGCTCTAAG AATTTCTGA	4140
AAGACATATT GATACTAGGC ACTAGGCAAA ATATAAGTT ATATGAAGTA CATGTACCA	4200
TACTTCAAA CATCACATCA ATAAACAATT CAACAAATAC AGTACAGATT CACATGGAGC	4260
ATTTCTTAA AAGAAGGAAG GACAAGGAAA CAAATTAGA AGGCTTGGTA AATAAACCA	4320
GAGAAATGGT AAAAAACTAT CCAAGCCAGA AGAATATTAC TACTCAACGT AGTAAACGGG	4380
CTTTGGGACA ATTCAAGACTG TCAACTCAAT GGCTTAAAC CATAAACTGT TCAACACAGT	4440
GTATCATTAA ACAGATAGAC CACAGCAAGG AAATGAAAAA GTTCATTACT AAATCTTCCT	4500
TATCAGATTG TTCTGTGATT AAAAGCACCA CTCAGACAAA TAGTTCTGAC TCACACATTG	4560
TAAAAACATC AGCATTCCA CCAATAGATC TCAAAAGGAG TCCATTCAA AACAAATT	4620
CTCATGTTCA AGCATCATCC TACATTATG ACTTTAAGAC AAAAGTTCA AGAATTCAAG	4680
AAAGCAATAA TTCTTAAAGA GAAACCAAAA TAAATAACCC TTCTTAGCC ATTCTACCAT	4740
GGAATATGTT CATAGATCAA GGAAAATTAA CCTCCCCAGG GAAAAGTAAC ACAAACTCAG	4800
TCACATATAA GAAACGTGAG AACATTATT TCTTGAAACC AACTTGCCT GAAGAATCTG	4860
GCAAAATTGA ATTGCTTCCT CAAGTTCCA TTCAAGAGGA AGAAATTAA CCTACAGAAA	4920
CTAGCCATGG ATCTCCTGGA CACTGAATC TCATGAAAGA GGTCTTCTT CAGAAAATAC	4980
AGGGGCCTAC TAAATGGAAT AAAGCAAAGA GGCATGGAGA AAGTATAAAA GGTAAAACAG	5040
AGAGCTCTAA AAATACTCGC TCAAAACTGC TAAATCATCA TGCTTGGGAT TATCATTATG	5100
CTGCACAGAT ACCAAAAGAT ATGTGGAAAT CCAAGAGAAC GTCACCAAGAA ATTATATCCA	5160

TTAAGCAAGA GGACACCATT TTGTCTCTGA GGCCTCATGG AAACAGTCAT TCAATAGGGG	5220
CAAATGAGAA ACAAAATTGG CCTCAAAGAG AAACCACTTG GGTAAAGCAA GGCCAAACTC	5280
AAAGGACATG CTCTCAAATC CCACCAGTGT TGAAACGACA TCAAAGGGAA CTTAGTGCTT	5340
TTCAATCAGA ACAAGAACAGCA ACTGACTATG ATGATGCCAT CACCATTGAA ACAATCGAGG	5400
ATTTTGACAT TTACAGTGAG GACATAAAGC AAGGTCCCCG CAGCTTCAGA CAGAAAACAA	5460
GGCACTATTT TATTGCAGCT GTGGAACGAC TCTGGGACTA TGGGATGAGT ACATCTCATG	5520
TTCTACGAAA TAGGTATCAA AGTGACAATG TACCTCAGTT CAAGAAAGTA GTTTCCAGG	5580
AATTTACTGA TGGCTCCTTT AGTCAGCCCT TATATCGTGG AGAATTAAAT GAACACCTGG	5640
GGTTGTTGGG CCCATATATA AGAGCAGAAG TTGAAGACAA CATTATGGTA ACTTTCAAAA	5700
ACCAGGCCTC CCGTCCCTAC TCCTTCTATT CTAGCCTCAT TTCTTATAAA GAAGATCAGA	5760
GAGGAGAAGA ACCTAGAAGA AACCTTGTCA AGCCTAATGA AACCAAAATT TATTTTGGA	5820
AAGTACAACA TCATATGGCA CCCACAGAAG ATGAGTTTGA CTGCAAGGCC TGGGCTTATT	5880
TCTCTGATGT TGATCTTGAA AGAGATATGC ACTCGGGATT AATTGGACCC CTTCTGATTT	5940
GCCACGCGAA CACACTGAAT CCTGCTCATG GGAGACAAAGT GTCAGTACAG GAATTTGCTC	6000
TGCTTTTCAC TATCTTGAT GAGACCAAGA GCTGGTACTT CACTGAAAAC GTGAAAAGGA	6060
ACTGCAAGAC ACCCTGCAAT TTCCAGATGG AAGACCCCAC TTTGAAAGAG AATTATCGCT	6120
TCCATGCAAT CAATGGTTAT GTAATGGATA CCCTACCAGG CTTAGTAATG GCTCAAGATC	6180
AAAGGATTCTG ATGGTATCTT CTCAGCATGG GCAACAAATGA GAACATCCAA TCTATTCTATT	6240
TCAGTGGACA TGTTTCACT GTACGGAAAA AAGAGGAGTA TAAAATGGCA GTGTACAACC	6300
TCTACCCAGG TGTTTTGAG ACTCTGGAAA TGATACCATC CAGAGCTGGA ATATGGCGAG	6360
TAGAATGCCT TATTGGCGAG CACTTACAGG CTGGGATGAG CACTCTTTT CTGGTGTACA	6420
GCAAGCAGTG TCAGATTCTT CTTGGAATGG CTTCTGGAAG CATCCGTGAT TTCCAGATTA	6480
CAGCTTCAGG ACATTATGGA CAGTGGGCC CAAACCTGGC AAGACTTCAT TATTCCGGAT	6540
CAATCAATGC CTGGAGTACC AAGGAGCCCT TTTCTTGGAT CAAGGTAGAT CTGTTGGCAC	6600
CAATGATTGT TCATGGCATC AAGACTCAGG GTGCTCGTCA GAAATTTCC AGCCTTTATA	6660
TCTCTCAATT TATCATCATG TATAGCCTGG ATGGGAAGAA GTGGCTGAGT TATCAAGGAA	6720
ATTCCACTGG AACCTTAATG GTTTCTTTG GCAATGTGGA CTCATCTGGG ATTAAGCATA	6780
ATAGTTTTAA TCCTCCAATT ATTGCTCGAT ATATCCGTTT GCACCCCACT CATTCTAGCA	6840

TCCGTAGTAC TCTTCGCATG GAGTTGATGG GCTGTGATT AAACAGTTGC AGCATACCAT	6900
TGGGAATGGA AAGTAAAGTA ATATCAGATA CACAAATCAC TGCCCTCATCC TACTTCACCA	6960
ACATGTTGC TACTTGGTCT CCTTCACAAG CTCGACTTCA CCTCCAGGGA AGGACTAATG	7020
CCTGGCGACC TCAGGTGAAT GATCCAAAAC AATGGTTGCA AGTGGACTTA CAAAAGACAA	7080
TGAAAGTCAC TGGAATAATA ACCCAGGGAG TGAAATCTCT CTTTACCCAGC ATGTTTGTA	7140
AAGAGTTCCCT TATTTCCAGC AGTCAAGATG GCCATCACTG GACTCAAATT TTATACAATG	7200
GCAAGGTAAA GGTTTTTCAG GGGATCAGG ACTCATCCAC ACCTATGATG AATTCTCTAG	7260
ACCCACCATT ACTCACTCGC TATCTCGAA TTCACCCCCA GATCTGGAG CACCAAATTG	7320
CTCTGAGGCT TGAGATTCTA GGATGTGAGG CCCAGCAGCA ATACTGAGGT AGCCTCTGCA	7380
TCACCTGCTT ATTCCCCCTTC CTCAGCTCAA AGATTGTCTT AATGTTTAT TGCTGTGAAG	7440
AGACACTATG ACCATGGCAA CTCTTATAA AATAAAGCAT TTAATCAGGG CTT	7493

## (2) INFORMATION FOR SEQ ID NO:6:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2319 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Mus musculus*

## (x) PUBLICATION INFORMATION:

- (A) AUTHORS: Elder, F.  
Lakich, D.  
Gitschier, J.
- (B) TITLE: Sequence of the Murine Factor VIII cDNA
- (C) JOURNAL: Genomics
- (D) VOLUME: 16
- (F) PAGES: 374-379
- (G) DATE: 1993
- (K) RELEVANT RESIDUES IN SEQ ID NO:6: FROM 1 TO 2319

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met Gln Ile Ala Leu Phe Ala Cys Phe Phe Leu Ser Leu Phe Asn Phe  
1 5 10 15

Cys Ser Ser Ala Ile Arg Arg Tyr Tyr Leu Gly Ala Val Glu Leu Ser  
20 25 30

Trp Asn Tyr Ile Gln Ser Asp Leu Leu Ser Val Leu His Thr Asp Ser  
35 40 45

Arg Phe Leu Pro Arg Met Ser Thr Ser Phe Pro Phe Asn Thr Ser Ile  
50 55 60

Met Tyr Lys Lys Thr Val Phe Val Glu Tyr Lys Asp Gln Leu Phe Asn  
65 70 75 80

Ile Ala Lys Pro Arg Pro Pro Trp Met Gly Leu Leu Gly Pro Thr Ile  
85 90 95

Trp Thr Glu Val His Asp Thr Val Val Ile Thr Leu Lys Asn Met Ala  
100 105 110

Ser His Pro Val Ser Leu His Ala Val Gly Val Ser Tyr Trp Lys Ala  
115 120 125

Ser Glu Gly Asp Glu Tyr Glu Asp Gln Thr Ser Gln Met Glu Lys Glu  
130 135 140

Asp Asp Lys Val Phe Pro Gly Glu Ser His Thr Tyr Val Trp Gln Val  
145 150 155 160

Leu Lys Glu Asn Gly Pro Met Ala Ser Asp Pro Pro Cys Leu Thr Tyr  
165 170 175

Ser Tyr Met Ser His Val Asp Leu Val Lys Asp Leu Asn Ser Gly Leu  
180 185 190

Ile Gly Ala Leu Leu Val Cys Lys Glu Gly Ser Leu Ser Lys Glu Arg  
195 200 205

Thr Gln Met Leu Tyr Gln Phe Val Leu Leu Phe Ala Val Phe Asp Glu  
210 215 220

Gly Lys Ser Trp His Ser Glu Thr Asn Asp Ser Tyr Thr Gln Ser Met  
225 230 235 240

Asp Ser Ala Ser Ala Arg Asp Trp Pro Lys Met His Thr Val Asn Gly  
245 250 255

Tyr Val Asn Arg Ser Leu Pro Gly Leu Ile Gly Cys His Arg Lys Ser  
260 265 270

Val Tyr Trp His Val Ile Gly Met Gly Thr Thr Pro Glu Ile His Ser  
275 280 285

Ile Phe Leu Glu Gly His Thr Phe Phe Val Arg Asn His Arg Gln Ala  
290 295 300

Ser Leu Glu Ile Ser Pro Ile Thr Phe Leu Thr Ala Gln Thr Leu Leu  
 305                    310                    315                    320  
  
 Ile Asp Leu Gly Gln Phe Leu Leu Phe Cys His Ile Ser Ser His Lys  
 325                    330                    335  
  
 His Asp Gly Met Glu Ala Tyr Val Lys Val Asp Ser Cys Pro Glu Glu  
 340                    345                    350  
  
 Ser Gln Trp Gln Lys Lys Asn Asn Asn Glu Glu Met Glu Asp Tyr Asp  
 355                    360                    365  
  
 Asp Asp Leu Tyr Ser Glu Met Asp Met Phe Thr Leu Asp Tyr Asp Ser  
 370                    375                    380  
  
 Ser Pro Phe Ile Gln Ile Arg Ser Val Ala Lys Lys Tyr Pro Lys Thr  
 385                    390                    395                    400  
  
 Trp Ile His Tyr Ile Ser Ala Glu Glu Asp Trp Asp Tyr Ala Pro  
 405                    410                    415  
  
 Ser Val Pro Thr Ser Asp Asn Gly Ser Tyr Lys Ser Gln Tyr Leu Ser  
 420                    425                    430  
  
 Asn Gly Pro His Arg Ile Gly Arg Lys Tyr Lys Lys Val Arg Phe Ile  
 435                    440                    445  
  
 Ala Tyr Thr Asp Glu Thr Phe Lys Thr Arg Glu Thr Ile Gln His Glu  
 450                    455                    460  
  
 Ser Gly Leu Leu Gly Pro Leu Leu Tyr Gly Glu Val Gly Asp Thr Leu  
 465                    470                    475                    480  
  
 Leu Ile Ile Phe Lys Asn Gln Ala Ser Arg Pro Tyr Asn Ile Tyr Pro  
 485                    490                    495  
  
 His Gly Ile Thr Asp Val Ser Pro Leu His Ala Arg Arg Leu Pro Arg  
 500                    505                    510  
  
 Gly Ile Lys His Val Lys Asp Leu Pro Ile His Pro Gly Glu Ile Phe  
 515                    520                    525  
  
 Lys Tyr Lys Trp Thr Val Thr Val Glu Asp Gly Pro Thr Lys Ser Asp  
 530                    535                    540  
  
 Pro Arg Cys Leu Thr Arg Tyr Tyr Ser Ser Phe Ile Asn Pro Glu Arg  
 545                    550                    555                    560  
  
 Asp Leu Ala Ser Gly Leu Ile Gly Pro Leu Leu Ile Cys Tyr Lys Glu  
 565                    570                    575  
  
 Ser Val Asp Gln Arg Gly Asn Gln Met Met Ser Asp Lys Arg Asn Val  
 580                    585                    590  
  
 Ile Leu Phe Ser Ile Phe Asp Glu Asn Gln Ser Trp Tyr Ile Thr Glu  
 595                    600                    605

Asn Met Gln Arg Phe Leu Pro Asn Ala Ala Lys Thr Gln Pro Gln Asp  
 610 615 620

Pro Gly Phe Gln Ala Ser Asn Ile Met His Ser Ile Asn Gly Tyr Val  
 625 630 635 640

Phe Asp Ser Leu Glu Leu Thr Val Cys Leu His Glu Val Ala Tyr Trp  
 645 650 655

His Ile Leu Ser Val Gly Ala Gln Thr Asp Phe Leu Ser Ile Phe Phe  
 660 665 670

Ser Gly Tyr Thr Phe Lys His Lys Met Val Tyr Glu Asp Thr Leu Thr  
 675 680 685

Leu Phe Pro Phe Ser Gly Glu Thr Val Phe Met Ser Met Glu Asn Pro  
 690 695 700

Gly Leu Trp Val Leu Gly Cys His Asn Ser Asp Phe Arg Lys Arg Gly  
 705 710 715 720

Met Thr Ala Leu Leu Lys Val Ser Ser Cys Asp Lys Ser Thr Ser Asp  
 725 730 735

Tyr Tyr Glu Glu Ile Tyr Glu Asp Ile Pro Thr Gln Leu Val Asn Glu  
 740 745 750

Asn Asn Val Ile Asp Pro Arg Ser Phe Phe Gln Asn Thr Asn His Pro  
 755 760 765

Asn Thr Arg Lys Lys Phe Lys Asp Ser Thr Ile Pro Lys Asn Asp  
 770 775 780

Met Glu Lys Ile Glu Pro Gln Phe Glu Glu Ile Ala Glu Met Leu Lys  
 785 790 795 800

Val Gln Ser Val Ser Val Ser Asp Met Leu Met Leu Leu Gly Gln Ser  
 805 810 815

His Pro Thr Pro His Gly Leu Phe Leu Ser Asp Gly Gln Glu Ala Ile  
 820 825 830

Tyr Glu Ala Ile His Asp Asp His Ser Pro Asn Ala Ile Asp Ser Asn  
 835 840 845

Glu Gly Pro Ser Lys Val Thr Gln Leu Arg Pro Glu Ser His His Ser  
 850 855 860

Glu Lys Ile Val Phe Thr Pro Gln Pro Gly Leu Gln Leu Arg Ser Asn  
 865 870 875 880

Lys Ser Leu Glu Thr Thr Ile Glu Val Lys Trp Lys Lys Leu Gly Leu  
 885 890 895

Gln Val Ser Ser Leu Pro Ser Asn Leu Met Thr Thr Thr Ile Leu Ser  
 900 905 910

Asp Asn Leu Lys Ala Thr Phe Glu Lys Thr Asp Ser Ser Gly Phe Pro  
 915 920 925

Asp Met Pro Val His Ser Ser Ser Lys Leu Ser Thr Thr Ala Phe Gly  
 930 935 940

Lys Lys Ala Tyr Ser Leu Val Gly Ser His Val Pro Leu Asn Ala Ser  
 945 950 955 960

Glu Glu Asn Ser Asp Ser Asn Ile Leu Asp Ser Thr Leu Met Tyr Ser  
 965 970 975

Gln Glu Ser Leu Pro Arg Asp Asn Ile Leu Ser Ile Glu Asn Asp Arg  
 980 985 990

Leu Leu Arg Glu Lys Arg Phe His Gly Ile Ala Leu Leu Thr Lys Asp  
 995 1000 1005

Asn Thr Leu Phe Lys Asp Asn Val Ser Leu Met Lys Thr Asn Lys Thr  
 1010 1015 1020

Tyr Asn His Ser Thr Thr Asn Glu Lys Leu His Thr Glu Ser Pro Thr  
 1025 1030 1035 1040

Ser Ile Glu Asn Ser Thr Thr Asp Leu Gln Asp Ala Ile Leu Lys Val  
 1045 1050 1055

Asn Ser Glu Ile Gln Glu Val Thr Ala Leu Ile His Asp Gly Thr Leu  
 1060 1065 1070

Leu Gly Lys Asn Ser Thr Tyr Leu Arg Leu Asn His Met Leu Asn Arg  
 1075 1080 1085

Thr Thr Ser Thr Lys Asn Lys Asp Ile Phe His Arg Lys Asp Glu Asp  
 1090 1095 1100

Pro Ile Pro Gln Asp Glu Glu Asn Thr Ile Met Pro Phe Ser Lys Met  
 1105 1110 1115 1120

Leu Phe Leu Ser Glu Ser Ser Asn Trp Phe Lys Lys Thr Asn Gly Asn  
 1125 1130 1135

Asn Ser Leu Asn Ser Glu Gln Glu His Ser Pro Lys Gln Leu Val Tyr  
 1140 1145 1150

Leu Met Phe Lys Lys Tyr Val Lys Asn Gln Ser Phe Leu Ser Glu Lys  
 1155 1160 1165

Asn Lys Val Thr Val Glu Gln Asp Gly Phe Thr Lys Asn Ile Gly Leu  
 1170 1175 1180

Lys Asp Met Ala Phe Pro His Asn Met Ser Ile Phe Leu Thr Thr Leu  
 1185 1190 1195 1200

Ser Asn Val His Glu Asn Gly Arg His Asn Gln Glu Lys Asn Ile Gln  
 1205 1210 1215

Glu Glu Ile Glu Lys Glu Ala Leu Ile Glu Glu Lys Val Val Leu Pro  
 1220 1225 1230

Gln Val His Glu Ala Thr Gly Ser Lys Asn Phe Leu Lys Asp Ile Leu  
 1235 1240 1245

Ile Leu Gly Thr Arg Gln Asn Ile Ser Leu Tyr Glu Val His Val Pro  
 1250 1255 1260

Val Leu Gln Asn Ile Thr Ser Ile Asn Asn Ser Thr Asn Thr Val Gln  
 1265 1270 1275 1280

Ile His Met Glu His Phe Phe Lys Arg Arg Lys Asp Lys Glu Thr Asn  
 1285 1290 1295

Ser Glu Gly Leu Val Asn Lys Thr Arg Glu Met Val Lys Asn Tyr Pro  
 1300 1305 1310

Ser Gln Lys Asn Ile Thr Thr Gln Arg Ser Lys Arg Ala Leu Gly Gln  
 1315 1320 1325

Phe Arg Leu Ser Thr Gln Trp Leu Lys Thr Ile Asn Cys Ser Thr Gln  
 1330 1335 1340

Cys Ile Ile Lys Gln Ile Asp His Ser Lys Glu Met Lys Lys Phe Ile  
 1345 1350 1355 1360

Thr Lys Ser Ser Leu Ser Asp Ser Ser Val Ile Lys Ser Thr Thr Gln  
 1365 1370 1375

Thr Asn Ser Ser Asp Ser His Ile Val Lys Thr Ser Ala Phe Pro Pro  
 1380 1385 1390

Ile Asp Leu Lys Arg Ser Pro Phe Gln Asn Lys Phe Ser His Val Gln  
 1395 1400 1405

Ala Ser Ser Tyr Ile Tyr Asp Phe Lys Thr Lys Ser Ser Arg Ile Gln  
 1410 1415 1420

Glu Ser Asn Asn Phe Leu Lys Glu Thr Lys Ile Asn Asn Pro Ser Leu  
 1425 1430 1435 1440

Ala Ile Leu Pro Trp Asn Met Phe Ile Asp Gln Gly Lys Phe Thr Ser  
 1445 1450 1455

Pro Gly Lys Ser Asn Thr Asn Ser Val Thr Tyr Lys Lys Arg Glu Asn  
 1460 1465 1470

Ile Ile Phe Leu Lys Pro Thr Leu Pro Glu Glu Ser Gly Lys Ile Glu  
 1475 1480 1485

Leu Leu Pro Gln Val Ser Ile Gln Glu Glu Glu Ile Leu Pro Thr Glu  
 1490 1495 1500

Thr Ser His Gly Ser Pro Gly His Leu Asn Leu Met Lys Glu Val Phe  
 1505 1510 1515 1520

Leu Gln Lys Ile Gln Gly Pro Thr Lys Trp Asn Lys Ala Lys Arg His  
                   1525                  1530                  1535  
  
 Gly Glu Ser Ile Lys Gly Lys Thr Glu Ser Ser Lys Asn Thr Arg Ser  
                   1540                  1545                  1550  
  
 Lys Leu Leu Asn His His Ala Trp Asp Tyr His Tyr Ala Ala Gln Ile  
                   1555                  1560                  1565  
  
 Pro Lys Asp Met Trp Lys Ser Lys Glu Lys Ser Pro Glu Ile Ile Ser  
                   1570                  1575                  1580  
  
 Ile Lys Gln Glu Asp Thr Ile Leu Ser Leu Arg Pro His Gly Asn Ser  
                   1585                  1590                  1595                  1600  
  
 His Ser Ile Gly Ala Asn Glu Lys Gln Asn Trp Pro Gln Arg Glu Thr  
                   1605                  1610                  1615  
  
 Thr Trp Val Lys Gln Gly Gln Thr Gln Arg Thr Cys Ser Gln Ile Pro  
                   1620                  1625                  1630  
  
 Pro Val Leu Lys Arg His Gln Arg Glu Leu Ser Ala Phe Gln Ser Glu  
                   1635                  1640                  1645  
  
 Gln Glu Ala Thr Asp Tyr Asp Asp Ala Ile Thr Ile Glu Thr Ile Glu  
                   1650                  1655                  1660  
  
 Asp Phe Asp Ile Tyr Ser Glu Asp Ile Lys Gln Gly Pro Arg Ser Phe  
                   1665                  1670                  1675                  1680  
  
 Gln Gln Lys Thr Arg His Tyr Phe Ile Ala Ala Val Glu Arg Leu Trp  
                   1685                  1690                  1695  
  
 Asp Tyr Gly Met Ser Thr Ser His Val Leu Arg Asn Arg Tyr Gln Ser  
                   1700                  1705                  1710  
  
 Asp Asn Val Pro Gln Phe Lys Lys Val Val Phe Gln Glu Phe Thr Asp  
                   1715                  1720                  1725  
  
 Gly Ser Phe Ser Gln Pro Leu Tyr Arg Gly Glu Leu Asn Glu His Leu  
                   1730                  1735                  1740  
  
 Gly Leu Leu Gly Pro Tyr Ile Arg Ala Glu Val Glu Asp Asn Ile Met  
                   1745                  1750                  1755                  1760  
  
 Val Thr Phe Lys Asn Gln Ala Ser Arg Pro Tyr Ser Phe Tyr Ser Ser  
                   1765                  1770                  1775  
  
 Leu Ile Ser Tyr Lys Glu Asp Gln Arg Gly Glu Glu Pro Arg Arg Asn  
                   1780                  1785                  1790  
  
 Phe Val Lys Pro Asn Glu Thr Lys Ile Tyr Phe Trp Lys Val Gln His  
                   1795                  1800                  1805  
  
 His Met Ala Pro Thr Glu Asp Glu Phe Asp Cys Lys Ala Trp Ala Tyr  
                   1810                  1815                  1820

Phe Ser Asp Val Asp Leu Glu Arg Asp Met His Ser Gly Leu Ile Gly  
 1825                    1830                    1835                    1840

Pro Leu Leu Ile Cys His Ala Asn Thr Leu Asn Pro Ala His Gly Arg  
 1845                    1850                    1855

Gln Val Ser Val Gln Glu Phe Ala Leu Leu Phe Thr Ile Phe Asp Glu  
 1860                    1865                    1870

Thr Lys Ser Trp Tyr Phe Thr Glu Asn Val Lys Arg Asn Cys Lys Thr  
 1875                    1880                    1885

Pro Cys Asn Phe Gln Met Glu Asp Pro Thr Leu Lys Glu Asn Tyr Arg  
 1890                    1895                    1900

Phe His Ala Ile Asn Gly Tyr Val Met Asp Thr Leu Pro Gly Leu Val  
 1905                    1910                    1915                    1920

Met Ala Gln Asp Gln Arg Ile Arg Trp Tyr Leu Leu Ser Met Gly Asn  
 1925                    1930                    1935

Asn Glu Asn Ile Gln Ser Ile His Phe Ser Gly His Val Phe Thr Val  
 1940                    1945                    1950

Arg Lys Lys Glu Glu Tyr Lys Met Ala Val Tyr Asn Leu Tyr Pro Gly  
 1955                    1960                    1965

Val Phe Glu Thr Leu Glu Met Ile Pro Ser Arg Ala Gly Ile Trp Arg  
 1970                    1975                    1980

Val Glu Cys Leu Ile Gly Glu His Leu Gln Ala Gly Met Ser Thr Leu  
 1985                    1990                    1995                    2000

Phe Leu Val Tyr Ser Lys Gln Cys Gln Ile Pro Leu Gly Met Ala Ser  
 2005                    2010                    2015

Gly Ser Ile Arg Asp Phe Gln Ile Thr Ala Ser Gly His Tyr Gly Gln  
 2020                    2025                    2030

Trp Ala Pro Asn Leu Ala Arg Leu His Tyr Ser Gly Ser Ile Asn Ala  
 2035                    2040                    2045

Trp Ser Thr Lys Glu Pro Phe Ser Trp Ile Lys Val Asp Leu Leu Ala  
 2050                    2055                    2060

Pro Met Ile Val His Gly Ile Lys Thr Gln Gly Ala Arg Gln Lys Phe  
 2065                    2070                    2075                    2080

Ser Ser Leu Tyr Ile Ser Gln Phe Ile Ile Met Tyr Ser Leu Asp Gly  
 2085                    2090                    2095

Lys Lys Trp Leu Ser Tyr Gln Gly Asn Ser Thr Gly Thr Leu Met Val  
 2100                    2105                    2110

Phe Phe Gly Asn Val Asp Ser Ser Gly Ile Lys His Asn Ser Phe Asn  
 2115                    2120                    2125

Pro Pro Ile Ile Ala Arg Tyr Ile Arg Leu His Pro Thr His Ser Ser  
 2130                    2135                    2140  
  
 Ile Arg Ser Thr Leu Arg Met Glu Leu Met Gly Cys Asp Leu Asn Ser  
 2145                    2150                    2155                    2160  
  
 Cys Ser Ile Pro Leu Gly Met Glu Ser Lys Val Ile Ser Asp Thr Gln  
 2165                    2170                    2175  
  
 Ile Thr Ala Ser Ser Tyr Phe Thr Asn Met Phe Ala Thr Trp Ser Pro  
 2180                    2185                    2190  
  
 Ser Gln Ala Arg Leu His Leu Gln Gly Arg Thr Asn Ala Trp Arg Pro  
 2195                    2200                    2205  
  
 Gln Val Asn Asp Pro Lys Gln Trp Leu Gln Val Asp Leu Gln Lys Thr  
 2210                    2215                    2220  
  
 Met Lys Val Thr Gly Ile Ile Thr Gln Gly Val Lys Ser Leu Phe Thr  
 2225                    2230                    2235                    2240  
  
 Ser Met Phe Val Lys Glu Phe Leu Ile Ser Ser Ser Gln Asp Gly His  
 2245                    2250                    2255  
  
 His Trp Thr Gln Ile Leu Tyr Asn Gly Lys Val Lys Val Phe Gln Gly  
 2260                    2265                    2270  
  
 Asn Gln Asp Ser Ser Thr Pro Met Met Asn Ser Leu Asp Pro Pro Leu  
 2275                    2280                    2285  
  
 Leu Thr Arg Tyr Leu Arg Ile His Pro Gln Ile Trp Glu His Gln Ile  
 2290                    2295                    2300  
  
 Ala Leu Arg Leu Glu Ile Leu Gly Cys Glu Ala Gln Gln Gln Tyr  
 2305                    2310                    2315

## (2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 40 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CCTTCCTTTA TCCAAATACG TAGATCAAGA GGAAATTGAC

40

## (2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 29 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GTAGCGTTGC CAAGAACAC CCTAAGACG

29

## (2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 37 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GAAGAGTAGT ACGAGTTATT TCTCTGGGTT CAATGAC

37

## (2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 33 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CCTTTATCCA AATAACGTAGC GTTTGCCAAG AAG

33

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(ix) FEATURE:

- (A) NAME/KEY: misc\_feature
- (B) LOCATION: 1..19
- (D) OTHER INFORMATION: /note= "R is A or G and N is A, T, G or C."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

AARCA~~Y~~CCNA ARACNTGGG

19

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GCTCGCACTA GGGGGTCTTG AATTC

25

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 44 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid  
(A) DESCRIPTION: /desc = "oligonucleotide primer,  
double-stranded from nucleotide 37-44, 3' end of short strand  
blocked with amino group."

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(ix) FEATURE:

- (A) NAME/KEY: misc\_feature
- (B) LOCATION: 37..44
- (D) OTHER INFORMATION: /note= "Double stranded in the  
region from nucleotides 37-44, the 3' end is blocked with an  
amino group to reduce non-specific priming."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CTAATACGAC TCACTATAGG GCTCGAGCGG CCGCCCGGGC AGGT

44

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 27 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

CCATCCTAAT ACGACTCACT ATAGGGC

27

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 24 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

CCATTGACAT GAAGACCGTT TCTC

24

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 23 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

ACTCACTATA GGGCTCGAGC GGC

23

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 24 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GGGTGCAAAG CGCTGACATC AGTG

24

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 50 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

CCTCTCGAGC CACCATGTCG AGCCACCATG CAGCTAGAGC TCTCCACCTG

50

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 31 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

CGCGCGGCCG CGCATCTGGC AAAGCTGAGT T

31

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 27 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(ix) FEATURE:

- (A) NAME/KEY: misc\_feature
- (B) LOCATION: 25..27
- (D) OTHER INFORMATION: /note= "At position 25, R is A or G."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

GAAATAAGCC CAGGCTTTGC AGTCRAA

27

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 22 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(ix) FEATURE:

- (A) NAME/KEY: misc\_feature
- (B) LOCATION: 21..22
- (D) OTHER INFORMATION: /note= "At position 22, N is A, G, C or T."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

AGGAAATTCC ACTGGAACCT TN

22

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 25 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(ix) FEATURE:

- (A) NAME/KEY: misc\_feature
- (B) LOCATION: 1..25
- (D) OTHER INFORMATION: /note= "At position 25, N is A, G, C or T."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

CTGGGGGTGA ATTCAAGGT AGCGN

25

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

GAGTTCATCG GGAAGACCTG TTG

23

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

ACAGCCCATC AACTCCATGC GAAG

24

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

TCAGGGCAAT CAGGACTCC

19

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

CCGTGGTGAA CGCTCTGGAC C

21

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

GTAGAGGTCC TGTGCCTCGC AGCC

24

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(ix) FEATURE:

- (A) NAME/KEY: misc\_feature
- (B) LOCATION: 1..27
- (D) OTHER INFORMATION: /note= "S is G or C, K is G or T, R is A or G, and Y is C or T."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

GTAGAGSTSC TGKGCCCTCRC AKCCYAG

27

(2) INFORMATION FOR SEQ ID NO:29:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 24 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

CTTCGCATGG AGTTGATGGG CTGT

24

(2) INFORMATION FOR SEQ ID NO:30:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 22 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

AATCAGGACT CCTCCACCCC CG

22

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

GGATCCACCC CACGAGCTGG

20

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

CGCCCTGAGG CTCGAGGTTC TAGG

24

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

AATCAGGACT CCTCCACCCC CG

22

(2) INFORMATION FOR SEQ ID NO:34:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 20 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

CCTTGCAGGA ATTCGATTCA

20

(2) INFORMATION FOR SEQ ID NO:35:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 21 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

CCGTGGTGAA CGCTCTGGAC C

21

## (2) INFORMATION FOR SEQ ID NO:36:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6402 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Pig

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..6402

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

ATG CAG CTA GAG CTC TCC ACC TGT GTC TTT CTG TGT CTC TTG CCA CTC Met Gln Leu Glu Leu Ser Thr Cys Val Phe Leu Cys Leu Leu Pro Leu	48
1 5 10 15	
GGC TTT AGT GCC ATC AGG AGA TAC TAC CTG GGC GCA GTG GAA CTG TCC Gly Phe Ser Ala Ile Arg Arg Tyr Tyr Leu Gly Ala Val Glu Leu Ser	96
20 25 30	
TGG GAC TAC CGG CAA AGT GAA CTC CTC CGT GAG CTG CAC GTG GAC ACC Trp Asp Tyr Arg Gln Ser Glu Leu Leu Arg Glu Leu His Val Asp Thr	144
35 40 45	
AGA TTT CCT GCT ACA GCG CCA GGA GCT CTT CCG TTG GGC CCG TCA GTC Arg Phe Pro Ala Thr Ala Pro Gly Ala Leu Pro Leu Gly Pro Ser Val	192
50 55 60	
CTG TAC AAA AAG ACT GTG TTC GTA GAG TTC ACG GAT CAA CTT TTC AGC Leu Tyr Lys Thr Val Phe Val Glu Phe Thr Asp Gln Leu Phe Ser	240
65 70 75 80	
GTT GCC AGG CCC AGG CCA CCA TGG ATG GGT CTG CTG GGT CCT ACC ATC Val Ala Arg Pro Arg Pro Trp Met Gly Leu Leu Gly Pro Thr Ile	288
85 90 95	
CAG GCT GAG GTT TAC GAC ACG GTG GTC GTT ACC CTG AAG AAC ATG GCT Gln Ala Glu Val Tyr Asp Thr Val Val Val Thr Leu Lys Asn Met Ala	336
100 105 110	
TCT CAT CCC GTT AGT CTT CAC GCT GTC GGC GTC TCC TTC TGG AAA TCT Ser His Pro Val Ser Leu His Ala Val Gly Val Ser Phe Trp Lys Ser	384
115 120 125	

TCC GAA GGC GCT GAA TAT GAG GAT CAC ACC AGC CAA AGG GAG AAG GAA Ser Glu Gly Ala Glu Tyr Glu Asp His Thr Ser Gln Arg Glu Lys Glu 130 135 140	432
GAC GAT AAA GTC CTT CCC GGT AAA AGC CAA ACC TAC GTC TGG CAG GTC Asp Asp Lys Val Leu Pro Gly Lys Ser Gln Thr Tyr Val Trp Gln Val 145 150 155 160	480
CTG AAA GAA AAT GGT CCA ACA GCC TCT GAC CCA CCA TGT CTC ACC TAC Leu Lys Glu Asn Gly Pro Thr Ala Ser Asp Pro Pro Cys Leu Thr Tyr 165 170 175	528
TCA TAC CTG TCT CAC GTG GAC CTG GTG AAA GAC CTG AAT TCG GGC CTC Ser Tyr Leu Ser His Val Asp Leu Val Lys Asp Leu Asn Ser Gly Leu 180 185 190	576
ATT GGA GCC CTG CTG GTT TGT AGA GAA GGG AGT CTG ACC AGA GAA AGG Ile Gly Ala Leu Leu Val Cys Arg Glu Gly Ser Leu Thr Arg Glu Arg 195 200 205	624
ACC CAG AAC CTG CAC GAA TTT GTA CTA CTT TTT GCT GTC TTT GAT GAA Thr Gln Asn Leu His Glu Phe Val Leu Leu Phe Ala Val Phe Asp Glu 210 215 220	672
GGG AAA AGT TGG CAC TCA GCA AGA AAT GAC TCC TGG ACA CGG GCC ATG Gly Lys Ser Trp His Ser Ala Arg Asn Asp Ser Trp Thr Arg Ala Met 225 230 235 240	720
GAT CCC GCA CCT GCC AGG GCC CAG CCT GCA ATG CAC ACA GTC AAT GGC Asp Pro Ala Pro Ala Arg Ala Gln Pro Ala Met His Thr Val Asn Gly 245 250 255	768
TAT GTC AAC AGG TCT CTG CCA GGT CTG ATC GGA TGT CAT AAG AAA TCA Tyr Val Asn Arg Ser Leu Pro Gly Leu Ile Gly Cys His Lys Lys Ser 260 265 270	816
GTC TAC TGG CAC GTG ATT GGA ATG GGC ACC AGC CCG GAA GTG CAC TCC Val Tyr Trp His Val Ile Gly Met Gly Thr Ser Pro Glu Val His Ser 275 280 285	864
ATT TTT CTT GAA GGC CAC ACG TTT CTC GTG AGG CAC CAT CGC CAG GCT Ile Phe Leu Glu Gly His Thr Phe Leu Val Arg His His Arg Gln Ala 290 295 300	912
TCC TTG GAG ATC TCG CCA CTA ACT TTC CTC ACT GCT CAG ACA TTC CTG Ser Leu Glu Ile Ser Pro Leu Thr Phe Leu Thr Ala Gln Thr Phe Leu 305 310 315 320	960
ATG GAC CTT GGC CAG TTC CTA CTG TTT TGT CAT ATC TCT TCC CAC CAC Met Asp Leu Gly Gln Phe Leu Leu Phe Cys His Ile Ser Ser His His 325 330 335	1008
CAT GGT GGC ATG GAG GCT CAC GTC AGA GTA GAA AGC TGC GCC GAG GAG His Gly Gly Met Glu Ala His Val Arg Val Glu Ser Cys Ala Glu Glu 340 345 350	1056

CCC CAG CTG CGG AGG AAA GCT GAT GAA GAG GAA GAT TAT GAT GAC AAT Pro Gln Leu Arg Arg Lys Ala Asp Glu Glu Glu Asp Tyr Asp Asp Asn 355                   360                   365	1104
TTG TAC GAC TCG GAC ATG GAC GTG GTC CGG CTC GAT GGT GAC GAC GTG Leu Tyr Asp Ser Asp Met Asp Val Val Arg Leu Asp Gly Asp Asp Val 370                   375                   380	1152
TCT CCC TTT ATC CAA ATC CGC TCG GTT GCC AAG AAG CAT CCC AAA ACC Ser Pro Phe Ile Gln Ile Arg Ser Val Ala Lys Lys His Pro Lys Thr 385                   390                   395                   400	1200
TGG GTG CAC TAC ATC TCT GCA GAG GAG GAC TGG GAC TAC GCC CCC Trp Val His Tyr Ile Ser Ala Glu Glu Asp Trp Asp Tyr Ala Pro 405                   410                   415	1248
GCG GTC CCC AGC CCC AGT GAC AGA AGT TAT AAA AGT CTC TAC TTG AAC Ala Val Pro Ser Pro Ser Asp Arg Ser Tyr Lys Ser Leu Tyr Leu Asn 420                   425                   430	1296
AGT GGT CCT CAG CGA ATT GGT AGG AAA TAC AAA AAA GCT CGA TTC GTC Ser Gly Pro Gln Arg Ile Gly Arg Lys Tyr Lys Lys Ala Arg Phe Val 435                   440                   445	1344
GCT TAC ACG GAT GTA ACA TTT AAG ACT CGT AAA GCT ATT CCG TAT GAA Ala Tyr Thr Asp Val Thr Phe Lys Thr Arg Lys Ala Ile Pro Tyr Glu 450                   455                   460	1392
TCA GGA ATC CTG GGA CCT TTA CTT TAT GGA GAA GTT GGA GAC ACA CTT Ser Gly Ile Leu Gly Pro Leu Leu Tyr Gly Glu Val Gly Asp Thr Leu 465                   470                   475                   480	1440
TTG ATT ATA TTT AAG AAT AAA GCG AGC CGA CCA TAT AAC ATC TAC CCT Leu Ile Ile Phe Lys Asn Lys Ala Ser Arg Pro Tyr Asn Ile Tyr Pro 485                   490                   495	1488
CAT GGA ATC ACT GAT GTC AGC GCT TTG CAC CCA GGG AGA CTT CTA AAA His Gly Ile Thr Asp Val Ser Ala Leu His Pro Gly Arg Leu Leu Lys 500                   505                   510	1536
GGT TGG AAA CAT TTG AAA GAC ATG CCA ATT CTG CCA GGA GAG ACT TTC Gly Trp Lys His Leu Lys Asp Met Pro Ile Leu Pro Gly Glu Thr Phe 515                   520                   525	1584
AAG TAT AAA TGG ACA GTG ACT GTG GAA GAT GGG CCA ACC AAG TCC GAT Lys Tyr Lys Trp Thr Val Thr Val Glu Asp Gly Pro Thr Lys Ser Asp 530                   535                   540	1632
CCT CGG TGC CTG ACC CGC TAC TAC TCG AGC TCC ATT AAT CTA GAG AAA Pro Arg Cys Leu Thr Arg Tyr Tyr Ser Ser Ser Ile Asn Leu Glu Lys 545                   550                   555                   560	1680
GAT CTG GCT TCG GGA CTC ATT GGC CCT CTC CTC ATC TGC TAC AAA GAA Asp Leu Ala Ser Gly Leu Ile Gly Pro Leu Leu Ile Cys Tyr Lys Glu 565                   570                   575	1728

TCT GTA GAC CAA AGA GGA AAC CAG ATG ATG TCA GAC AAG AGA AAC GTC Ser Val Asp Gln Arg Gly Asn Gln Met Met Ser Asp Lys Arg Asn Val 580 585 590	1776
ATC CTG TTT TCT GTA TTC GAT GAG AAT CAA AGC TGG TAC CTC GCA GAG Ile Leu Phe Ser Val Phe Asp Glu Asn Gln Ser Trp Tyr Leu Ala Glu 595 600 605	1824
AAT ATT CAG CGC TTC CTC CCC AAT CCG GAT GGA TTA CAG CCC CAG GAT Asn Ile Gln Arg Phe Leu Pro Asn Pro Asp Gly Leu Gln Pro Gln Asp 610 615 620	1872
CCA GAG TTC CAA GCT TCT AAC ATC ATG CAC AGC ATC AAT GGC TAT GTT Pro Glu Phe Gln Ala Ser Asn Ile Met His Ser Ile Asn Gly Tyr Val 625 630 635 640	1920
TTT GAT AGC TTG CAG CTG TCG GTT TGT TTG CAC GAG GTG GCA TAC TGG Phe Asp Ser Leu Gln Leu Ser Val Cys Leu His Glu Val Ala Tyr Trp 645 650 655	1968
TAC ATT CTA AGT GTT GGA GCA CAG ACG GAC TTC CTC TCC GTC TTC TTC Tyr Ile Leu Ser Val Gly Ala Gln Thr Asp Phe Leu Ser Val Phe Phe 660 665 670	2016
TCT GGC TAC ACC TTC AAA CAC AAA ATG GTC TAT GAA GAC ACA CTC ACC Ser Gly Tyr Thr Phe Lys His Lys Met Val Tyr Glu Asp Thr Leu Thr 675 680 685	2064
CTG TTC CCC TTC TCA GGA GAA ACG GTC TTC ATG TCA ATG GAA AAC CCA Leu Phe Pro Phe Ser Gly Glu Thr Val Phe Met Ser Met Glu Asn Pro 690 695 700	2112
GGT CTC TGG GTC CTA GGG TGC CAC AAC TCA GAC TTG CGG AAC AGA GGG Gly Leu Trp Val Leu Gly Cys His Asn Ser Asp Leu Arg Asn Arg Gly 705 710 715 720	2160
ATG ACA GCC TTA CTG AAG GTG TAT AGT TGT GAC AGG GAC ATT GGT GAT Met Thr Ala Leu Lys Val Tyr Ser Cys Asp Arg Asp Ile Gly Asp 725 730 735	2208
TAT TAT GAC AAC ACT TAT GAA GAT ATT CCA GGC TTC TTG CTG AGT GGA Tyr Tyr Asp Asn Thr Tyr Glu Asp Ile Pro Gly Phe Leu Leu Ser Gly 740 745 750	2256
AAG AAT GTC ATT GAA CCC AGA AGC TTT GCC CAG AAT TCA AGA CCC CCT Lys Asn Val Ile Glu Pro Arg Ser Phe Ala Gln Asn Ser Arg Pro Pro 755 760 765	2304
AGT GCG AGC CAA AAG CAA TTC CAA ACC ATC ACA AGT CCA GAA GAT GAC Ser Ala Ser Gln Lys Gln Phe Gln Thr Ile Thr Ser Pro Glu Asp Asp 770 775 780	2352
GTG GAG CTT GAC CCG CAG TCT GGA GAG AGA ACC CAA GCA CTG GAA GAA Val Glu Leu Asp Pro Gln Ser Gly Glu Arg Thr Gln Ala Leu Glu Glu 785 790 795 800	2400

CTA AGT GTC CCC TCT GGT GAT GGG TCG ATG CTC TTG GGA CAG AAT CCT Leu Ser Val Pro Ser Gly Asp Gly Ser Met Leu Leu Gly Gln Asn Pro 805	810	815	2448
GCT CCA CAT GGC TCA TCC TCA TCT GAT CTT CAA GAA GCC AGG AAT GAG Ala Pro His Gly Ser Ser Ser Asp Leu Gln Glu Ala Arg Asn Glu 820	825	830	2496
GCT GAT GAT TAT TTA CCT GGA GCA AGA GAA AGA AAC ACG GCC CCA TCC Ala Asp Asp Tyr Leu Pro Gly Ala Arg Glu Arg Asn Thr Ala Pro Ser 835	840	845	2544
GCA GCG GCA CGT CTC AGA CCA GAG CTG CAT CAC AGT GCC GAA AGA GTA Ala Ala Ala Arg Leu Arg Pro Glu Leu His His Ser Ala Glu Arg Val 850	855	860	2592
CTT ACT CCT GAG CCA GAG AAA GAG TTG AAG AAA CTT GAT TCA AAA ATG Leu Thr Pro Glu Pro Glu Lys Glu Leu Lys Lys Leu Asp Ser Lys Met 865	870	875	2640
TCT AGT TCA TCA GAC CTT CTA AAG ACT TCG CCA ACA ATT CCA TCA GAC Ser Ser Ser Ser Asp Leu Leu Lys Thr Ser Pro Thr Ile Pro Ser Asp 885	890	895	2688
ACG TTG TCA GCG GAG ACT GAA AGG ACA CAT TCC TTA GGC CCC CCA CAC Thr Leu Ser Ala Glu Thr Glu Arg Thr His Ser Leu Gly Pro Pro His 900	905	910	2736
CCG CAG GTT AAT TTC AGG AGT CAA TTA GGT GCC ATT GTA CTT GGC AAA Pro Gln Val Asn Phe Arg Ser Gln Leu Gly Ala Ile Val Leu Gly Lys 915	920	925	2784
AAT TCA TCT CAC TTT ATT GGG GCT GGT GTC CCT TTG GGC TCG ACT GAG Asn Ser Ser His Phe Ile Gly Ala Gly Val Pro Leu Gly Ser Thr Glu 930	935	940	2832
GAG GAT CAT GAA AGC TCC CTG GGA GAA AAT GTA TCA CCA GTG GAG AGT Glu Asp His Glu Ser Ser Leu Gly Glu Asn Val Ser Pro Val Glu Ser 945	950	955	2880
GAC GGG ATA TTT GAA AAG GAA AGA GCT CAT GGA CCT GCT TCA CTG ACC Asp Gly Ile Phe Glu Lys Glu Arg Ala His Gly Pro Ala Ser Leu Thr 965	970	975	2928
AAA GAC GAT GTT TTA TTT AAA GTT AAT ATC TCT TTG GTA AAG ACA AAC Lys Asp Asp Val Leu Phe Lys Val Asn Ile Ser Leu Val Lys Thr Asn 980	985	990	2976
AAG GCA CGA GTT TAC TTA AAA ACT AAT AGA AAG ATT CAC ATT GAT GAC Lys Ala Arg Val Tyr Leu Lys Thr Asn Arg Lys Ile His Ile Asp Asp 995	1000	1005	3024
GCA GCT TTA TTA ACT GAG AAT AGG GCA TCT GCA ACG TTT ATG GAC AAA Ala Ala Leu Leu Thr Glu Asn Arg Ala Ser Ala Thr Phe Met Asp Lys 1010	1015	1020	3072

AAT ACT ACA GCT TCG GGA TTA AAT CAT GTG TCA AAT TGG ATA AAA GGG Asn Thr Thr Ala Ser Gly Leu Asn His Val Ser Asn Trp Ile Lys Gly 1025                   1030                   1035                   1040	3120
CCC CTT GGC AAG AAC CCC CTA AGC TCG GAG CGA GGC CCC AGT CCA GAG Pro Leu Gly Lys Asn Pro Leu Ser Ser Glu Arg Gly Pro Ser Pro Glu 1045                   1050                   1055	3168
CTT CTG ACA TCT TCA GGA TCA GGA AAA TCT GTG AAA GGT CAG AGT TCT Leu Leu Thr Ser Ser Gly Ser Gly Lys Ser Val Lys Gly Gln Ser Ser 1060                   1065                   1070	3216
GGG CAG GGG AGA ATA CGG GTG GCA GTG GAA GAG GAA GAA CTG AGC AAA Gly Gln Gly Arg Ile Arg Val Ala Val Glu Glu Glu Leu Ser Lys 1075                   1080                   1085	3264
GGC AAA GAG ATG ATG CTT CCC AAC AGC GAG CTC ACC TTT CTC ACT AAC Gly Lys Glu Met Met Leu Pro Asn Ser Glu Leu Thr Phe Leu Thr Asn 1090                   1095                   1100	3312
TCG GCT GAT GTC CAA GGA AAC GAT ACA CAC AGT CAA GGA AAA AAG TCT Ser Ala Asp Val Gln Gly Asn Asp Thr His Ser Gln Gly Lys Lys Ser 1105                   1110                   1115                   1120	3360
CGG GAA GAG ATG GAA AGG AGA GAA AAA TTA GTC CAA GAA AAA GTC GAC Arg Glu Glu Met Glu Arg Arg Glu Lys Leu Val Gln Glu Lys Val Asp 1125                   1130                   1135	3408
TTG CCT CAG GTG TAT ACA GCG ACT GGA ACT AAG AAT TTC CTG AGA AAC Leu Pro Gln Val Tyr Thr Ala Thr Gly Thr Lys Asn Phe Leu Arg Asn 1140                   1145                   1150	3456
ATT TTT CAC CAA AGC ACT GAG CCC AGT GTA GAA GGG TTT GAT GGG GGG Ile Phe His Gln Ser Thr Glu Pro Ser Val Glu Gly Phe Asp Gly Gly 1155                   1160                   1165	3504
TCA CAT GCG CCG GTG CCT CAA GAC AGC AGG TCA TTA AAT GAT TCG GCA Ser His Ala Pro Val Pro Gln Asp Ser Arg Ser Leu Asn Asp Ser Ala 1170                   1175                   1180	3552
GAG AGA GCA GAG ACT CAC ATA GCC CAT TTC TCA GCA ATT AGG GAA GAG Glu Arg Ala Glu Thr His Ile Ala His Phe Ser Ala Ile Arg Glu Glu 1185                   1190                   1195                   1200	3600
GCA CCC TTG GAA GCC CCG GGA AAT CGA ACA GGT CCA GGT CCG AGG AGT Ala Pro Leu Glu Ala Pro Gly Asn Arg Thr Gly Pro Gly Pro Arg Ser 1205                   1210                   1215	3648
GCG GTT CCC CGC CGC GTT AAG CAG AGC TTG AAA CAG ATC AGA CTC CCG Ala Val Pro Arg Arg Val Lys Gln Ser Leu Lys Gin Ile Arg Leu Pro 1220                   1225                   1230	3696
CTA GAA GAA ATA AAG CCT GAA AGG GGG GTG GTT CTG AAT GCC ACC TCA Leu Glu Glu Ile Lys Pro Glu Arg Gly Val Val Leu Asn Ala Thr Ser 1235                   1240                   1245	3744

ACC CGG TGG TCT GAA AGC AGT CCT ATC TTA CAA GGA GCC AAA AGA AAT Thr Arg Trp Ser Glu Ser Ser Pro Ile Leu Gln Gly Ala Lys Arg Asn 1250 1255 1260	3792
AAC CTT TCT TTA CCT TTC CTG ACC TTG GAA ATG GCC GGA GGT CAA GGA Asn Leu Ser Leu Pro Phe Leu Thr Leu Glu Met Ala Gly Gly Gln Gly 1265 1270 1275 1280	3840
AAG ATC AGC GCC CTG GGG AAA AGT GCC GCA GGC CCG CTG GCG TCC GGG Lys Ile Ser Ala Leu Gly Lys Ser Ala Ala Gly Pro Leu Ala Ser Gly 1285 1290 1295	3888
AAG CTG GAG AAG GCT GTT CTC TCT TCA GCA GGC TTG TCT GAA GCA TCT Lys Leu Glu Lys Ala Val Leu Ser Ser Ala Gly Leu Ser Glu Ala Ser 1300 1305 1310	3936
GCG AAA GCT GAG TTT CTT CCT AAA GTT CGA GTT CAT CGG GAA GAC CTG Gly Lys Ala Glu Phe Leu Pro Lys Val Arg Val His Arg Glu Asp Leu 1315 1320 1325	3984
TTG CCT CAA AAA ACC AGC AAT GTT TCT TGC GCA CAC GGG GAT CTC GGC Leu Pro Gln Lys Thr Ser Asn Val Ser Cys Ala His Gly Asp Leu Gly 1330 1335 1340	4032
CAG GAG ATC TTC CTG CAG AAA ACA CGG GGA CCT GTT AAC CTG AAC AAA Gln Glu Ile Phe Leu Gln Lys Thr Arg Gly Pro Val Asn Leu Asn Lys 1345 1350 1355 1360	4080
GTA AAT AGA CCT GGA AGG ACT CCC TCC AAG CTT CTG GGT CCC CCG ATG Val Asn Arg Pro Gly Arg Thr Pro Ser Lys Leu Leu Gly Pro Pro Met 1365 1370 1375	4128
CCC AAA GAG TGG GAA TCC CTA GAG AAG TCA CCA AAA AGC ACA GCT CTC Pro Lys Glu Trp Glu Ser Leu Glu Lys Ser Pro Lys Ser Thr Ala Leu 1380 1385 1390	4176
AGG ACG AAA GAC ATC ATC AGT TTA CCC CTG GAC CGT CAC GAA AGC AAT Arg Thr Lys Asp Ile Ile Ser Leu Pro Leu Asp Arg His Glu Ser Asn 1395 1400 1405	4224
CAT TCA ATA GCA GCA AAA AAT GAA GGA CAA GCC GAG ACC CAA AGA GAA His Ser Ile Ala Ala Lys Asn Glu Gly Gln Ala Glu Thr Gln Arg Glu 1410 1415 1420	4272
GCC GCC TGG ACG AAG CAG GGA GGG CCT GGA AGG CTG TGC GCT CCA AAG Ala Ala Trp Thr Lys Gln Gly Gly Pro Gly Arg Leu Cys Ala Pro Lys 1425 1430 1435 1440	4320
CCT CCG GTC CTG CGA CGG CAT CAG AGG GAC ATA AGC CTT CCT ACT TTT Pro Pro Val Leu Arg Arg His Gln Arg Asp Ile Ser Leu Pro Thr Phe 1445 1450 1455	4368
CAG CCG GAG GAA GAC AAA ATG GAC TAT GAT GAT ATC TTC TCA ACT GAA Gln Pro Glu Glu Asp Lys Met Asp Tyr Asp Asp Ile Phe Ser Thr Glu 1460 1465 1470	4416

ACG AAG GGA GAA GAT TTT GAC ATT TAC GGT GAG GAT GAA AAT CAG GAC Thr Lys Gly Glu Asp Phe Asp Ile Tyr Gly Glu Asp Glu Asn Gln Asp 1475 1480 1485	4464
CCT CGC AGC TTT CAG AAG AGA ACC CGA CAC TAT TTC ATT GCT GCG GTG Pro Arg Ser Phe Gln Lys Arg Thr Arg His Tyr Phe Ile Ala Ala Val 1490 1495 1500	4512
GAG CAG CTC TGG GAT TAC GGG ATG AGC GAA TCC CCC CGG GCG CTA AGA Glu Gln Leu Trp Asp Tyr Gly Met Ser Glu Ser Pro Arg Ala Leu Arg 1505 1510 1515 1520	4560
AAC AGG GCT CAG AAC GGA GAG GTG CCT CGG TTC AAG AAG GTG GTC TTC Asn Arg Ala Gln Asn Gly Glu Val Pro Arg Phe Lys Lys Val Val Phe 1525 1530 1535	4608
CGG GAA TTT GCT GAC GGC TCC TTC ACG CAG CCG TCG TAC CGC GGG GAA Arg Glu Phe Ala Asp Gly Ser Phe Thr Gln Pro Ser Tyr Arg Gly Glu 1540 1545 1550	4656
CTC AAC AAA CAC TTG GGG CTC TTG GGA CCC TAC ATC AGA GCG GAA GTT Leu Asn Lys His Leu Gly Leu Leu Gly Pro Tyr Ile Arg Ala Glu Val 1555 1560 1565	4704
GAA GAC AAC ATC ATG GTA ACT TTC AAA AAC CAG GCG TCT CGT CCC TAT Glu Asp Asn Ile Met Val Thr Phe Lys Asn Gln Ala Ser Arg Pro Tyr 1570 1575 1580	4752
TCC TTC TAC TCG AGC CTT ATT TCT TAT CCG GAT GAT CAG GAG CAA GGG Ser Phe Tyr Ser Ser Leu Ile Ser Tyr Pro Asp Asp Gln Glu Gln Gly 1585 1590 1595 1600	4800
GCA GAA CCT CGA CAC AAC TTC GTC CAG CCA AAT GAA ACC AGA ACT TAC Ala Glu Pro Arg His Asn Phe Val Gln Pro Asn Glu Thr Arg Thr Tyr 1605 1610 1615	4848
TTT TGG AAA GTG CAG CAT CAC ATG GCA CCC ACA GAA GAC GAG TTT GAC Phe Trp Lys Val Gln His His Met Ala Pro Thr Glu Asp Glu Phe Asp 1620 1625 1630	4896
TGC AAA GCC TGG GCC TAC TTT TCT GAT GTT GAC CTG GAA AAA GAT GTG Cys Lys Ala Trp Ala Tyr Phe Ser Asp Val Asp Leu Glu Lys Asp Val 1635 1640 1645	4944
CAC TCA GGC TTG ATC GGC CCC CTT CTG ATC TGC CGC GCC AAC ACC CTG His Ser Gly Leu Ile Gly Pro Leu Leu Ile Cys Arg Ala Asn Thr Leu 1650 1655 1660	4992
AAC GCT GCT CAC GGT AGA CAA GTG ACC GTG CAA GAA TTT GCT CTG TTT Asn Ala Ala His Gly Arg Gln Val Thr Val Gln Glu Phe Ala Leu Phe 1665 1670 1675 1680	5040
TTC ACT ATT TTT GAT GAG ACA AAG AGC TGG TAC TTC ACT GAA AAT GTG Phe Thr Ile Phe Asp Glu Thr Lys Ser Trp Tyr Phe Thr Glu Asn Val 1685 1690 1695	5088

GAA AGG AAC TGC CGG GCC CCC TGC CAC CTG CAG ATG GAG GAC CCC ACT Glu Arg Asn Cys Arg Ala Pro Cys His Leu Gln Met Glu Asp Pro Thr 1700 1705 1710	5136
CTG AAA GAA AAC TAT CGC TTC CAT GCA ATC AAT GGC TAT GTG ATG GAT Leu Lys Glu Asn Tyr Arg Phe His Ala Ile Asn Gly Tyr Val Met Asp 1715 1720 1725	5184
ACA CTC CCT GGC TTA GTA ATG GCT CAG AAT CAA AGG ATC CGA TGG TAT Thr Leu Pro Gly Leu Val Met Ala Gln Asn Gln Arg Ile Arg Trp Tyr 1730 1735 1740	5232
CTG CTC AGC ATG GGC AGC AAT GAA AAT ATC CAT TCG ATT CAT TTT AGC Leu Leu Ser Met Gly Ser Asn Glu Asn Ile His Ser Ile His Phe Ser 1745 1750 1755 1760	5280
GGA CAC GTG TTC AGT GTA CGG AAA AAG GAG GAG TAT AAA ATG GCC GTG Gly His Val Phe Ser Val Arg Lys Lys Glu Glu Tyr Lys Met Ala Val 1765 1770 1775	5328
TAC AAT CTC TAT CCG GGT GTC TTT GAG ACA GTG GAA ATG CTA CCG TCC Tyr Asn Leu Tyr Pro Gly Val Phe Glu Thr Val Glu Met Leu Pro Ser 1780 1785 1790	5376
AAA GTT GGA ATT TGG CGA ATA GAA TGC CTG ATT GGC GAG CAC CTG CAA Lys Val Gly Ile Trp Arg Ile Glu Cys Leu Ile Gly Glu His Leu Gln 1795 1800 1805	5424
GCT GGG ATG AGC ACG ACT TTC CTG GTG TAC AGC AAG GAG TGT CAG GCT Ala Gly Met Ser Thr Thr Phe Leu Val Tyr Ser Lys Glu Cys Gln Ala 1810 1815 1820	5472
CCA CTG GGA ATG GCT TCT GGA CGC ATT AGA GAT TTT CAG ATC ACA GCT Pro Leu Gly Met Ala Ser Gly Arg Ile Arg Asp Phe Gln Ile Thr Ala 1825 1830 1835 1840	5520
TCA GGA CAG TAT GGA CAG TGG GCC CCA AAG CTG GCC AGA CTT CAT TAT Ser Gly Gln Tyr Gly Gln Trp Ala Pro Lys Leu Ala Arg Leu His Tyr 1845 1850 1855	5568
TCC GGA TCA ATC AAT GCC TGG AGC ACC AAG GAT CCC CAC TCC TGG ATC Ser Gly Ser Ile Asn Ala Trp Ser Thr Lys Asp Pro His Ser Trp Ile 1860 1865 1870	5616
AAG GTG GAT CTG TTG GCA CCA ATG ATC ATT CAC GGC ATC ATG ACC CAG Lys Val Asp Leu Leu Ala Pro Met Ile Ile His Gly Ile Met Thr Gln 1875 1880 1885	5664
GGT GCC CGT CAG AAG TTT TCC AGC CTC TAC ATC TCC CAG TTT ATC ATC Gly Ala Arg Gln Lys Phe Ser Ser Leu Tyr Ile Ser Gln Phe Ile Ile 1890 1895 1900	5712
ATG TAC AGT CTT GAC GGG AGG AAC TGG CAG AGT TAC CGA GGG AAT TCC Met Tyr Ser Leu Asp Gly Arg Asn Trp Gln Ser Tyr Arg Gly Asn Ser 1905 1910 1915 1920	5760

ACG GGC ACC TTA ATG GTC TTC TTT GGC AAT GTG GAC GCA TCT GGG ATT Thr Gly Thr Leu Met Val Phe Phe Gly Asn Val Asp Ala Ser Gly Ile 1925 1930 1935	5808
AAA CAC AAT ATT TTT AAC CCT CCG ATT GTG GCT CGG TAC ATC CGT TTG Lys His Asn Ile Phe Asn Pro Pro Ile Val Ala Arg Tyr Ile Arg Leu 1940 1945 1950	5856
CAC CCA ACA CAT TAC AGC ATC CGC AGC ACT CTT CGC ATG GAG TTG ATG His Pro Thr His Tyr Ser Ile Arg Ser Thr Leu Arg Met Glu Leu Met 1955 1960 1965	5904
GGC TGT GAT TTA AAC AGT TGC AGC ATG CCC CTG GGA ATG CAG AAT AAA Gly Cys Asp Leu Asn Ser Cys Ser Met Pro Leu Gly Met Gln Asn Lys 1970 1975 1980	5952
GCG ATA TCA GAC TCA CAG ATC ACG GCC TCC TCC CAC CTA AGC AAT ATA Ala Ile Ser Asp Ser Gln Ile Thr Ala Ser Ser His Leu Ser Asn Ile 1985 1990 1995 2000	6000
TTT GCC ACC TGG TCT CCT TCA CAA GCC CGA CTT CAC CTC CAG GGG CGG Phe Ala Thr Trp Ser Pro Ser Gln Ala Arg Leu His Leu Gln Gly Arg 2005 2010 2015	6048
ACG AAT GCC TGG CGA CCC CGG GTG AGC AGC GCA GAG GAG TGG CTG CAG Thr Asn Ala Trp Arg Pro Arg Val Ser Ser Ala Glu Glu Trp Leu Gln 2020 2025 2030	6096
GTG GAC CTG CAG AAG ACG GTG AAG GTC ACA GGC ATC ACC ACC CAG GGC Val Asp Leu Gln Lys Thr Val Lys Val Thr Gly Ile Thr Thr Gln Gly 2035 2040 2045	6144
G TG AAG TCC CTG CTC AGC AGC ATG TAT GTG AAG GAG TTC CTC GTG TCC Val Lys Ser Leu Leu Ser Ser Met Tyr Val Lys Glu Phe Leu Val Ser 2050 2055 2060	6192
AGT AGT CAG GAC GGC CGC CGC TGG ACC CTG TTT CTT CAG GAC GGC CAC Ser Ser Gln Asp Gly Arg Arg Trp Thr Leu Phe Leu Gln Asp Gly His 2065 2070 2075 2080	6240
ACG AAG GTT TTT CAG GGC AAT CAG GAC TCC TCC ACC CCC GTG GTG AAC Thr Lys Val Phe Gln Gly Asn Gln Asp Ser Ser Thr Pro Val Val Asn 2085 2090 2095	6288
GCT CTG GAC CCC CCG CTG TTC ACG CGC TAC CTG AGG ATC CAC CCC ACG Ala Leu Asp Pro Pro Leu Phe Thr Arg Tyr Leu Arg Ile His Pro Thr 2100 2105 2110	6336
AGC TGG GCG CAG CAC ATC GCC CTG AGG CTC GAG GTT CTA GGA TGT GAG Ser Trp Ala Gln His Ile Ala Leu Arg Leu Glu Val Leu Gly Cys Glu 2115 2120 2125	6384
GCA CAG GAT CTC TAC TGA Ala Gln Asp Leu Tyr * 2130	6402

## (2) INFORMATION FOR SEQ ID NO:37:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2134 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

Met Gln Leu Glu Leu Ser Thr Cys Val Phe Leu Cys Leu Leu Pro Leu  
1 5 10 15

Gly Phe Ser Ala Ile Arg Arg Tyr Tyr Leu Gly Ala Val Glu Leu Ser  
20 25 30

Trp Asp Tyr Arg Gln Ser Glu Leu Leu Arg Glu Leu His Val Asp Thr  
35 40 45

Arg Phe Pro Ala Thr Ala Pro Gly Ala Leu Pro Leu Gly Pro Ser Val  
50 55 60

Leu Tyr Lys Lys Thr Val Phe Val Glu Phe Thr Asp Gln Leu Phe Ser  
65 70 75 80

Val Ala Arg Pro Arg Pro Pro Trp Met Gly Leu Leu Gly Pro Thr Ile  
85 90 95

Gln Ala Glu Val Tyr Asp Thr Val Val Val Thr Leu Lys Asn Met Ala  
100 105 110

Ser His Pro Val Ser Leu His Ala Val Gly Val Ser Phe Trp Lys Ser  
115 120 125

Ser Glu Gly Ala Glu Tyr Glu Asp His Thr Ser Gln Arg Glu Lys Glu  
130 135 140

Asp Asp Lys Val Leu Pro Gly Lys Ser Gln Thr Tyr Val Trp Gln Val  
145 150 155 160

Leu Lys Glu Asn Gly Pro Thr Ala Ser Asp Pro Pro Cys Leu Thr Tyr  
165 170 175

Ser Tyr Leu Ser His Val Asp Leu Val Lys Asp Leu Asn Ser Gly Leu  
180 185 190

Ile Gly Ala Leu Leu Val Cys Arg Glu Gly Ser Leu Thr Arg Glu Arg  
195 200 205

Thr Gln Asn Leu His Glu Phe Val Leu Leu Phe Ala Val Phe Asp Glu  
210 215 220

Gly Lys Ser Trp His Ser Ala Arg Asn Asp Ser Trp Thr Arg Ala Met  
225 230 235 240

Asp Pro Ala Pro Ala Arg Ala Gln Pro Ala Met His Thr Val Asn Gly  
245 250 255

Tyr Val Asn Arg Ser Leu Pro Gly Leu Ile Gly Cys His Lys Lys Ser  
260 265 270

Val Tyr Trp His Val Ile Gly Met Gly Thr Ser Pro Glu Val His Ser  
275 280 285

Ile Phe Leu Glu Gly His Thr Phe Leu Val Arg His His Arg Gln Ala  
290 295 300

Ser Leu Glu Ile Ser Pro Leu Thr Phe Leu Thr Ala Gln Thr Phe Leu  
305 310 315 320

Met Asp Leu Gly Gln Phe Leu Leu Phe Cys His Ile Ser Ser His His  
325 330 335

His Gly Gly Met Glu Ala His Val Arg Val Glu Ser Cys Ala Glu Glu  
340 345 350

Pro Gln Leu Arg Arg Lys Ala Asp Glu Glu Glu Asp Tyr Asp Asp Asn  
355 360 365

Leu Tyr Asp Ser Asp Met Asp Val Val Arg Leu Asp Gly Asp Asp Val  
370 375 380

Ser Pro Phe Ile Gln Ile Arg Ser Val Ala Lys Lys His Pro Lys Thr  
385 390 395 400

Trp Val His Tyr Ile Ser Ala Glu Glu Asp Trp Asp Tyr Ala Pro  
405 410 415

Ala Val Pro Ser Pro Ser Asp Arg Ser Tyr Lys Ser Leu Tyr Leu Asn  
420 425 430

Ser Gly Pro Gln Arg Ile Gly Arg Lys Tyr Lys Lys Ala Arg Phe Val  
435 440 445

Ala Tyr Thr Asp Val Thr Phe Lys Thr Arg Lys Ala Ile Pro Tyr Glu  
450 455 460

Ser Gly Ile Leu Gly Pro Leu Leu Tyr Gly Glu Val Gly Asp Thr Leu  
465 470 475 480

Leu Ile Ile Phe Lys Asn Lys Ala Ser Arg Pro Tyr Asn Ile Tyr Pro  
485 490 495

His Gly Ile Thr Asp Val Ser Ala Leu His Pro Gly Arg Leu Leu Lys  
500 505 510

Gly Trp Lys His Leu Lys Asp Met Pro Ile Leu Pro Gly Glu Thr Phe  
515 520 525

Lys Tyr Lys Trp Thr Val Thr Val Glu Asp Gly Pro Thr Lys Ser Asp  
530 535 540

Pro Arg Cys Leu Thr Arg Tyr Tyr Ser Ser Ser Ile Asn Leu Glu Lys  
545 550 555 560

Asp Leu Ala Ser Gly Leu Ile Gly Pro Leu Leu Ile Cys Tyr Lys Glu  
565 570 575

Ser Val Asp Gln Arg Gly Asn Gln Met Met Ser Asp Lys Arg Asn Val  
580 585 590

Ile Leu Phe Ser Val Phe Asp Glu Asn Gln Ser Trp Tyr Leu Ala Glu  
595 600 605

Asn Ile Gln Arg Phe Leu Pro Asn Pro Asp Gly Leu Gln Pro Gln Asp  
610 615 620

Pro Glu Phe Gln Ala Ser Asn Ile Met His Ser Ile Asn Gly Tyr Val  
625 630 635 640

Phe Asp Ser Leu Gln Leu Ser Val Cys Leu His Glu Val Ala Tyr Trp  
645 650 655

Tyr Ile Leu Ser Val Gly Ala Gln Thr Asp Phe Leu Ser Val Phe Phe  
660 665 670

Ser Gly Tyr Thr Phe Lys His Lys Met Val Tyr Glu Asp Thr Leu Thr  
675 680 685

Leu Phe Pro Phe Ser Gly Glu Thr Val Phe Met Ser Met Glu Asn Pro  
690 695 700

Gly Leu Trp Val Leu Gly Cys His Asn Ser Asp Leu Arg Asn Arg Gly  
705 710 715 720

Met Thr Ala Leu Leu Lys Val Tyr Ser Cys Asp Arg Asp Ile Gly Asp  
725 730 735

Tyr Tyr Asp Asn Thr Tyr Glu Asp Ile Pro Gly Phe Leu Leu Ser Gly  
740 745 750

Lys Asn Val Ile Glu Pro Arg Ser Phe Ala Gln Asn Ser Arg Pro Pro  
755 760 765

Ser Ala Ser Gln Lys Gln Phe Gln Thr Ile Thr Ser Pro Glu Asp Asp  
770 775 780

Val Glu Leu Asp Pro Gln Ser Gly Glu Arg Thr Gln Ala Leu Glu Glu  
785 790 795 800

Leu Ser Val Pro Ser Gly Asp Gly Ser Met Leu Leu Gly Gln Asn Pro  
805 810 815

Ala Pro His Gly Ser Ser Ser Asp Leu Gln Glu Ala Arg Asn Glu  
820 825 830

Ala Asp Asp Tyr Leu Pro Gly Ala Arg Glu Arg Asn Thr Ala Pro Ser  
835 840 845

Ala Ala Ala Arg Leu Arg Pro Glu Leu His His Ser Ala Glu Arg Val  
 850 855 860  
  
 Leu Thr Pro Glu Pro Glu Lys Glu Leu Lys Lys Leu Asp Ser Lys Met  
 865 870 875 880  
  
 Ser Ser Ser Ser Asp Leu Leu Lys Thr Ser Pro Thr Ile Pro Ser Asp  
 885 890 895  
  
 Thr Leu Ser Ala Glu Thr Glu Arg Thr His Ser Leu Gly Pro Pro His  
 900 905 910  
  
 Pro Gln Val Asn Phe Arg Ser Gln Leu Gly Ala Ile Val Leu Gly Lys  
 915 920 925  
  
 Asn Ser Ser His Phe Ile Gly Ala Gly Val Pro Leu Gly Ser Thr Glu  
 930 935 940  
  
 Glu Asp His Glu Ser Ser Leu Gly Glu Asn Val Ser Pro Val Glu Ser  
 945 950 955 960  
  
 Asp Gly Ile Phe Glu Lys Glu Arg Ala His Gly Pro Ala Ser Leu Thr  
 965 970 975  
  
 Lys Asp Asp Val Leu Phe Lys Val Asn Ile Ser Leu Val Lys Thr Asn  
 980 985 990  
  
 Lys Ala Arg Val Tyr Leu Lys Thr Asn Arg Lys Ile His Ile Asp Asp  
 995 1000 1005  
  
 Ala Ala Leu Leu Thr Glu Asn Arg Ala Ser Ala Thr Phe Met Asp Lys  
 1010 1015 1020  
  
 Asn Thr Thr Ala Ser Gly Leu Asn His Val Ser Asn Trp Ile Lys Gly  
 1025 1030 1035 1040  
  
 Pro Leu Gly Lys Asn Pro Leu Ser Ser Glu Arg Gly Pro Ser Pro Glu  
 1045 1050 1055  
  
 Leu Leu Thr Ser Ser Gly Ser Gly Lys Ser Val Lys Gly Gln Ser Ser  
 1060 1065 1070  
  
 Gly Gln Gly Arg Ile Arg Val Ala Val Glu Glu Glu Leu Ser Lys  
 1075 1080 1085  
  
 Gly Lys Glu Met Met Leu Pro Asn Ser Glu Leu Thr Phe Leu Thr Asn  
 1090 1095 1100  
  
 Ser Ala Asp Val Gln Gly Asn Asp Thr His Ser Gln Gly Lys Lys Ser  
 1105 1110 1115 1120  
  
 Arg Glu Glu Met Glu Arg Arg Glu Lys Leu Val Gln Glu Lys Val Asp  
 1125 1130 1135  
  
 Leu Pro Gln Val Tyr Thr Ala Thr Gly Thr Lys Asn Phe Leu Arg Asn  
 1140 1145 1150

Ile Phe His Gln Ser Thr Glu Pro Ser Val Glu Gly Phe Asp Gly Gly  
1155 1160 1165

Ser His Ala Pro Val Pro Gln Asp Ser Arg Ser Leu Asn Asp Ser Ala  
1170 1175 1180

Glu Arg Ala Glu Thr His Ile Ala His Phe Ser Ala Ile Arg Glu Glu  
1185 1190 1195 1200

Ala Pro Leu Glu Ala Pro Gly Asn Arg Thr Gly Pro Gly Pro Arg Ser  
1205 1210 1215

Ala Val Pro Arg Arg Val Lys Gln Ser Leu Lys Gln Ile Arg Leu Pro  
1220 1225 1230

Leu Glu Glu Ile Lys Pro Glu Arg Gly Val Val Leu Asn Ala Thr Ser  
1235 1240 1245

Thr Arg Trp Ser Glu Ser Ser Pro Ile Leu Gln Gly Ala Lys Arg Asn  
1250 1255 1260

Asn Leu Ser Leu Pro Phe Leu Thr Leu Glu Met Ala Gly Gly Gln Gly  
1265 1270 1275 1280

Lys Ile Ser Ala Leu Gly Lys Ser Ala Ala Gly Pro Leu Ala Ser Gly  
1285 1290 1295

Lys Leu Glu Lys Ala Val Leu Ser Ser Ala Gly Leu Ser Glu Ala Ser  
1300 1305 1310

Gly Lys Ala Glu Phe Leu Pro Lys Val Arg Val His Arg Glu Asp Leu  
1315 1320 1325

Leu Pro Gln Lys Thr Ser Asn Val Ser Cys Ala His Gly Asp Leu Gly  
1330 1335 1340

Gln Glu Ile Phe Leu Gln Lys Thr Arg Gly Pro Val Asn Leu Asn Lys  
1345 1350 1355 1360

Val Asn Arg Pro Gly Arg Thr Pro Ser Lys Leu Leu Gly Pro Pro Met  
1365 1370 1375

Pro Lys Glu Trp Glu Ser Leu Glu Lys Ser Pro Lys Ser Thr Ala Leu  
1380 1385 1390

Arg Thr Lys Asp Ile Ile Ser Leu Pro Leu Asp Arg His Glu Ser Asn  
1395 1400 1405

His Ser Ile Ala Ala Lys Asn Glu Gly Gln Ala Glu Thr Gln Arg Glu  
1410 1415 1420

Ala Ala Trp Thr Lys Gln Gly Gly Pro Gly Arg Leu Cys Ala Pro Lys  
1425 1430 1435 1440

Pro Pro Val Leu Arg Arg His Gln Arg Asp Ile Ser Leu Pro Thr Phe  
1445 1450 1455

Gln Pro Glu Glu Asp Lys Met Asp Tyr Asp Asp Ile Phe Ser Thr Glu  
 1460 1465 1470  
  
 Thr Lys Gly Glu Asp Phe Asp Ile Tyr Gly Glu Asp Glu Asn Gln Asp  
 1475 1480 1485  
  
 Pro Arg Ser Phe Gln Lys Arg Thr Arg His Tyr Phe Ile Ala Ala Val  
 1490 1495 1500  
  
 Glu Gln Leu Trp Asp Tyr Gly Met Ser Glu Ser Pro Arg Ala Leu Arg  
 1505 1510 1515 1520  
  
 Asn Arg Ala Gln Asn Gly Glu Val Pro Arg Phe Lys Lys Val Val Phe  
 1525 1530 1535  
  
 Arg Glu Phe Ala Asp Gly Ser Phe Thr Gln Pro Ser Tyr Arg Gly Glu  
 1540 1545 1550  
  
 Leu Asn Lys His Leu Gly Leu Leu Gly Pro Tyr Ile Arg Ala Glu Val  
 1555 1560 1565  
  
 Glu Asp Asn Ile Met Val Thr Phe Lys Asn Gln Ala Ser Arg Pro Tyr  
 1570 1575 1580  
  
 Ser Phe Tyr Ser Ser Leu Ile Ser Tyr Pro Asp Asp Gln Glu Gln Gly  
 1585 1590 1595 1600  
  
 Ala Glu Pro Arg His Asn Phe Val Gln Pro Asn Glu Thr Arg Thr Tyr  
 1605 1610 1615  
  
 Phe Trp Lys Val Gln His His Met Ala Pro Thr Glu Asp Glu Phe Asp  
 1620 1625 1630  
  
 Cys Lys Ala Trp Ala Tyr Phe Ser Asp Val Asp Leu Glu Lys Asp Val  
 1635 1640 1645  
  
 His Ser Gly Leu Ile Gly Pro Leu Leu Ile Cys Arg Ala Asn Thr Leu  
 1650 1655 1660  
  
 Asn Ala Ala His Gly Arg Gln Val Thr Val Gln Glu Phe Ala Leu Phe  
 1665 1670 1675 1680  
  
 Phe Thr Ile Phe Asp Glu Thr Lys Ser Trp Tyr Phe Thr Glu Asn Val  
 1685 1690 1695  
  
 Glu Arg Asn Cys Arg Ala Pro Cys His Leu Gln Met Glu Asp Pro Thr  
 1700 1705 1710  
  
 Leu Lys Glu Asn Tyr Arg Phe His Ala Ile Asn Gly Tyr Val Met Asp  
 1715 1720 1725  
  
 Thr Leu Pro Gly Leu Val Met Ala Gln Asn Gln Arg Ile Arg Trp Tyr  
 1730 1735 1740  
  
 Leu Leu Ser Met Gly Ser Asn Glu Asn Ile His Ser Ile His Phe Ser  
 1745 1750 1755 1760

Gly His Val Phe Ser Val Arg Lys Lys Glu Glu Tyr Lys Met Ala Val  
 1765 1770 1775

Tyr Asn Leu Tyr Pro Gly Val Phe Glu Thr Val Glu Met Leu Pro Ser  
 1780 1785 1790

Lys Val Gly Ile Trp Arg Ile Glu Cys Leu Ile Gly Glu His Leu Gln  
 1795 1800 1805

Ala Gly Met Ser Thr Thr Phe Leu Val Tyr Ser Lys Glu Cys Gln Ala  
 1810 1815 1820

Pro Leu Gly Met Ala Ser Gly Arg Ile Arg Asp Phe Gln Ile Thr Ala  
 1825 1830 1835 1840

Ser Gly Gln Tyr Gly Gln Trp Ala Pro Lys Leu Ala Arg Leu His Tyr  
 1845 1850 1855

Ser Gly Ser Ile Asn Ala Trp Ser Thr Lys Asp Pro His Ser Trp Ile  
 1860 1865 1870

Lys Val Asp Leu Leu Ala Pro Met Ile Ile His Gly Ile Met Thr Gln  
 1875 1880 1885

Gly Ala Arg Gln Lys Phe Ser Ser Leu Tyr Ile Ser Gln Phe Ile Ile  
 1890 1895 1900

Met Tyr Ser Leu Asp Gly Arg Asn Trp Gln Ser Tyr Arg Gly Asn Ser  
 1905 1910 1915 1920

Thr Gly Thr Leu Met Val Phe Phe Gly Asn Val Asp Ala Ser Gly Ile  
 1925 1930 1935

Lys His Asn Ile Phe Asn Pro Pro Ile Val Ala Arg Tyr Ile Arg Leu  
 1940 1945 1950

His Pro Thr His Tyr Ser Ile Arg Ser Thr Leu Arg Met Glu Leu Met  
 1955 1960 1965

Gly Cys Asp Leu Asn Ser Cys Ser Met Pro Leu Gly Met Gln Asn Lys  
 1970 1975 1980

Ala Ile Ser Asp Ser Gln Ile Thr Ala Ser Ser His Leu Ser Asn Ile  
 1985 1990 1995 2000

Phe Ala Thr Trp Ser Pro Ser Gln Ala Arg Leu His Leu Gln Gly Arg  
 2005 2010 2015

Thr Asn Ala Trp Arg Pro Arg Val Ser Ser Ala Glu Glu Trp Leu Gln  
 2020 2025 2030

Val Asp Leu Gln Lys Thr Val Lys Val Thr Gly Ile Thr Thr Gln Gly  
 2035 2040 2045

Val Lys Ser Leu Leu Ser Ser Met Tyr Val Lys Glu Phe Leu Val Ser  
 2050 2055 2060

Ser Ser Gln Asp Gly Arg Arg Trp Thr Leu Phe Leu Gln Asp Gly His  
 2065 2070 2075 2080  
 Thr Lys Val Phe Gln Gly Asn Gln Asp Ser Ser Thr Pro Val Val Asn  
 2085 2090 2095  
 Ala Leu Asp Pro Pro Leu Phe Thr Arg Tyr Leu Arg Ile His Pro Thr  
 2100 2105 2110  
 Ser Trp Ala Gln His Ile Ala Leu Arg Leu Glu Val Leu Gly Cys Glu  
 2115 2120 2125  
 Ala Gln Asp Leu Tyr \*  
 2130

## (2) INFORMATION FOR SEQ ID NO:38:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 4334 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: not relevant
- (ii) MOLECULE TYPE: cDNA to mRNA
- (iii) HYPOTHETICAL: NO
- (vi) ORIGINAL SOURCE:
  - (C) INDIVIDUAL ISOLATE: Factor VIII lacking B domain
- (ix) FEATURE:
  - (A) NAME/KEY: CDS
  - (B) LOCATION: 3..4334

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

GA ATG CAG CTA GAG CTC TCC ACC TGT GTC TTT CTG TGT CTC TTG CCA	47
Met Gln Leu Glu Leu Ser Thr Cys Val Phe Leu Cys Leu Leu Pro	
1 5 10 15	
CTC GGC TTT AGT GCC ATC AGG AGA TAC TAC CTG GGC GCA GTG GAA CTG	95
Leu Gly Phe Ser Ala Ile Arg Arg Tyr Tyr Leu Gly Ala Val Glu Leu	
20 25 30	
TCC TGG GAC TAC CGG CAA AGT GAA CTC CTC CGT GAG CTG CAC GTG GAC	143
Ser Trp Asp Tyr Arg Gln Ser Glu Leu Leu Arg Glu Leu His Val Asp	
35 40 45	
ACC AGA TTT CCT GCT ACA GCG CCA GGA GCT CTT CCG TTG GGC CCG TCA	191
Thr Arg Phe Pro Ala Thr Ala Pro Gly Ala Leu Pro Leu Gly Pro Ser	
50 55 60	
GTC CTG TAC AAA AAG ACT GTG TTC GTA GAG TTC ACG GAT CAA CTT TTC	239
Val Leu Tyr Lys Lys Thr Val Phe Val Glu Phe Thr Asp Gln Leu Phe	
65 70 75	

AGC GTT GCC AGG CCC AGG CCA CCA TGG ATG GGT CTG CTG GGT CCT ACC Ser Val Ala Arg Pro Arg Pro Pro Trp Met Gly Leu Leu Gly Pro Thr 80 85 90 95	287
ATC CAG GCT GAG GTT TAC GAC ACG GTG GTC GTT ACC CTG AAG AAC ATG Ile Gln Ala Glu Val Tyr Asp Thr Val Val Thr Leu Lys Asn Met 100 105 110	335
GCT TCT CAT CCC GTT AGT CTT CAC GCT GTC GGC GTC TCC TTC TGG AAA Ala Ser His Pro Val Ser Leu His Ala Val Gly Val Ser Phe Trp Lys 115 120 125	383
TCT TCC GAA GGC GCT GAA TAT GAG GAT CAC ACC AGC CAA AGG GAG AAG Ser Ser Glu Gly Ala Glu Tyr Glu Asp His Thr Ser Gln Arg Glu Lys 130 135 140	431
GAA GAC GAT AAA GTC CTT CCC GGT AAA AGC CAA ACC TAC GTC TGG CAG Glu Asp Asp Lys Val Leu Pro Gly Lys Ser Gln Thr Tyr Val Trp Gln 145 150 155	479
GTC CTG AAA GAA AAT GGT CCA ACA GCC TCT GAC CCA CCA TGT CTC ACC Val Leu Lys Glu Asn Gly Pro Thr Ala Ser Asp Pro Pro Cys Leu Thr 160 165 170 175	527
TAC TCA TAC CTG TCT CAC GTG GAC CTG GTG AAA GAC CTG AAT TCG GGC Tyr Ser Tyr Leu Ser His Val Asp Leu Val Lys Asp Leu Asn Ser Gly 180 185 190	575
CTC ATT GGA GCC CTG CTG GTT TGT AGA GAA GGG AGT CTG ACC AGA GAA Leu Ile Gly Ala Leu Leu Val Cys Arg Glu Gly Ser Leu Thr Arg Glu 195 200 205	623
AGG ACC CAG AAC CTG CAC GAA TTT GTA CTA CTT TTT GCT GTC TTT GAT Arg Thr Gln Asn Leu His Glu Phe Val Leu Leu Phe Ala Val Phe Asp 210 215 220	671
GAA GGG AAA AGT TGG CAC TCA GCA AGA AAT GAC TCC TGG ACA CGG GCC Glu Gly Lys Ser Trp His Ser Ala Arg Asn Asp Ser Trp Thr Arg Ala 225 230 235	719
ATG GAT CCC GCA CCT GCC AGG GCC CAG CCT GCA ATG CAC ACA GTC AAT Met Asp Pro Ala Pro Ala Arg Ala Gln Pro Ala Met His Thr Val Asn 240 245 250 255	767
GGC TAT GTC AAC AGG TCT CTG CCA GGT CTG ATC GGA TGT CAT AAG AAA Gly Tyr Val Asn Arg Ser Leu Pro Gly Leu Ile Gly Cys His Lys Lys 260 265 270	815
TCA GTC TAC TGG CAC GTG ATT GGA ATG GGC ACC AGC CCG GAA GTG CAC Ser Val Tyr Trp His Val Ile Gly Met Gly Thr Ser Pro Glu Val His 275 280 285	863
TCC ATT TTT CTT GAA GGC CAC ACG TTT CTC GTG AGG CAC CAT CGC CAG Ser Ile Phe Leu Glu Gly His Thr Phe Leu Val Arg His His Arg Gln 290 295 300	911

GCT TCC TTG GAG ATC TCG CCA CTA ACT TTC CTC ACT GCT CAG ACA TTC Ala Ser Leu Glu Ile Ser Pro Leu Thr Phe Leu Thr Ala Gln Thr Phe 305	310	315	959
CTG ATG GAC CTT GGC CAG TTC CTA CTG TTT TGT CAT ATC TCT TCC CAC Leu Met Asp Leu Gly Gln Phe Leu Leu Phe Cys His Ile Ser Ser His 320	325	330	1007
CAC CAT GGT GGC ATG GAG GCT CAC GTC AGA GTA GAA AGC TGC GCC GAG His His Gly Gly Met Glu Ala His Val Arg Val Glu Ser Cys Ala Glu 340	345	350	1055
GAG CCC CAG CTG CGG AGG AAA GCT GAT GAA GAG GAA GAT TAT GAT GAC Glu Pro Gln Leu Arg Arg Lys Ala Asp Glu Glu Asp Tyr Asp Asp 355	360	365	1103
AAT TTG TAC GAC TCG GAC ATG GAC GTG GTC CGG CTC GAT GGT GAC GAC Asn Leu Tyr Asp Ser Asp Met Asp Val Val Arg Leu Asp Gly Asp Asp 370	375	380	1151
GTG TCT CCC TTT ATC CAA ATC CGC TCG GTT GCC AAG AAG CAT CCC AAA Val Ser Pro Phe Ile Gln Ile Arg Ser Val Ala Lys Lys His Pro Lys 385	390	395	1199
ACC TGG GTG CAC TAC ATC TCT GCA GAG GAG GAC TGG GAC TAC GCC Thr Trp Val His Tyr Ile Ser Ala Glu Glu Asp Trp Asp Tyr Ala 400	405	410	1247
CCC GCG GTC CCC AGC CCC AGT GAC AGA AGT TAT AAA AGT CTC TAC TTG Pro Ala Val Pro Ser Pro Asp Arg Ser Tyr Lys Ser Leu Tyr Leu 420	425	430	1295
AAC AGT GGT CCT CAG CGA ATT GGT AGG AAA TAC AAA AAA GCT CGA TTC Asn Ser Gly Pro Gln Arg Ile Gly Arg Lys Tyr Lys Lys Ala Arg Phe 435	440	445	1343
GTC GCT TAC ACG GAT GTA ACA TTT AAG ACT CGT AAA GCT ATT CCG TAT Val Ala Tyr Thr Asp Val Thr Phe Lys Thr Arg Lys Ala Ile Pro Tyr 450	455	460	1391
GAA TCA GGA ATC CTG GGA CCT TTA CTT TAT GGA GAA GTT GGA GAC ACA Glu Ser Gly Ile Leu Gly Pro Leu Leu Tyr Gly Glu Val Gly Asp Thr 465	470	475	1439
CTT TTG ATT ATA TTT AAG AAT AAA GCG AGC CGA CCA TAT AAC ATC TAC Leu Leu Ile Ile Phe Lys Asn Lys Ala Ser Arg Pro Tyr Asn Ile Tyr 480	485	490	1487
CCT CAT GGA ATC ACT GAT GTC AGC GCT TTG CAC CCA GGG AGA CTT CTA Pro His Gly Ile Thr Asp Val Ser Ala Leu His Pro Gly Arg Leu Leu 500	505	510	1535
AAA GGT TGG AAA CAT TTG AAA GAC ATG CCA ATT CTG CCA GGA GAG ACT Lys Gly Trp Lys His Leu Lys Asp Met Pro Ile Leu Pro Gly Glu Thr 515	520	525	1583

TTC AAG TAT AAA TGG ACA GTG ACT GTG GAA GAT GGG CCA ACC AAG TCC Phe Lys Tyr Lys Trp Thr Val Thr Val Glu Asp Gly Pro Thr Lys Ser 530 535 540	1631
GAT CCT CGG TGC CTG ACC CGC TAC TAC TCG AGC TCC ATT AAT CTA GAG Asp Pro Arg Cys Leu Thr Arg Tyr Tyr Ser Ser Ile Asn Leu Glu 545 550 555	1679
AAA GAT CTG GCT TCG GGA CTC ATT GGC CCT CTC CTC ATC TGC TAC AAA Lys Asp Leu Ala Ser Gly Leu Ile Gly Pro Leu Leu Ile Cys Tyr Lys 560 565 570 575	1727
GAA TCT GTA GAC CAA AGA GGA AAC CAG ATG ATG TCA GAC AAG AGA AAC Glu Ser Val Asp Gln Arg Gly Asn Gln Met Met Ser Asp Lys Arg Asn 580 585 590	1775
GTC ATC CTG TTT TCT GTA TTC GAT GAG AAT CAA AGC TGG TAC CTC GCA Val Ile Leu Phe Ser Val Phe Asp Glu Asn Gln Ser Trp Tyr Leu Ala 595 600 605	1823
GAG AAT ATT CAG CGC TTC CTC CCC AAT CCG GAT GGA TTA CAG CCC CAG Glu Asn Ile Gln Arg Phe Leu Pro Asn Pro Asp Gly Leu Gln Pro Gln 610 615 620	1871
GAT CCA GAG TTC CAA GCT TCT AAC ATC ATG CAC AGC ATC AAT GGC TAT Asp Pro Glu Phe Gln Ala Ser Asn Ile Met His Ser Ile Asn Gly Tyr 625 630 635	1919
GTT TTT GAT AGC TTG CAG CTG TCG GTT TGT TTG CAC GAG GTG GCA TAC Val Phe Asp Ser Leu Gln Leu Ser Val Cys Leu His Glu Val Ala Tyr 640 645 650 655	1967
TGG TAC ATT CTA AGT GTT GGA GCA CAG ACG GAC TTC CTC TCC GTC TTC Trp Tyr Ile Leu Ser Val Gly Ala Gln Thr Asp Phe Leu Ser Val Phe 660 665 670	2015
TTC TCT GGC TAC ACC TTC AAA CAC AAA ATG GTC TAT GAA GAC ACA CTC Phe Ser Gly Tyr Thr Phe Lys His Lys Met Val Tyr Glu Asp Thr Leu 675 680 685	2063
ACC CTG TTC CCC TCA GGA GAA ACG GTC TTC ATG TCA ATG GAA AAC Thr Leu Phe Pro Phe Ser Gly Glu Thr Val Phe Met Ser Met Glu Asn 690 695 700	2111
CCA GGT CTC TGG GTC CTA GGG TGC CAC AAC TCA GAC TTG CGG AAC AGA Pro Gly Leu Trp Val Leu Gly Cys His Asn Ser Asp Leu Arg Asn Arg 705 710 715	2159
GGG ATG ACA GCC TTA CTG AAG GTG TAT AGT TGT GAC AGG GAC ATT GGT Gly Met Thr Ala Leu Leu Lys Val Tyr Ser Cys Asp Arg Asp Ile Gly 720 725 730 735	2207
GAT TAT TAT GAC AAC ACT TAT GAA GAT ATT CCA GGC TTC TTG CTG AGT Asp Tyr Tyr Asp Asn Thr Tyr Glu Asp Ile Pro Gly Phe Leu Leu Ser 740 745 750	2255

GGA AAG AAT GTC ATT GAA CCC AGA GAC ATA AGC CTT CCT ACT TTT CAG Gly Lys Asn Val Ile Glu Pro Arg Asp Ile Ser Leu Pro Thr Phe Gln 755 760 765	2303
CCG GAG GAA GAC AAA ATG GAC TAT GAT GAT ATC TTC TCA ACT GAA ACG Pro Glu Glu Asp Lys Met Asp Tyr Asp Asp Ile Phe Ser Thr Glu Thr 770 775 780	2351
AAG GGA GAA GAT TTT GAC ATT TAC GGT GAG GAT GAA AAT CAG GAC CCT Lys Gly Glu Asp Phe Asp Ile Tyr Gly Glu Asp Glu Asn Gln Asp Pro 785 790 795	2399
CGC AGC TTT CAG AAG AGA ACC CGA CAC TAT TTC ATT GCT GCG GTG GAG Arg Ser Phe Gln Lys Arg Thr Arg His Tyr Phe Ile Ala Ala Val Glu 800 805 810 815	2447
CAG CTC TGG GAT TAC GGG ATG AGC GAA TCC CCC CGG GCG CTA AGA AAC Gln Leu Trp Asp Tyr Gly Met Ser Glu Ser Pro Arg Ala Leu Arg Asn 820 825 830	2495
AGG GCT CAG AAC GGA GAG GTG CCT CGG TTC AAG AAG GTG GTC TTC CGG Arg Ala Gln Asn Gly Glu Val Pro Arg Phe Lys Lys Val Val Phe Arg 835 840 845	2543
GAA TTT GCT GAC GGC TCC TTC ACG CAG CCG TCG TAC CGC GGG GAA CTC Glu Phe Ala Asp Gly Ser Phe Thr Gln Pro Ser Tyr Arg Gly Glu Leu 850 855 860	2591
AAC AAA CAC TTG GGG CTC TTG GGA CCC TAC ATC AGA GCG GAA GTT GAA Asn Lys His Leu Gly Leu Gly Pro Tyr Ile Arg Ala Glu Val Glu 865 870 875	2639
GAC AAC ATC ATG GTA ACT TTC AAA AAC CAG GCG TCT CGT CCC TAT TCC Asp Asn Ile Met Val Thr Phe Lys Asn Gln Ala Ser Arg Pro Tyr Ser 880 885 890 895	2687
TTC TAC TCG AGC CTT ATT TCT TAT CCG GAT GAT CAG GAG CAA GGG GCA Phe Tyr Ser Ser Leu Ile Ser Tyr Pro Asp Asp Gln Glu Gln Gly Ala 900 905 910	2735
GAA CCT CGA CAC AAC TTC GTC CAG CCA AAT GAA ACC AGA ACT TAC TTT Glu Pro Arg His Asn Phe Val Gln Pro Asn Glu Thr Arg Thr Tyr Phe 915 920 925	2783
TGG AAA GTG CAG CAT CAC ATG GCA CCC ACA GAA GAC GAG TTT GAC TGC Trp Lys Val Gln His His Met Ala Pro Thr Glu Asp Glu Phe Asp Cys 930 935 940	2831
AAA GCC TGG GCC TAC TTT TCT GAT GTT GAC CTG GAA AAA GAT GTG CAC Lys Ala Trp Ala Tyr Phe Ser Asp Val Asp Leu Glu Lys Asp Val His 945 950 955	2879
TCA GGC TTG ATC GGC CCC CTT CTG ATC TGC CGC GCC AAC ACC CTG AAC Ser Gly Leu Ile Gly Pro Leu Leu Ile Cys Arg Ala Asn Thr Leu Asn 960 965 970 975	2927

GCT GCT CAC GGT AGA CAA GTG ACC GTG CAA GAA TTT GCT CTG TTT TTC Ala Ala His Gly Arg Gln Val Thr Val Gln Glu Phe Ala Leu Phe Phe 980 985 990	2975
ACT ATT TTT GAT GAG ACA AAG AGC TGG TAC TTC ACT GAA AAT GTG GAA Thr Ile Phe Asp Glu Thr Lys Ser Trp Tyr Phe Thr Glu Asn Val Glu 995 1000 1005	3023
AGG AAC TGC CGG GCC CCC TGC CAC CTG CAG ATG GAG GAC CCC ACT CTG Arg Asn Cys Arg Ala Pro Cys His Leu Gln Met Glu Asp Pro Thr Leu 1010 1015 1020	3071
AAA GAA AAC TAT CGC TTC CAT GCA ATC AAT GGC TAT GTG ATG GAT ACA Lys Glu Asn Tyr Arg Phe His Ala Ile Asn Gly Tyr Val Met Asp Thr 1025 1030 1035	3119
CTC CCT GGC TTA GTA ATG GCT CAG AAT CAA AGG ATC CGA TGG TAT CTG Leu Pro Gly Leu Val Met Ala Gln Asn Gln Arg Ile Arg Trp Tyr Leu 1040 1045 1050 1055	3167
CTC AGC ATG GGC AGC AAT GAA AAT ATC CAT TCG ATT CAT TTT AGC GGA Leu Ser Met Gly Ser Asn Glu Asn Ile His Ser Ile His Phe Ser Gly 1060 1065 1070	3215
CAC GTG TTC AGT GTA CGG AAA AAG GAG GAG TAT AAA ATG GCC GTG TAC His Val Phe Ser Val Arg Lys Lys Glu Glu Tyr Lys Met Ala Val Tyr 1075 1080 1085	3263
AAT CTC TAT CCG GGT GTC TTT GAG ACA GTG GAA ATG CTA CCG TCC AAA Asn Leu Tyr Pro Gly Val Phe Glu Thr Val Glu Met Leu Pro Ser Lys 1090 1095 1100	3311
GTT GGA ATT TGG CGA ATA GAA TGC CTG ATT GGC GAG CAC CTG CAA GCT Val Gly Ile Trp Arg Ile Glu Cys Leu Ile Gly Glu His Leu Gln Ala 1105 1110 1115	3359
GGG ATG AGC ACG ACT TTC CTG GTG TAC AGC AAG GAG TGT CAG GCT CCA Gly Met Ser Thr Thr Phe Leu Val Tyr Ser Lys Glu Cys Gln Ala Pro 1120 1125 1130 1135	3407
CTG GGA ATG GCT TCT GGA CGC ATT AGA GAT TTT CAG ATC ACA GCT TCA Leu Gly Met Ala Ser Gly Arg Ile Arg Asp Phe Gln Ile Thr Ala Ser 1140 1145 1150	3455
GGA CAG TAT GGA CAG TGG GCC CCA AAG CTG GCC AGA CTT CAT TAT TCC Gly Gln Tyr Gly Gln Trp Ala Pro Lys Leu Ala Arg Leu His Tyr Ser 1155 1160 1165	3503
GGA TCA ATC AAT GCC TGG AGC ACC AAG GAT CCC CAC TCC TGG ATC AAG Gly Ser Ile Asn Ala Trp Ser Thr Lys Asp Pro His Ser Trp Ile Lys 1170 1175 1180	3551
GTG GAT CTG TTG GCA CCA ATG ATC ATT CAC GGC ATC ATG ACC CAG GGT Val Asp Leu Leu Ala Pro Met Ile Ile His Gly Ile Met Thr Gln Gly 1185 1190 1195	3599

GCC CGT CAG AAG TTT TCC AGC CTC TAC ATC TCC CAG TTT ATC ATC ATG Ala Arg Gln Lys Phe Ser Ser Leu Tyr Ile Ser Gln Phe Ile Ile Met 1200 1205 1210 1215	3647
TAC AGT CTT GAC GGG AGG AAC TGG CAG AGT TAC CGA GGG AAT TCC ACG Tyr Ser Leu Asp Gly Arg Asn Trp Gln Ser Tyr Arg Gly Asn Ser Thr 1220 1225 1230	3695
GGC ACC TTA ATG GTC TTC TTT GGC AAT GTG GAC GCA TCT GGG ATT AAA Gly Thr Leu Met Val Phe Phe Gly Asn Val Asp Ala Ser Gly Ile Lys 1235 1240 1245	3743
CAC AAT ATT TTT AAC CCT CCG ATT GTG GCT CGG TAC ATC CGT TTG CAC His Asn Ile Phe Asn Pro Pro Ile Val Ala Arg Tyr Ile Arg Leu His 1250 1255 1260	3791
CCA ACA CAT TAC AGC ATC CGC AGC ACT CTT CGC ATG GAG TTG ATG GGC Pro Thr His Tyr Ser Ile Arg Ser Thr Leu Arg Met Glu Leu Met Gly 1265 1270 1275	3839
TGT GAT TTA AAC AGT TGC AGC ATG CCC CTG GGA ATG CAG AAT AAA GCG Cys Asp Leu Asn Ser Cys Ser Met Pro Leu Gly Met Gln Asn Lys Ala 1280 1285 1290 1295	3887
ATA TCA GAC TCA CAG ATC ACG GCC TCC TCC CAC CTA AGC AAT ATA TTT Ile Ser Asp Ser Gln Ile Thr Ala Ser Ser His Leu Ser Asn Ile Phe 1300 1305 1310	3935
GCC ACC TGG TCT CCT TCA CAA GCC CGA CTT CAC CTC CAG GGG CGG ACG Ala Thr Trp Ser Pro Ser Gln Ala Arg Leu His Leu Gln Gly Arg Thr 1315 1320 1325	3983
AAT GCC TGG CGA CCC CGG GTG AGC AGC GCA GAG GAG TGG CTG CAG GTG Asn Ala Trp Arg Pro Arg Val Ser Ser Ala Glu Glu Trp Leu Gln Val 1330 1335 1340	4031
GAC CTG CAG AAG ACG GTG AAG GTC ACA GGC ATC ACC ACC CAG GGC GTG Asp Leu Gln Lys Thr Val Lys Val Thr Gly Ile Thr Thr Gln Gly Val 1345 1350 1355	4079
AAG TCC CTG CTC AGC AGC ATG TAT GTG AAG GAG TTC CTC GTG TCC AGT Lys Ser Leu Leu Ser Ser Met Tyr Val Lys Glu Phe Leu Val Ser Ser 1360 1365 1370 1375	4127
AGT CAG GAC GGC CGC CGC TGG ACC CTG TTT CTT CAG GAC GGC CAC ACG Ser Gln Asp Gly Arg Arg Trp Thr Leu Phe Leu Gln Asp Gly His Thr 1380 1385 1390	4175
AAG GTT TTT CAG GGC AAT CAG GAC TCC TCC ACC CCC GTG GTG AAC GCT Lys Val Phe Gln Gly Asn Gln Asp Ser Ser Thr Pro Val Val Asn Ala 1395 1400 1405	4223
CTG GAC CCC CCG CTG TTC ACG CGC TAC CTG AGG ATC CAC CCC ACG AGC Leu Asp Pro Pro Leu Phe Thr Arg Tyr Leu Arg Ile His Pro Thr Ser 1410 1415 1420	4271

TGG GCG CAG CAC ATC GCC CTG AGG CTC GAG GTT CTA GGA TGT GAG GCA	4319
Trp Ala Gln His Ile Ala Leu Arg Leu Glu Val Leu Gly Cys Glu Ala	
1425	1430
CAG GAT CTC TAC TGA	4334
Gln Asp Leu Tyr *	
1440	

## (2) INFORMATION FOR SEQ ID NO:39:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1444 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

Met Gln Leu Glu Leu Ser Thr Cys Val Phe Leu Cys Leu Leu Pro Leu			
1	5	10	15
Gly Phe Ser Ala Ile Arg Arg Tyr Tyr Leu Gly Ala Val Glu Leu Ser			
20	25		30
Trp Asp Tyr Arg Gln Ser Glu Leu Leu Arg Glu Leu His Val Asp Thr			
35	40	45	
Arg Phe Pro Ala Thr Ala Pro Gly Ala Leu Pro Leu Gly Pro Ser Val			
50	55	60	
Leu Tyr Lys Lys Thr Val Phe Val Glu Phe Thr Asp Gln Leu Phe Ser			
65	70	75	80
Val Ala Arg Pro Arg Pro Pro Trp Met Gly Leu Leu Gly Pro Thr Ile			
85	90		95
Gln Ala Glu Val Tyr Asp Thr Val Val Val Thr Leu Lys Asn Met Ala			
100	105		110
Ser His Pro Val Ser Leu His Ala Val Gly Val Ser Phe Trp Lys Ser			
115	120	125	
Ser Glu Gly Ala Glu Tyr Glu Asp His Thr Ser Gln Arg Glu Lys Glu			
130	135	140	
Asp Asp Lys Val Leu Pro Gly Lys Ser Gln Thr Tyr Val Trp Gln Val			
145	150	155	160
Leu Lys Glu Asn Gly Pro Thr Ala Ser Asp Pro Pro Cys Leu Thr Tyr			
165	170		175
Ser Tyr Leu Ser His Val Asp Leu Val Lys Asp Leu Asn Ser Gly Leu			
180	185	190	

Ile Gly Ala Leu Leu Val Cys Arg Glu Gly Ser Leu Thr Arg Glu Arg  
195 200 205

Thr Gln Asn Leu His Glu Phe Val Leu Leu Phe Ala Val Phe Asp Glu  
210 215 220

Gly Lys Ser Trp His Ser Ala Arg Asn Asp Ser Trp Thr Arg Ala Met  
225 230 235 240

Asp Pro Ala Pro Ala Arg Ala Gln Pro Ala Met His Thr Val Asn Gly  
245 250 255

Tyr Val Asn Arg Ser Leu Pro Gly Leu Ile Gly Cys His Lys Lys Ser  
260 265 270

Val Tyr Trp His Val Ile Gly Met Gly Thr Ser Pro Glu Val His Ser  
275 280 285

Ile Phe Leu Glu Gly His Thr Phe Leu Val Arg His His Arg Gln Ala  
290 295 300

Ser Leu Glu Ile Ser Pro Leu Thr Phe Leu Thr Ala Gln Thr Phe Leu  
305 310 315 320

Met Asp Leu Gly Gln Phe Leu Leu Phe Cys His Ile Ser Ser His His  
325 330 335

His Gly Gly Met Glu Ala His Val Arg Val Glu Ser Cys Ala Glu Glu  
340 345 350

Pro Gln Leu Arg Arg Lys Ala Asp Glu Glu Asp Tyr Asp Asp Asn  
355 360 365

Leu Tyr Asp Ser Asp Met Asp Val Val Arg Leu Asp Gly Asp Asp Val  
370 375 380

Ser Pro Phe Ile Gln Ile Arg Ser Val Ala Lys Lys His Pro Lys Thr  
385 390 395 400

Trp Val His Tyr Ile Ser Ala Glu Glu Asp Trp Asp Tyr Ala Pro  
405 410 415

Ala Val Pro Ser Pro Ser Asp Arg Ser Tyr Lys Ser Leu Tyr Leu Asn  
420 425 430

Ser Gly Pro Gln Arg Ile Gly Arg Lys Tyr Lys Lys Ala Arg Phe Val  
435 440 445

Ala Tyr Thr Asp Val Thr Phe Lys Thr Arg Lys Ala Ile Pro Tyr Glu  
450 455 460

Ser Gly Ile Leu Gly Pro Leu Leu Tyr Gly Glu Val Gly Asp Thr Leu  
465 470 475 480

Leu Ile Ile Phe Lys Asn Lys Ala Ser Arg Pro Tyr Asn Ile Tyr Pro  
485 490 495

His Gly Ile Thr Asp Val Ser Ala Leu His Pro Gly Arg Leu Leu Lys  
500 505 510

Gly Trp Lys His Leu Lys Asp Met Pro Ile Leu Pro Gly Glu Thr Phe  
515 520 525

Lys Tyr Lys Trp Thr Val Thr Val Glu Asp Gly Pro Thr Lys Ser Asp  
530 535 540

Pro Arg Cys Leu Thr Arg Tyr Tyr Ser Ser Ser Ile Asn Leu Glu Lys  
545 550 555 560

Asp Leu Ala Ser Gly Leu Ile Gly Pro Leu Leu Ile Cys Tyr Lys Glu  
565 570 575

Ser Val Asp Gln Arg Gly Asn Gln Met Met Ser Asp Lys Arg Asn Val  
580 585 590

Ile Leu Phe Ser Val Phe Asp Glu Asn Gln Ser Trp Tyr Leu Ala Glu  
595 600 605

Asn Ile Gln Arg Phe Leu Pro Asn Pro Asp Gly Leu Gln Pro Gln Asp  
610 615 620

Pro Glu Phe Gln Ala Ser Asn Ile Met His Ser Ile Asn Gly Tyr Val  
625 630 635 640

Phe Asp Ser Leu Gln Leu Ser Val Cys Leu His Glu Val Ala Tyr Trp  
645 650 655

Tyr Ile Leu Ser Val Gly Ala Gln Thr Asp Phe Leu Ser Val Phe Phe  
660 665 670

Ser Gly Tyr Thr Phe Lys His Lys Met Val Tyr Glu Asp Thr Leu Thr  
675 680 685

Leu Phe Pro Phe Ser Gly Glu Thr Val Phe Met Ser Met Glu Asn Pro  
690 695 700

Gly Leu Trp Val Leu Gly Cys His Asn Ser Asp Leu Arg Asn Arg Gly  
705 710 715 720

Met Thr Ala Leu Leu Lys Val Tyr Ser Cys Asp Arg Asp Ile Gly Asp  
725 730 735

Tyr Tyr Asp Asn Thr Tyr Glu Asp Ile Pro Gly Phe Leu Leu Ser Gly  
740 745 750

Lys Asn Val Ile Glu Pro Arg Asp Ile Ser Leu Pro Thr Phe Gln Pro  
755 760 765

Glu Glu Asp Lys Met Asp Tyr Asp Asp Ile Phe Ser Thr Glu Thr Lys  
770 775 780

Gly Glu Asp Phe Asp Ile Tyr Gly Glu Asp Glu Asn Gln Asp Pro Arg  
785 790 795 800

Ser Phe Gln Lys Arg Thr Arg His Tyr Phe Ile Ala Ala Val Glu Gln  
 805 810 815

Leu Trp Asp Tyr Gly Met Ser Glu Ser Pro Arg Ala Leu Arg Asn Arg  
 820 825 830

Ala Gln Asn Gly Glu Val Pro Arg Phe Lys Lys Val Val Phe Arg Glu  
 835 840 845

Phe Ala Asp Gly Ser Phe Thr Gln Pro Ser Tyr Arg Gly Glu Leu Asn  
 850 855 860

Lys His Leu Gly Leu Leu Gly Pro Tyr Ile Arg Ala Glu Val Glu Asp  
 865 870 875 880

Asn Ile Met Val Thr Phe Lys Asn Gln Ala Ser Arg Pro Tyr Ser Phe  
 885 890 895

Tyr Ser Ser Leu Ile Ser Tyr Pro Asp Asp Gln Glu Gln Gly Ala Glu  
 900 905 910

Pro Arg His Asn Phe Val Gln Pro Asn Glu Thr Arg Thr Tyr Phe Trp  
 915 920 925

Lys Val Gln His His Met Ala Pro Thr Glu Asp Glu Phe Asp Cys Lys  
 930 935 940

Ala Trp Ala Tyr Phe Ser Asp Val Asp Leu Glu Lys Asp Val His Ser  
 945 950 955 960

Gly Leu Ile Gly Pro Leu Leu Ile Cys Arg Ala Asn Thr Leu Asn Ala  
 965 970 975

Ala His Gly Arg Gln Val Thr Val Gln Glu Phe Ala Leu Phe Phe Thr  
 980 985 990

Ile Phe Asp Glu Thr Lys Ser Trp Tyr Phe Thr Glu Asn Val Glu Arg  
 995 1000 1005

Asn Cys Arg Ala Pro Cys His Leu Gln Met Glu Asp Pro Thr Leu Lys  
 1010 1015 1020

Glu Asn Tyr Arg Phe His Ala Ile Asn Gly Tyr Val Met Asp Thr Leu  
 1025 1030 1035 1040

Pro Gly Leu Val Met Ala Gln Asn Gln Arg Ile Arg Trp Tyr Leu Leu  
 1045 1050 1055

Ser Met Gly Ser Asn Glu Asn Ile His Ser Ile His Phe Ser Gly His  
 1060 1065 1070

Val Phe Ser Val Arg Lys Lys Glu Glu Tyr Lys Met Ala Val Tyr Asn  
 1075 1080 1085

Leu Tyr Pro Gly Val Phe Glu Thr Val Glu Met Leu Pro Ser Lys Val  
 1090 1095 1100

Gly Ile Trp Arg Ile Glu Cys Leu Ile Gly Glu His Leu Gln Ala Gly  
1105 1110 1115 1120

Met Ser Thr Thr Phe Leu Val Tyr Ser Lys Glu Cys Gln Ala Pro Leu  
1125 1130 1135

Gly Met Ala Ser Gly Arg Ile Arg Asp Phe Gln Ile Thr Ala Ser Gly  
1140 1145 1150

Gln Tyr Gly Gln Trp Ala Pro Lys Leu Ala Arg Leu His Tyr Ser Gly  
1155 1160 1165

Ser Ile Asn Ala Trp Ser Thr Lys Asp Pro His Ser Trp Ile Lys Val  
1170 1175 1180

Asp Leu Leu Ala Pro Met Ile Ile His Gly Ile Met Thr Gln Gly Ala  
1185 1190 1195 1200

Arg Gln Lys Phe Ser Ser Leu Tyr Ile Ser Gln Phe Ile Ile Met Tyr  
1205 1210 1215

Ser Leu Asp Gly Arg Asn Trp Gln Ser Tyr Arg Gly Asn Ser Thr Gly  
1220 1225 1230

Thr Leu Met Val Phe Phe Gly Asn Val Asp Ala Ser Gly Ile Lys His  
1235 1240 1245

Asn Ile Phe Asn Pro Pro Ile Val Ala Arg Tyr Ile Arg Leu His Pro  
1250 1255 1260

Thr His Tyr Ser Ile Arg Ser Thr Leu Arg Met Glu Leu Met Gly Cys  
1265 1270 1275 1280

Asp Leu Asn Ser Cys Ser Met Pro Leu Gly Met Gln Asn Lys Ala Ile  
1285 1290 1295

Ser Asp Ser Gln Ile Thr Ala Ser Ser His Leu Ser Asn Ile Phe Ala  
1300 1305 1310

Thr Trp Ser Pro Ser Gln Ala Arg Leu His Leu Gln Gly Arg Thr Asn  
1315 1320 1325

Ala Trp Arg Pro Arg Val Ser Ser Ala Glu Glu Trp Leu Gln Val Asp  
1330 1335 1340

Leu Gln Lys Thr Val Lys Val Thr Gly Ile Thr Thr Gln Gly Val Lys  
1345 1350 1355 1360

Ser Leu Leu Ser Ser Met Tyr Val Lys Glu Phe Leu Val Ser Ser Ser  
1365 1370 1375

Gln Asp Gly Arg Arg Trp Thr Leu Phe Leu Gln Asp Gly His Thr Lys  
1380 1385 1390

Val Phe Gln Gly Asn Gln Asp Ser Ser Thr Pro Val Val Asn Ala Leu  
1395 1400 1405

Asp Pro Pro Leu Phe Thr Arg Tyr Leu Arg Ile His Pro Thr Ser Trp  
1410                    1415                    1420

Ala Gln His Ile Ala Leu Arg Leu Glu Val Leu Gly Cys Glu Ala Gln  
1425                    1430                    1435                    1440

Asp Leu Tyr \*

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 1..19
- (D) OTHER INFORMATION: /note= "Signal peptide of human Factor VIII."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

Met Gln Ile Glu Leu Ser Thr Cys Phe Phe Leu Cys Leu Leu Arg Phe  
1                        5                        10                        15

Cys Phe Ser

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/05193

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C07H 21/00; C0K 14/755; C12N 15/11 15/12  
 US CL :435/69.6, 440; 530/383; 536/23.5

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.6, 440; 530/383; 536/23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, BIOSIS, MEDLINE, EMBASE

Search terms: porcine factor VIII, variant, deletion, substitution

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,663,060 A (LOLLAR et al) 02 September 1997, abstract, figures, claims.	1-16
Y	US 5,563,045 A (PITTMAN et al.) 08 October 1996, figures, claims.	3-4, 13-14
Y	EATON, D.L. et al. Construction and Characterization of an Active Factor VIII Variant Lacking the Central One-Third of the Molecule. Biochemistry. 30 December 1986, Vol. 25, No. 26, pages 8343-8347, especially abstract.	17-20



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

14 APRIL 1999

Date of mailing of the international search report

25 MAY 1999

Name and mailing address of the ISA/US  
 Commissioner of Patents and Trademarks  
 Box PCT  
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer  
  
 DIAN JACOBSON

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/05193

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SCANDELLA, D. et al. Some Factor VIII Inhibitor Antibodies Recognize a Common Epitope Corresponding to C2 Domain Amino Acids 2248 Through 2312, Which Overlap a Phospholipid-binding Site. Blood. 01 September 1995, Vol. 86, No. 5, pages 1811-1819, especially abstract.	21-28